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ABSTRACT 
1. Profiles df the glycolytic intermediates were determined in 
freeze-clamped rat spleen and thymus . Hexokinase, phosphofructokinase 
and pyruvate kinase were all found to catalyze "non-equilibrium" reactions 
in vivo in both tissues, whilst the glucose carrier and aldolase were 
found to catalyze reactions intermediate between "equilibrium" and 
"non-equilibrium" position. 
2. Under a variety of conditions where glycolytic flux rates were 
altered in both tissues, the glucose carrier/hexokinase and 
phosphofructokinase were both found to be regulatory. 
3. The data presented on the regulation of glycolysi s 1n lymphoid 
tissue indicates that two separate patterns of regulation may be 
distinguished: 
(i) emergency glycolysis~ which occurs when either 
the tissue's respiratory system is perturbed or 
cytoplasmic phosphorylation potential is lowered; 
and 
(ii) immunological glycolysis~ which occurs when the 
tissue is presented with an immunological 
challenge, by either mitogenic lectins or 
allogeneic lymphocytes. This regulatory pattern 
is characterized by elevated levels of the 
hexose-monophosphates. 
4. Pig spleen phosphofructokinase has been purified 800-fold with a 
yield of 17%. Two isoenzymes were separated by DEAE-cellulose column 
L·hronwtography. In conunon with the cn 3yme from other mammalian sources, 
pig spleen phosphofructokinase has a pH optimum of 8.2. It displays 
111 
sigmoidal kinetics with respect to F6P concentration, and its cooperative 
behaviour is very dependent upon pH, protein concentration and the 
concentration of MgATP. 
5. The spleen enzyme was tested for its response to a wide variety of 
potential effector molecules, and it was found that possible in vivo 
2-
effector molecules included ADP, AMP, F6P, FDP, aspartate and P04 as 
Mg 2+ 2+ activators, whilst ATP, citrate and and Ca may be important 
inhibitors. 
6. A series of experiments was conducted to investigate more fully the 
mechanism of action of some of the enzyme's effector molecules, and it 
was found that while AMP, ADP, Po4
2
- and FDP activate phosphofructokinase 
and protect it from inactivation by MgATP, aspartate activates without 
+ + protecting the enzyme, and K and NH4 are potent activators that appear 
to offer some protection, but only when F6P is present. 
7. The in vitro properties of phosphofructokinase were compared with 
the data relating to the in vivo regulation of glycolysis . It is concluded 
that phosphofructokinase activity in lymphoid tissues in vivo correlates 
with, and is altered primarily by changes in the levels of intracellular 
Po4
2
- and perhaps FDP. 
8. A brief resum~ of work done at the whole cell level is presented, 
1n order to give a wider metabolic context to the experimental work 
contained within this thesis. 
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CHAPTER 1 
INTRODUCTION 
CHAPTER 1 
INTRODUCTION 
1.1 ELUCIDATION OF THE GLYCOLYTIC SEQUENCE 
The term glycolysis was first used to describe the disappearance 
of carbohydrate during metabolic activity. Warburg later refined this 
definition to the splitting of carbohydrate into lactic acid (1). 
Elucidation of the complex enzymatic reactions involved 1n carbohydrate 
metabolism has led to a further restriction in definition, and the term 
is now used to denote "the stepwise degradation of glucose to pyruvate 
by way of fructose-diphosphate" (2). 
Investigations into the structure and components of the glycolytic 
pathway arose from early experimental work on alcoholic fermentation in 
extracts of microorganismic cells. Harden and Young (3) observed that 
phosphate appeared to be essential for the operation of the pathway. 
They found that adding inorganic phosphate to a fermenting yeast juice 
containing glucose or fructose caused a large stimulation in fermentation 
rate. Careful measurement demonstrated that the increased quantities of 
co2 
and alcohol produced were exactly equimolar with the phosphate 
utilized, implying that phosphate took a direct role in the pathway. 
They were able to demonstrate that added inorganic phosphate was bound 
to a hexose, and the phosphorylated compound was later identified as FOP. 
This phosphorylated sugar, when added to fermenting yeast juice, caused 
a large increase in fermentation rate, and from this result it appeared 
that the first intermediate of the glycolytic pathway had been identified. 
The involvement of inorganic phosphate was further investigated by 
Robison (4) who demonstrated the presence of hexose-monophosphate 1n 
fermenting yeast-juice, and showed the molecular species involved to be 
a mixture of glucose- and fructose-6-phosphates. Later, in 1927, when 
Meyerhof was able to demonstrate (5) a specific enzyme which had the 
capacity to phosphorylate glucose and other hexoses (hexokinase), the 
first section of the glycolytic pathway had been firmly established. 
Identification of the intermediates between FDP and pyruvate was 
accomplished by a variety of methods. It was found, for example, that 
when iodoacetic acid was added to fermenting juice containing either 
glucose or FDP, although the added substrates disappeared, neither lactate 
nor ethanol were formed. Instead, an accumulation of triose-phosphates 
was observed. The triose-phosphates were shown to be glycolytic 
intermediates by demonstrating their utilization in, and stimulation of, 
the fermentation process. 
Embden et al (6) found, whilst investigating the effect of ions on 
hexosephosphate synthesis, that in the presence of sodium lactate, 
fluoride or oxalate, abundant quantities of a compound, which they 
identified as phosphoglyceric acid, could be isolated as the barium salt. 
Careful measurement showed that for each mole of glyceraldehyde-3-phosphate 
converted to 3-phosphoglyceric acid, one mole of inorganic phosphate was 
consumed, and one mole of ATP was formed from ADP, implying the transient 
existence of a further intermediate. Negelein and Bromel (7) were able 
to isolate a compound which decomposed spontaneously in aqueous solution 
to 3-phosphoglyceric acid and which, by their criteria, was identical 
with 1,3-diphosphoglyceric acid. 
3-phosphoglyceric acid can also be fermented to ethanol and C02 (6). 
When NaF was added to fermenting yeast juice containing 3-phosphoglyceric 
acid, the rate of fermentation fell, and concomitant with this, compounds 
later identified as 2-phosphoglyceric acid and phosphoenolpyruvate 
accumuLtted. With these demonstrations, the identity of all the 
intermediates of the glycolytic pathway had been established. 
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The Buchner's original term for their cell-free fermenting system 
was "zymase", and it was realised that the interconversion of the 
intermediates of the glycolytic system was dependent on a heat-labile 
component of the "zymase", i.e. the catalytic proteins, enzymes. However, 
as early as 1906, Harden and Young (3) were able to demonstrate that the 
function of the pathway was also dependent on a heat-stable, dialyzable 
fraction which they called "co-zymase". Extensive research has 
demonstrated that "co-zymase" is in reality a complex mixture of 
chemicals; and Krebs (8) lists 8 eo-factors required before fermentation 
can occur. 
Although the identification and sequenc1ng of the glycolytic 
intermediates began very shortly after the Buchners' demonstration of 
cell-free fermentation, the identification, extraction and purification 
of the individual enzymes responsible for these interconversions, did not 
commence until 1927, when Meyerhof (5) reported the isolation of 
hexokinase. Much of the work on identification and characterization of 
the individual enzymes was done in Meyerhof's laboratory during the 1930's 
(e.g. 9, 10). However it was not until the mid-1960's that the most 
labile of these enzymes, phosphofructokinase, was purified to homogeneity 
1n stable form (11). More will be said later of those enzymes involved 
1n the regulation of glycolysis. 
Clearly the work above describes a means by which the sequential 
fragmentation of sugars can occur. It does not, however, indicate any 
means by which the rate of this process can be controlled. Fletcher and 
Hopkins (12) noted as early as 1907 that glycolysis proceeds faster in 
working than in resting muscle. Since this early discovery, the work of 
numerous investigators has demonstrated that the rate of glycolysis can 
hl' v:tried hy subjecting the C'Xpcrimental organism or organ to a variety 
of conditions, and that these cl1angcs in flux rate are controlled at 
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specific enzyme loci. In recent years a systematic procedure for 
identifying regulatory enzymes has been developed. The next section will 
discuss the essential features of this procedure. 
1.2 SYSTEMATIC IDENTIFICATION OF REGULATORY STEPS 
In 1967, Newsholme and Gevers (13) presented a theory of metabolic 
control, referring specifically to regulation of the interrelated 
pathways of glycblysis and gluconeogenesis in liver and kidney cortex. 
In essence, the principles underlying their approach, as applied to the 
glycolytic pathway alone, may be formulated in the following terms. 
Glycolytic flux is controlled by certain specific enzymes -- regulatory 
enzymes. 
(i) Those enzymes which are of major importance in 
regulating glycolytic flux are identified by specific 
criteria. 
(ii) The properties of these regulatory enzymes are 
investigated in detail; this requires purifying the 
enzymes at least to the stage where metabolites and 
other enzymes which may obscure or interfere with 
the assay are removed. 
(iii) On the basis of the properties observed, a theory 
for the control of glycolysis is proposed; and 
(iv) The theory, or predictions which arise from it, are 
tested and the theory is modified or expanded 
accordingly. 
Sections of this approach have been further elaborated by Newsholme 
(14) and Rolleston (15). 
Although a large number of criteria have been employed for 
identifying regulatory enzymes, only four are considered here. 
1. 2. 1 Teleological considerations 
The living cell performs a variety of metabolic functions and in 
the interests of its own viability may be expected to develop mechanisms 
whereby this task is accomplished most efficiently i.e. with the least 
expenditure of energy. For this reason, one might predict that a 
5 
regulatory site will occur early in the pathway (to minimize uncontrolled 
metabolism) and/or at a site which is either unique for the pathway, or 
has minimal overlap with other pathways (so that regulation can be 
specific). This will be considered as it actually applies to the glycolytic 
pathway later. 
1.2.2 Maximal enzyme activities in vitro 
Flux through a metabolic pathway can proceed only as fast as the 
slowest reaction in its sequence. For this reason, one might expect an 
enzyme with regulatory capability to have a lower maximal catalytic 
capacity than other enzymes of the same pathway. Hence it is of value to 
determine the maximal catalytic activity of each enzyme 1n the pathway. 
Unfortunately, measurements must be made on tissue extracts, where the 
procedures involved in disrupting the tissue and extracting the enzymes, 
may cause unknown and uncontrollable losses in activity. However, most 
non-regulatory enzymes have catalytic capacities ten to one hundred times 
greater than their regulatory counterparts, so that it may be considered 
unlikely that enzyme loss during extraction would be sufficient to 
disguise this difference. 
1.2.3 Identification of "non-equilibrium" reactions 
Krebs stated in 1946 (16), that freely reversible reactions are 
unlikely to be of importance in controlling metabolism, as the enzymes 
responsible will be able to freely intcrconvcrt their substrates so that 
the reactions involved remain near their equilibrium positions. Only 
when an enzyme's activity falls below that of the preceding enzymes of 
6 
the pathway, caus1ng an accumulation of its substrate, i s the en zyme able 
to exert the rate-limiting capacity necessary for regulat i on . This will 
result in a marked deviation of the reaction from its equilibrium 
position, and the reaction will become non-equilibrium . Non-equil i brium 
reactions may be identified by determining the concentration of sub s trates 
and products for each reaction in freeze-clamped tissue, and subsequently 
determining the mass-action ratio. Comparison of the calculated mass-
action ratio with the apparent equilibrium constant indicates whether 
the particular enzyme is catalyzing an equilibrium or non-equilibrium 
reaction. It must be pointed out that regulation can occur at equilibrium 
steps, but this is of the "open loop" type, where a substrate or cofactor 
of one of the reactions of a reversible enzyme may become limited 
e.g . pyridine nucleotide regulation of glyceraldehyde-3 phosphate 
dehydrogenase. Non-equilibrium reactions, which proceed with large 
changes in free energy are, in practice at least, irreversible. 
1 . 2.4 Use of altered flux rates to positively identify regulatory 
enzymes 
Rolleston and Newsholme (17) defined a regulatory enzyme as one 
"whose activity controls the rate of flux through a metabolic pathway 
(i.e. a non-equilibrium reaction) and whose activity is regulated by 
factors other than the substrate concentration". 
To determine which non-equilibrium enzymes are regulatory, is best 
done by adoption of a principle suggested by Krebs (18). That 1s, if the 
substrate concentration of a non-equilibrium enzyme changes in the opposi t e 
direction to a change in flux through the pathway, then that enzyme is 
considered to be regulatory under the conditions which induced the flux 
change. This identification is only a positive one however; failure to 
comply with this criterion does not constitute evidence that the enzyme 
is non-regulatory. 
Clearly it is necessary to know the in vivo levels of substrates 
and cofactors for the different enzymes, in order to determine 
I 
regulatory sites by the above criteria. This can be accompli shed by 
crushing the whole organ between aluminium tongs cooled to -180°C 1n 
liquid nitrogen (19). This very rapidly lowers the intracellular 
temperature to a level where significant metabolic activity can no longer 
occur. Glycolytic intermediates can then be extracted by perchloric acid 
treatment, and their concentrations determined by assay. 
There is a major problem associated with this technique. Free ze-
clamped values indicate the total amount of a particular intermediate, 
but give no indication of its intracellular distribution 1n relation to 
the enzyme for which it is a substrate. Thjs problem is of particular 
importance when an enzyme is located within an organelle whose membranes 
are not freely permeable to the reactants and products of that enzyme. 
Suter (20) has recently discussed this problem in relation to the pyruvate 
dehydrogenase reaction. Fortunately, in investigations of glycolysis, 
compartmentation is not a major problem, as both the enzymes and 
intermediates are located predominantly in one compartment, the cytoplasm. 
The problem of compartmentation of glucose between the intracellular and 
extracellular spaces will be discussed in ·:he experimental section of 
this thesis. 
1.3 EXPERIMENTAL DETERMINATION OF REGULATORY LOCI 
In this section, the four criteria hat were discussed 1n Section 
1.2 above, will be considered in the ligh t of the experimental evidence 
available. 
1.3.1 Teleological considerations 
On a teleological basis, both hexol<inase and phosphofructokinase 
might be expected to catalyze regulated ·~eactions. Hexokinase catalyzes 
the first reaction involved in the metabolism of glucose, and 
phosphofructokinase catalyzes the first reaction which uses a substrate 
unique to glycolysis and which is not involved in branch point s to any 
other pathway. 
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Although not strictly part of glycolysis, the transport of glucose 
into the cell is a logical site for regulation, and rate limitation at 
this point would clearly have important consequences for carbon flux 
through the pathway. 
1.3.2 Maximal enzyme activities in vitro 
Maximal in vitro glycolytic enzyme activities have been measured 1n 
a number of rat and mouse tissues (e.g. 21, 22), and in several human 
tissues, both normal and malignant (e.g. 23, 24). In all cases the same 
basic pattern has been observed: 1.e., 
1.3.3 
(i) all enzymes have catalytic capacities many times 
greater than the overall flux rates estimated; 
(ii) the ratios of the enzyme activities along the 
pathway are strikingly similar from tissue to tissue; 
and 
(iii) there 1s always one small group of enzymes, whose 
activities are consistently lower than those of 
other members of the pathway; members of this group 
are hexokinase, phosphofructokinase, aldolase and, 
perhaps, enolase. 
Identification of non-equilibrium reactions 
Comparison of the mass-action ratios observed in liver (25), 
perfused rat heart (26), rat brain (27) and Ehrlich ascites tumour cells 
(28) with the apparent equilibrium constants for the different enzyme s , 
show that hexokinase, phosphofructokinase and pyruvate kinase are a ll far 
removed from equilibrium. In addition, in rat brain and heart, 
9 
glyceraldehyde-3-phosphate dehydrogenase appears to catalyze a 
non-equilibrium reaction. 
1.3.4 Use of altered flux rates to positively identify regulatory 
enzymes 
From the data considered to date, both hexokinase and 
phosphofructokinase fit the criteria for a potentially regulatory en zyme 
in every way, i.e. they are at logical locations for regulation, they 
have comparatively low activities in vitro, and both catalyze irreversible 
non-equilibrium reactions. In contrast, glyceraldehyde-3-phosphate 
dehydrogenase and pyruvate kinase are comparatively high activity enzymes. 
Glyceraldehyde-3-phosphate dehydrogenase catalyzes a reversible reaction 
+ 
and appears to be regulatory only if the level of NAD or NADH drops to 
a level low enough to limit catalytic activity to one particular direction. 
The only obvious reason for pyruvate kinase to be regulatory is that it 
catalyzes the last reaction before the pathway splits into oxidative and 
anaerobic branches. It does catalyze a virtually irreversible reaction, 
with an apparent equilibrium constant (of the order of 104) that is very 
much 1n favour of the products. 
To finally determine which non-equilibrium enzymes are regulatory, 
it is necessary to alter the rate of flux through the pathway, and to see 
which enzymes show the changes in substrate concentration, characteristic 
of a regulatory role (see 1.2.4). Examples of experiments conducted to 
determine the regulatory loci of glycolysis are given below. 
When muscle is stimulated repetitively, flow of carbon through the 
glycolytic system may increase by several hundred fold. Karpatkin et al 
(29), using electrical stimulus of frog sartorius muscle as their model, 
were able to show by determination of glycolytic intermediate 
concentrations, that the large and rapid increase in glycolytic rate from 
glycogen was accompanied by a correspondingly large and rapid activation 
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of both phosphorylase and phosphofructokinase. Furthermore, when 
exogenous glucose was the substrate, the increased flux rate was 
accompanied by an activation of hexokinase. During electrical 
stimulation, the intracellular pH rises initially, apparently due to tltc 
hydrolysis of phosphocreatine (30). Hexokinase and phosphofructok i nase 
are known to be more active at pH values higher than 7.0, so the pH 
change alone may be sufficient to account for part of the observed 
stimulation. Additionally, the concentrations of several of the effector 
molecules which regulate phosphofructokinase activity in vitro change 
during stimulation, and the direction of change is consistent with a 
sustained activation of this enzyme (31). The complex processes 
associated with phosphofructokinase activation will be discussed later. 
Perfusion of isolated organs of rodents and other small mammals 
has become extremely popular as a means of investigating metabolic 
regulation in functioning tissues. It has considerable advantage over 
other fn vitro tissue preparations such as slices and homogenates, 
because less damage is caused to the organ during its preparation, and 
because the supply of oxygen and substrates can be more precisely varied 
and controlled. 
Newsholme and Randle (32) have looked at glycolytic regulation in 
the perfused rat heart. Perfusion was terminated by freezing, and the 
levels of the various hexosemonophosphates measured. Making the tissue 
anoxic was found to increase the activities of phosphofructokinase and 
hexokinase, both 1n the presence and absence of insulin. Because the 
phosphohexose-isomerase reaction is reversible, one effect of stimulating 
phosphofructokinase will be to lower G6P levels. G6P inhibits hexokinase 
(33), and it was suggested that the observed stimulation of hexokinase 
was due to the removal of this constraint and was thus secondary to the 
stimulation of phosphofructokinase. Regen et al (34), and Hems and Gaja 
(35) have also shown that anox1a stimulates phosphofructokinase 1n 
perfused rat heart and rat kidney. 
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Weidemann et al (36) looked at the effects of added adenine 
nucleotides on glycolysis and gluconeogenesis 1n the perfused rat kidney. 
In their system, part of any ATP added to the perfusate was rapidly 
converted to AMP, but further hydrolysis was prevented by ATP- and 
Po4
2
--mediated inhibition of the AMP-degrading enzymes (37). They found 
that addition of ATP together with glucose caused an increase in the 
concentration of glycolytic intermediates between FDP and pyruvate. 
From this data they concluded that the AMP formed was stimulating 
phosphofructokinase and inhibiting fructose-diphosphatase (see Section 
1.4.5 below). 
The experimental work described above is intended only to provide 
selected examples of the methods available for determining the regulatory 
loci of glycolysis. Clearly, the most common sites of regulation are 
found at hexokinase and phosphofructokinase. This section will close by 
briefly considering some of the information available on the properties 
of enzymes located at the major regulatory sites of glycolysis. 
1.3.5 The regulatory loci of glycolysis 
A regulatory enzyme was defined earlier, as one which controls the 
rate of flux through a pathway, and whose activity 1s regulated by factors 
other than the concentration of its substrate. 
Although not strictly an enzyme of the glycolytic pathway, the 
possible rate~limiting role of the glucose carrier must be considered 
in any discussion of glycolytic regulation. Transport of exogenous 
glucose into the cell is obviously necessary for the pathway to function 
in the absence of unlimited supplies of stored glycogen, and in rat 
cardiac muscle (38), diaphragm (39) and adipose tissue (40), it 1s a 
major rate-limiting step involved in glucose utilization. In these tissues, 
entry of glucose is greatly accelerated by insulin and, as described 
above, anoxia also appears to stimulate transport. 
Mammalian hexokinase has a high sensitivity to inhibition by its 
2-product, G6P. This inhibition may be overcome by P04 . In addition, 
MgADP is an inhibitor, acting apparently in competition with the other 
substrate, MgATP. The evidence available suggests that G6P and PO 2-4 
bind at a separate "allosteric" site (2). 
The evidence available implicating phosphofructokinase as a 
regulatory enzyme is much greater. In all mammalian tissues where 
1:2 
glycolytic flux is altered, rapid changes in phosphofructokinase activity 
are usually found to be principally responsible. In the experimental 
section of this thesis, phosphofructokinase is shown to be a maJor 
regulator of glycolytic flux in rat spleen and thymus and, additionally, 
a purification and detailed investigation of the kinetic properties of 
the enzyme from pig spleen has been undertaken. For this reason , the 
known properties of phosphofructokinase will be reviewed in some detail, 
concentrating mainly on the information available up to the commencement 
of work on this project (in March 1971). 
1.4 PHOSPHOFRUCTOKINASE 
1.4.1 Introduction 
The hexose-phosphates, which are the substrate and product of the 
phosphofructokinase reaction, were identified during early investigations 
into the sequence of the glycolytic pathway. It was not until 1936, 
however, that a specific enzyme was shown to be responsible for this 
reaction (41). The first suggestion that phosphofructokinase may play 
a significant role in Tegulating glycolysis came in 1942, when Cori (42) 
reported that under certain circumstances, hexosemonophosphates may 
accumulate in muscle cxt r;Jcts, without any corresponding increase in the 
1~ 
amount of lactic acid formed. In 1951, Muntz and Hurwitz (43) demonstrated 
that rat brain phosphofructokinase is greatly stimulated by NH4+. Since 
this time, phosphofructokinase has been positively identified as the 
principal regulatory enzyme of glycolysis in ev~ry major mammalian tissue 
studied. It has been purified from a number of sources and its properties 
exhaustively examined. In addition to investigations of the allosteric 
regulatory properties of phosphofructokinase in vitro, a large body of 
work has been devoted to examining the physical structure of the enzyme 
and, more recently, to the role different isoenzymes may play in 
fulfilling the metabolic requirements of different tissues. All of these 
aspects will be considered in detail below. 
1.4.2 The purification of phosphofructokinase from different tissues 
Mammalian phosphofructokinase is very labile. The first reported 
purifications were by Taylor in 1951 (44), from skeletal muscle, and by 
Muntz in 1953 (45) from dog brain. Taylor achieved a 30-fold 
purification by repeated (NH4) 2so4 precipitation whilst Muntz, although 
achieving only a small degree of purification, was able to markedly 
increase the stability over that obtained in crude homogenates. 
The relative amounts of phosphofructokinase in different tissues 
varies considerably. For example, Shank and Boxer (22) reported that 
skeletal muscle, on the basis of units of enzyme per g. wet wt. tissue, 
has twice as much phosphofructokinase as brain, four times as much as 
cardiac muscle and sixteen tim~s as much as liver. When considered in 
terms of specific activity, 1.e. 1n units of enzyme/mg. protein, the 
difference is even greater, as liver, for example, contains more protein 
per g. tissue than does muscle. For these reasons, most of the initial 
attempts to purify phosphofruct okinase were made using skeletal muscle 
I 
from various animals. 
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Although several laboratories worked on the purifica t ion of 
skeletal muscle phosphofructokinase during the 1950's and ea rl y 1960 ' s 
(e.g. 46, 47, 48), it was not until 1965 that both homo geneous and s t abl e 
preparations of the enzyme were reported. Almost simultaneously , Li ng 
et aZ (11), Uyeda and Racker (49), and Parmeggiani et aZ (50) r eported 
the purification of the skeletal muscle enzyme to homogeneity, whilst 
Mansour et aZ (51) reported a similar result for the heart enzyme. 
Highly biosynthetic tissues such as liver and kidney cortex, which 
also possess a gluconeogenic capacity, are unlikely to have the same 
energy requirements from glycolysis as muscle. For this reason it was 
considered that the enzyme from these sources might have kinetic properties 
significantly different to those of the muscle enzyme. Although 
phosphofructokinase is present in much smaller quantities in tissues 
other than muscle, purifications from a number of other tissues have been 
made. 
The first substantial purification from liver was made by Underwood 
and Newsholme (52), who in 1965 reported a 35-fold increase in the 
specific activity of the rat liver enzyme. More recently, Brock (53) and 
Kemp (54) have reported 500- and 2500-fold purifications of the sheep and 
rabbit liver enzymes respectively. 
In 1969, it was reported that a SO% decrease 1n phosphofructokinase 
content led to a significantly reduced erythrocyte survival (55). This 
decrease 1s apparently hereditary, and was classified as a Type VII 
glycogen storage disease. Interest in the disease led to attempts to 
purify the erythrocyte enzyme, and in 1969 Layzer et aZ (56) reported 
the partial purification of human erythrocyte phosphofructokinase. 
Finally, in 1972, Tarui e t al (57) purified the rabbit erythrocyte enzyme 
to homogeneity, giving it :1 spec ific :1ctivity similar to that of th e 
homogeneous muscle enzyme, i.e. 140 U/mg. protein. 
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Investigations into the purification and properties of the brain 
enzyme have been conducted largely by Lowry and Passoneau. In 1966, 
they reported (58) a 240-fold purification of the enzyme from sheep brain 
with a final specific activity of 18 U/mg. protein. Krzanowski and 
Matchinsky (59) have partially purified phosphofructokinase from rat 
brain, but only to a specific activity of approximately 1 U/mg. protein. 
These represent the major tissues from which purifications have 
been attempted. Other purifications have been made of the enzyme from 
kidney cortex (60), sperm (61), jejunal mucosa (62), thymus (63), and 
hepatoma (64). 
1.4.3 The molecular structure of phosphofructokinase 
It was not until homogeneous preparations of phosphofructokinase 
were available that attempts were made to investigate the physical 
structure of the enzyme. What was most obvious to workers at the outset, 
was the ability of the enzyme to exist in forms of several different 
molecular weights (11, 50, 65, 66). Paetkau and Lardy (67) and Mansour 
and Ahlfors (65) were able to show that the smallest active form of the 
enzyme had a molecular weight of approximately 380,000 daltons. 
Paetkau et al (68) and Paetkau and Lardy (67) investigated the 
subunit structure of the skeletal muscle enzyme in detail. Using 
ultracentrifugation techniques allied to urea and SOS treatments, they 
found forms of phosphofructokinase with molecular weights 93,000, 
192,000 and higher multiples. From amino acid analyses, they concluded 
that the species with molecular weight 93,000 constituted the basic unit 
or protomer* of phosphofructokinase. In support of this, Kemp and Krebs 
(69) found 90,000 daltons to be the binding unit molecular weight for F6P, 
AMP and ADP, although this unit could bind three molecules of ATP. 
*"The identical subunits associated within an oligomeric protein are 
designated as protomers" (Changeux, 72). 
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Paetkau et al (68) found additionally that treatment of the 93,000 
dalton molecular spec1es with 6M guanidinium chloride generated species 
with molecular weights of about 24,000. These however were of more than 
one kind, as shown by paper chromatography of tryptic digests. 
Considering their results alongside those of Kemp and Krebs, 
Paetkau et al concluded that each protomer consisted of one catalytic and 
three regulatory subunits. Mansour and coworkers (70, 71) have also 
examined the binding properties of phosphofructokinase. They found that 
each protomer of enzyme bound two molecules of F6P, four molecules of 
ATP and two molecules of citrate. From these results, they proposed that 
each protomer consists of two catalytic and two regulatory subunits. 
More recently, Lardy's laboratory has reported (73) that they are 
unable to generate species with molecular weights less than 50,000 by 
any means. They suggested that the guanidine used in the earlier studies 
may have degraded the enzyme. Although this now throws doubt on the 
structure of phosphofructokinase as proposed by Mansour (103, 1.e. 
association/dissociation between dimer and tetrarner) subsequent data will 
still be discussed in these terms, although it will be implicit in this 
discussion that where "active tetrarner" is referred to, "active hexamer" 
may be the correct form. Concomitantly with this, there may be a need 
to accept slightly different molecular weights for the various species. 
It appeaFs that the basic active unit of phosphofructokinase, in 
vivo, 1s the 360,000 dalton tetrarner. At approximately pH 7.0 or below, 
the enzyme may reversibly dissociate into inactive dimers of molecular 
weigh~ 180,000 daltons. The inactivation process is enhanced by ATP and 
other inhibitors, and blocked by activators such as AMP and FOP. It 1s 
not known if the higher molecular weight forms seen in the ultracentrifuge 
exist in vivo. The biological importance of the interconversion between 
dimcric and tctramcric species, and the mechanism involved, will be 
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discussed 1n Section 1.4.5(d) below. Figure 1-1 summarizes the data 
available on the different molecular-weight forms of phosphofructokinase. 
1.4.4 Isoenzymes of phosphofructokinase 
The first demonstration that mammalian phosphofructokinases from 
different tissues had different kinetic properties was made in 1964 by 
Lowry and Passoneau (74). They found that the response of the enzyme to 
several of its effectors in crude extracts of several rat tissues was 
quantitatively different. 
Further interest in the isoenzymes of phosphofructokinase was 
aroused with the discovery of a glycogen storage disease characterized by 
a deficiency of the enzyme in some tissues only. Sufferers of this 
disease had no enzyme activity in their muscles, only half normal activity 
in their erythrocytes, and essentially normal activity in their white 
blood cells (75, 76). Because of the selective involvement of certain 
tissues, Layzer and coworkers suspected the occurrence of isoenzymes. 
They examined the enzyme from several human tissues and, on the basis 
of kinetic, chromatographic and immunological methods, were able to 
demonstrate the existence of at least four different 1soenzymes (56, 77). 
Taylor an~ Bew (78) reported at about the same time, that rat 
tissues appeared to contain two different types of phosphofructokinase, 
a muscle-type and a liver-type. Enzyme extracts from a number of other 
tissues appeared to contain a mixture of these two main enzymatic forms. 
Kemp (54) has made a comparison of certain of the kinetic 
properties of the liver and skeletal muscle enzymes. The muscle enzyme 
is more sensitive to activation by the adenine nucleotides and to 
inhibition by citrate and 3-PGA, whilst the liver enzyme is more 
sensitive to inhibition by ATP and 2,3-diPGA. In vivo concentration of 
i\TP are or the order of S.O mM tn tmtscle (79) and 2. 7 mM in ljver (2 5) . 
Kcmp suggested that the differing sensitivities of the two enzymes to ATP 
Figure 1-1 The structure of mammalian phosphofructokinase 
The information in this figure is for work done on ei ther the 
heart or skeletal mus cle enzyme, and is drawn from the fo llowi ng 
references: 65, 68, 69, 70, 71, 80, 103 . Although the gener ation 
of sub-protomeric species has been reported (68), this dat a has since 
been retracted (73). 
Aggregates 
M.W. = -750,000 - several million daltons 
High protein concentration 
Stabilizers e.g. FOP 
Low protein concentration 
ATP 
pH 7.5 - 8.2 
Basic active form 
M.W. ~ 360,000 daltons 
High protein concentration 
Stabilizers e.g. FOP 
Low protein concentration 
Inhibitors e.g. ATP, citrate 
pH 5.8 - 7.0 pH 7.5 - 8.2 
pH 7. 0 + FOP 
Inactive form 
M.W. ~ 180,000 daltons 
4mM SOS 
pH 5.2 
Protomer (inactive) 
M.W. ~ 90,000 daltons 
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should be considered in the light of the concentration of ATP within the 
two tissues. Additionally he suggested that the muscle enzyme's greater 
sensitivity to adenine nucleotide activation was logical, as the muscle 
may at times, have to produce energy under partially anaerobic conditions. 
Tsai and Kemp had observed that different phosphofructokinases 
migrated at different rates during cellulose acetate electrophoresis, with 
muscle and liver enzymes being the slowest and fastest respectively (80 ) . 
They postulated that the intermediate species may be hybrids of these two 
enzymes. They dissociated the liver and muscle enzymes separately into 
their protomers by lowering the pH to 5.3, in the presence of FOP. These 
species were then mixed and neutralized to enable reassociation to occur. 
Electrophoresis revealed five bands instead of two, with muscle and liver 
controls again being the slowest and fastest. These results suggest that 
phosphofructokinases in all tissues may represent liver- and muscle-type 
hybrids. 
The situation has recently been shown to be more complex. The same 
authors raised anti-sera to both the liver and muscle enzymes, and tested 
their effects on the enzymes isolated from different tissues (81). They 
expected treatment with both anti-sera to inactivate all phosphofructokinases, 
but found that the enzymes from the brain and thymus retained considerable 
residual activity. Apparently there is a third basic form of enzyme, 
"brain-type" phosphofructokinase. Clearly the next stage in the 
investigation of phosphofructokinase isoenzymes will be to purify the 
brain-type species and characterize it. 
1.4.5 The allosteric regulation of phosphofructokinase 
Both Muntz and Hurwitz (43) and Taylor (44) reported that NH4+ 
greatly stimulated phosphofructokinase. These were amongst the first 
t·eports of molecules which, although not substrates for the reaction, 
\~ould ~1ffect the activity of the enzyme. With the availability of highly 
purified and stable phosphofructokinase, large scale investigations into 
the kinetic properties of the enzyme from various sources have been 
conducted. Table 1-1 lists the major reported allosteric effectors of 
phosphofructokinase. 
(a) Activators 
(i) Adenine nucleotides 
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The adenine nucleotides, AMP, cAMP and ADP, are potent activators of 
phosphofructokinase. They do however, have a differential effect on the 
enzyme from different sources. In muscle, the KA's for AMP, cAMP and ADP 
are 0.035, 0.015 and 0.04 mM respectively, whilst in liver the comparable 
KA's are 0.21, 0.075 and 0.31 mM (54). The concentrations of AMP in both 
normal liver and normal muscle, are such that phosphofructokinase will be 
at least partially activated. In normal aerobic liver, AMP levels are 
typically of the order 0.25 mM (25), whilst in muscle the concentration 1s 
usually about half of this value (calculated from 79). The AMP concentration 
in liver is below that which half-maximally activates phosphofructokinase, 
but in muscle is present at several times this concentration (54). Liver 
phosphofructokinase is more sensitive to ATP inhibition than the muscle 
enzyme, and the closeness of the in vivo AMP concentrations to the KA' 
suggest that AMP may be important in relieving ATP inhibition in this 
organ. Kemp (54) has suggested that AMP and ADP may be more important 
as regulators of phosphofructokinase in muscle, where energy may at times 
have to be produced under partially anaerobic conditions. 
(ii) Phosphate 
Phosphate is reported to activate phosphofructokinase (56, 58, 82). 
The true role of this ligand is somewhat uncertain, as in the earlier 
experiments (56, 58) it was added as the K+ salt. K+ is a potent 
activator of phosphofructokinase in its own right, and it was uncertain 
whether the activating effect observed was due to Po4
2
- or K+. However, 
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Table 1-1 
The major allosteric effectors of mammalian phosphofructokinase 
ACTIVATORS REFERENCE INHIBITORS REFERENCE 
AMP 52, 54 ATP or MgATP 52, 54, 58, 89 
cAMP 54, 65 Citrate 53, 90, 91, 92 
ADP 54, 58 PEP 49, 59 
PO 2- 56, 58, 82 P-creatine 49, 59 4 
FDP 52, 58, 87 3-PGA 54, 59 
NH+ 43, 83, 92 2-PGA 54, 59 4 
K+ 54, 58, 83 2,3-diPGA 54, 59 
F6P 53, 58, 60, 88 
+ Tejwani and Ramaiah (82) used the Na salt and got essentially similar 
results. The KA is reported to be of the order 4 - 5 mM. 
(iii) + + NH4 and K 
+ + NH
4 
and K greatly stimulate phosphofructokinase from all mammalian 
tissues studied (54, 58, 83). The activation constants for each effector 
+ 
seem to be identical for both major isoenzymes, the KA for K being 
+ 
approximately 17 mM, and for NH4 approximately 0.35 mM (54). Intracellular 
concentrations of K+ in various mammalian tissues vary between 60 and 100 mM 
(84), so that under normal in vivo conditions, phosphofructokinase will be 
fully activated with respect to K+. 
+ Several authors have suggested that NH4 
may be an important regulator of phosphofructokinase activity (e.g. 20, 83, 
85) . 
+ + 
However, pyruvate kinase is activated by both NH4 and K , and it 1s 
thought that they share the same binding site (86). If, in like manner, 
they should share the same binding site on phosphofructokinase, then it is 
. + unl1kely that NH4 would be a physiolog
ically important regulator. 
(iv) FDP 
FDP is perhaps the most potent activator of mammalian 
phosphofructokinase. Lowry and Passoneau (58) reported that the brain 
enzyme was half-maximally activated by only 1 ~M FDP. The enzymes from 
other tissues, including liver (52, 87), heart muscle (65) and kidney 
cortex (60) are also readily activated by FDP. 
(v) F6P 
Although F6P 1s a substrate, and apparently does not have a separate 
allosteric binding site (70), it must be considered to have activating or 
at least deinhibiting properties. It has been reported in many papers 
(56, 58, 59, 60, 88) that increasing the F6P concentration substantially 
reduces the sensitivity of the enzyme to inhibition by ATP, citrate, PEP, 
P-creatine and the phosphoglycerates. 
These molecules constitute the major known activators of 
phosphofructokinase. TI1eir mechanism of action and suggested role 1n 
regulating enzyme activity in vivo will be discussed l ater. 
(b) Inhibitors 
As a preface to this section, it is important to no te that the degree 
of inhibition observed with any given compound is strongl y influenced by 
pH, enzyme concentration, and the presence or absence of other effect or 
molecules, either positive or negative. For this reason, quantitative 
values for ihhibitor constants are perhaps not very meaningful, as different 
workers may have used significantly different conditions of assay. 
(i) ATP 
The first observation that ATP inhibited phosphofructokinase was 
made by Lardy and Parks (89) in 1956. They were uncertain of the mechanism 
involved and thought that it might act simply by chelating the essential 
2+ divalent metal ion, Mg . More recently it has been demonstrated that 
both ATP and MgATP inhibit phosphofructokinase (58, 67). Most studies 
on the regulatory properties of phosphofructokinase from mammalian tissues 
have reported ATP inhibition of the enzyme. Kemp (54) has observed 
differing sensitivities to MgATP inhibition (in his studies, Mg
2
+ was 
always at least 2 mM in excess of the ATP concentration) between the 
liver and muscle enzymes. He suggested that the greater sensitivity of 
the liver enzyme to ATP may be related to the lower concentration of ATP 
found in liver. To avoid subsequent confusion, it must be emphasized 
here that only MgATP will serve as a substrate for phosphofructokinase, 
whilst both MgATP and ATP will act as inhibitors. 
(ii) Citrate 
Citrate was identified as an inhibitor of phosphofructokinase al~ost 
simultaneously in 3 separate laboratories (90, 91, 92). Both Garland e t 
a l (90) and Parmeggiani and Bowman (91) discovered the effect of citrate 
durittg investigations into the regulation of glycolysis in the diabet i c 
rat heart. They observed an inhibition of glycolysis at the locus of 
phosphofructokinase, which was not accompanied by significant changes 1n 
the effector molecules known at that time, i.e. rto 1ncrease 1n ATP or 
decrease in AMP was observed. However, citrate levels rose nearly 3-fold 
in both hearts and livers of diabetic rats (91). Enzyme assays 
demonstrated that appropriate levels of citrate could indeed inhibit 
phosphofructokinase to the expected degree. 
More recent studies have demonstrated that citrate has a differential 
inhibitory effect on the enzyme from different sources (54). Under his 
assay cohditions (54), Kemp found citrate to be approximately six times 
as effective as an inhibitor of the muscle than of the liver enzyme. 
Citrate will inhibit muscle phosphofructokinase when ITP is used as 
phosphate donor instead of ATP (83). This effect has not been reported 
for the liver enzyme. However, at low levels of ATP (0.3 mM), citrate 
is a most effective inhibitor of the liver enzyme. Certainly, 1n the 
presence of physiological concentrations of ATP, citrate may be a potent 
inhibitor of the enzyme from both liver and muscle. 
(iii) Phosphorylated glycolytic intermediates and P-creatine. 
3-PGA, 2-PGA, 2,3-diPGA, PEP and P-creatine have all been reported 
to inhibit phosphofructokinase. Uyeda and Racker (49) reported that both 
P-creatine and PEP inhibited the skeletal muscle enzyme, although the 
reported K. 's were in the millimolar range. Krzanowski and Matchinsky 
1 
(59) examined the effect of all these compounds on phosphofructokinases 
from brain and muscle. In their assay system at pH 7.1, 3-PGA was an 
extremely potent inhibitor of both the brain and muscle enzymes, with a 
K. for both of approximately 0.01 mM. 2-PGA, 2,3-diPGA and PEP also were 
1 
highly inhibitory, all having nearly the same K. for the brain enzyme, 
1 
approximately 0.1 mM. P-creatine inhibited the brain enzyme more strongly 
than the muscle enzyme, the respective K. 's being approximately 1.0 and 
1 
1.5 mM. The inhibitory action of all these compounds was greatly 
potentiated by increasing the ATP concentration, and was reduced by 
increasing the F6P concentration. At pH 8.0, all the inhibitors, either 
singly or together, were ineffective. 
Kemp's work (54) on the isoenzymes from liver and muscle is partly in 
disagreement with the above results. He found P-creatine to be ineffective 
as an inhibitor, while PEP inhibited only the muscle enzyme, and even this 
only slightly (K. > 2 mM). 3-PGA was a relatively stronger inhibitor of 1 
the muscle enzyme (K. < 1 mM) but not of the liver enzyme. In his study 1 
only 2,3-diPGA was a significant inhibitor of the enzyme. Kemp sugges
ted 
that this may mean that the liver and erythrocyte enzymes are very simil
ar, 
a suggestion later verified when he demonstrated that anti-sera to the 
liver enzyme removed 96% of the activity of erythrocyte phosphofructokinase 
(81) . 
(c) Modulation of Fructose-diphosphatase activity by effectors 
of phosphofructokinase. 
Fructose-diphosphatase catalyzes the hydrolysis of FOP to F6P, i.e. 
the reversal of the phosphofructokinase reaction. It 1s found mainly in 
gluconeogenic tissues such as liver and kidney cortex, where its function 
is primarily to provide a means of bypassing the thermodynamically highly 
unfavourable reversal of the phosphofructokinase reaction. It is also found
, 
however, in non-gluconeogenic tissues such as muscle. Although this thesis
 
deals primarily with phosphofructokinase, it would clearly be too simplistic
 
to ignore fructose-diphosphatase entirely. Below will be considered 
briefly some of the properties of muscle fructose-diphosphatase, as 1n this 
tissue the enzyme is considered to be present primarily to increase the 
sensitivity of regulation at the level of F6P phosphorylation (93). 
Fructose-diphosphatase has a K of only 2 ~M for FOP. This ensures m 
that the enzyme will always be active at physiological concentrations of 
substrate. AMP is inhibitory at physiological concentrations (94), 
whilst P-creatine and citrate are stimulatory (95). These effectors are 
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also regulators of phosphofructokinase, but change its activity in the 
opposite manner. ca2+ inhibits phosphofructokinase, but this occurs at 
non-physiological concentrations (58, 96, 97). It has recently been 
demonstrated, however, that ca2+ will also inhibit fructose-diphosphatase, 
at concentrations which are found in working muscle (97). The net effect 
of ca2+ therefore, will be to stimulate glycolysis during muscle work. 
The net effect of phosphofructokinase and fructose-diphosphatase having 
common but oppositely directed effector molecules is to ensure that, 
under any given metabolic state, the activity of one enzyme will 
predominate, without excessive hydrolysis of ATP. 
Newsholme and Gevers (13) have emphasized the increased sensitivity 
conferred on weak effector signals by such a cycling system. From their 
examples, it is clear that small changes in concentration of a single 
effector molecule, which is common to both enzymes, but acts oppositely 
on each of them (i.e. AMP, P-creatine, citrate) will cause a much larger 
change in net flux than could occur in the absence of substrate cycling. 
Newsholme and Crabtree (93) have considered the role of fructose-
diphosphatase in muscle, and concluded that its function is to provide 
cycling at the F6P-FDP locus, which will markedly increase the rate of 
glycolysis through this site when AMP levels rise during work. Clearly 
the effects of P-creatine and citrate could be explained in a similar 
manner. 
(d) Mechanism of action of effector ligands 
In this section, an attempt will be made to explain how the binding 
of effector molecules to phosphofructokinase relates to its observed 
activity patterns. 
It is now clearly established that phosphofructokinase will readily 
associate and dissociate into various species which have molecular weights 
that are integral mult iJllcs of 180,000 daltons (11, SO, 65, 67, 68). At 
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neutral pH, the predominant species are those with molecular weights 
180,000 and 360,000 daltons. At alkaline pH, the enzyme exists in a 
variety of aggregated forms, with molecular weights from 360,000 up to 
several million daltons having been observed. Evidence has accumulated 
which suggests that a major means of regulating phosphofructokinase 
activity in vivo may be by interconverting the active 360,000 dalton 
tetramer with the inactive 180,000 dalton dimer (65, 67). Early work o.n 
the stabilization of purified phosphofructokinase showed that many of the 
activators of the enzyme are stabilizers, whilst some inhibitors may 
cause inactivation (58, 98, 99). It is now thought that those molecules 
which stabilize phosphofructokinase in solution, do so by maintaining 
the equilibrium between the 360,000 dalton tetramer and the 180,000 dalton 
dimer 1n favour of the active form. Before considering in detail the 
means by which association/dissociation may be important as a regulatory 
mechanism, it is necessary to consider what is known about the binding of 
certain key effectors to the enzyme. 
As discussed briefly before, Kemp and Krebs (69) examined the binding 
of various effectors to purified skeletal muscle phosphofructokinase. 
They found that one molecule each of F6P, AMP, cAMP and ADP bound per 
protomer of enzyme, but 3 molecules of ATP bound for the same amount of 
enzyme. AMP, cAMP, ADP and ATP apparently all bound competitively at the 
2-Increasing the pH, or the presence of AMP or P04 , increased one site. 
the affinity of the enzyme for F6P. Conversely, the presence of citrate 
decreased the affinity of the enzyme for F6P, but increased its affinity 
for ATP. On the basis of these results and their own, Paetkau et al (68) 
proposed that each protomer comprised 3 regulatory and 1 catalytic subunits. 
Mansour and coworkers (7(), 71) reported slightly different binding data, 
wh i.ch they fcl t were co11S i stcnt with each protomcr comprising 2 regulatory 
and 2 catalytic subunits. Although it is still not proven which model is 
valid, the following facts are clear: 
(i) each protomer of phosphofructokinase consists of 
catalytic and regulatory subunits; and 
(ii) binding of the substrate F6P is promoted by positive 
effectors, whilst binding of ATP is promoted by the 
negative effector, citrate. 
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Lowry and Passoneau (58), on the basis of purely kinetic experiments, 
suggested the presence of between 7 and 12 binding sites for substrate 
and effector molecules. Their results are difficult to interpret 
quantitatively, however, as some of the data was collected from 
experiments conducted at pH 8.0. At this pH, binding patterns are 
altered considerably from those observed at neutral pH (70). 
Mansour and Ahlfors (65), using the homogeneous sheep heart enzyme, 
have demonstrated that the interconversion of the 180,000 dalton dimer to 
the 360,000 tetramer is promoted by positive effectors. Incubation of 
the ynzyme at acid pH caused dissociation into the inactive form, whereas 
incubation at alkaline pH in the presence of FDP and ATP caused 
reappearance of the active associated form. (Note -- although ATP has 
been considered previously as an inhibitor, it is also a substrate and 
may be considered a positive effector at low concentrations.) 
On the basis of results such as these, several authors have 
suggested a model for phosphofructokinase action, based upon an 
association/dissociation mechanism (65, 67, 100, 101). In essence the 
model states: 
(i) the basic active unit of phosphofructokinase 1s 
the 360,000 dalton tetramer; 
(ii) the active 360,000 dalton tetramer may be 
dissociated to an inactive 180,000 dalton dimer, 
either by lowering the pH, by dilution, or by 
incubation with ncgutivc effectors; and 
(iii) convers1on of the enzyme from the inactive dimer 
back to the basic active unit or to forms of even 
higher molecular weight, may be effected by raising 
the pH, increasing the protein concentration, or by 
incubation with certain positive effectors (see 
Figure 1-1). 
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The binding data of Kemp and Krebs (69), and Mansour et al (70, 71) 
can be explained in terms of this association/dissociation model, i.e. 
(i) there are both substrate and allosteric binding sites 
on phosphofructokinase for MgATP (the absolute numbers 
have not been unequivocally determined); 
(ii) there are only substrate binding sites for F6P; 
(iii) binding of (Mg).ATP to its allosteric sites favours 
dissociation of the enzyme into the inactive form; 
(iv) citrate binding 1ncreases the affinity for (Mg).ATP 
binding to its allosteric site, thus increasing the 
proportion of dissociated enzyme; and 
(v) AMP, cAMP and ADP all compete with (Mg).ATP for 
binding at one of the allosteric sites and their 
binding blocks dissociation. Binding of these 
ligands to an allosteric site on the dissociated 
form of the enzyme causes reassociation, thus their 
apparent stimulatory effect. 
Although unequivocal binding data is available only for the ligands 
considered above, it is reasonable to assume that other effector molecules 
could act in a similar fashion. This model then allows for the division 
of positive effectors into two groups: those which stabilize 
phosphofructokinase, and those which activate the enzyme without 
nccC'ss~l ri ly protecting it from i nacti vat ion. + NH4 appears to belong to 
the latter group (58). Presumably it stimulates the enzyme by some 
entirely separate means, possibly by causing a conformational change 1n 
the active form of the enzyme. 
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At neutral or slightly lower pH, with ATP present at inhibitory 
concentrations, a sigmoidal curve is obtained when activity is plotted 
against increasing F6P concentration. Ahlfors and Mansour (102) have 
shown that photo-oxidation of the enzyme prevents ATP from binding at its 
allosteric sites. In addition, photo-oxidation destroys the sigmoidal 
response to increasing F6P concentration. This suggests that it is the 
binding of ATP to an allosteric site (or sites), which causes the 
sigmoidal response to F6P. As the sigmoidal response is due to cooperative 
interactions between F6P substrate sites, simultaneous binding of the 
two ligands at F6P substrate and ATP allosteric s1tes must be intimately 
involved. Indeed it has been clearly demonstrated that small increases 
in F6P concentration can be most effective in overcoming ATP inhibition 
(e.g. 56, 58). Additional ly, when F6P is added to an ATP-inactivated 
enzyme, a slow increase in activity is observed (101). This would suggest 
that F6P is either directly or indirectly displacing ATP from its 
allosteric site(s). The role of association/dissociation phenomena 1n 
controlling enzyme activity has recently been reviewed by Mansour (103). 
1.4.6 Alteration of in vivo concentrations of effector molecules, 
correlated with changes in phosphofructokinase activity 
In this section, several brief examples will be given of experiments 
which have attempted to correlate changes in effector concentrations with 
altered metabolic flux and changes in phosphofructokinase activity. 
Knowing that ACTH stimulates steroidogenesis, Bell et aZ (104) 
postulated that the increased energy demand for steroid hydroxylation 
upon administration of this hormone, was met by an increase in glycolysis, 
caused by direct activation of enzymes of the pathway. Using crossovers 
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of glycolytic intermediates in frozen rat adrenals as their definition of 
activation of individual enzymes, they reported a considerable increase 
in phosphofructokinase activity within two minutes of intravenous 
administration of ACTH. Concomitant with the increase in 
phosphofructokinase activity, the levels of ATP and citrate fell, whilst 
the levels of AMP and cAMP rose. Clearly the activation of 
phosphofructokinase can be explained by an effector-modulated deinhibition 
of the enzyme. 
Hems and Brosnan (25) measured the levels of glycolytic 
intermediates and other metabolites in rat livers and kidneys, freeze-
clamped at different time intervals during the onset of experimental 
ischaemia. In ischaemic kidneys, glycolytic flux increased four-fold 
(as determined by the increase in lactate) within 30 seconds of severing 
the blood supply. This was accompanied by a crossover which indicated 
stimulation of phosphofructokinase. Concomitantly, ATP levels fell, 
2- + 
whilst those of AMP, P04 and NH4 rose. As discussed earlier (1.4.S(c)), 
AMP inhibits fructose-diphosphatase. Thus, in addition to activating 
phosphofructokinase, the increase in AMP levels will greatly reduce 
substrate cycling, thus further enhancing the stimulatory effect. It has 
not been possible to definitely prove that phosphofructokinase is 
regulatory in the ischaemic liver, as the massive liberation of glycogen 
which accompanies anoxia prevents a crossover being observed. However, 
in the experiment of Hems and Brosnan glycolytic flux increased, and 
changes in the effector molecules of phosphofructokinase similar to those 
found 1n kidney were observed. These changes would be sufficient to 
cause an activation of phosphofructokinase and an inhibition of fructose-
diphosphatase, and can thus explain the increased flux rate to lactate. 
The third example is deliberately chosen because it demonstrates, 
firstly, that activation and inhibition of phosphofructokinase can be 
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difficult to determine by examination of effectors alone and, secondly, 
that phosphofructokinase is not necessarily responsible for controlling 
glycolytic flux rates at all times. 
Greenbaum et al (88) found that when rats were starved for 72 hours, 
hepatic glycolytic flux fell by a factor of 50. However, assay of 
glycolytic intermediates showed a crossover at phosphofructokinase which 
apparently indicated activation. Concomitantly, the levels of ATP and 
+ 
citrate fell, whilst the levels of AMP, cAMP, FOP and NH4 rose. Although 
the changes in effectors were not large, they would certainly support the 
observation that phosphofructokinase was activated, but left unresolved 
the reason for apparent enzyme activation during glycolytic inhibition. 
There is a possible way of reconciling this data. As stated 
earlier (Section 1.4.5(a)) F6P is most effective in overcoming citrate 
inhibition. After 72 hours of starvation, F6P had dropped by 60%, whilst 
the cytoplasmic citrate level remained high enough to become inhibitory 
in the presence of reduced F6P levels (88). Start and Newsholme (105) 
have suggested that this drop in F6P levels may be of great importance 
in the switching of metabolism from glycolysis to gluconeogenesis during 
starvation. Certainly Greenbaum et al (88) found a good correlation 
between the flux rate and the F6P content. 
Phosphohexose-isomerase is a high activity enzyme, so the observed 
level of F6P will be dependent upon the rate at which G6P is formed from 
glucose. During starvation, circulating blood glucose concentrations 
fall, and the supply of glucose and the resulting low glucokinase 
activity become the rate-limiting factors. 
1.5 LYMPHOID TISSUE GLYCOLYSIS 
Of the major mammalian tissues, no systematic study has yet been 
made of the regulation of glycolysis in lymphocytes or 1n solid lymphoid 
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tissues. This om1ss1on 1s puzzling, as it has been reported that 
glycolysis plays a key role during the early stages of lymphocyte 
transformation (106). Although lymphocytes of various sizes are the 
major cell type found in the solid lymphoid organs (thymus, spleen and 
lymph nodes), macrophages and polymorphonuclear leucocytes are also 
present in significant numbers, particularly in the spleen, and it would 
not be surprising if different regulatory patterns were found to be 
associated with altered glycolytic rates in these three cell types. 
Nevertheless, in view of Suter's contention (20) that lymphocytes are 
the cell type principally responsible for the consumption and oxidation 
of glucose by rat spleen slices, the present work was undertaken to 
elucidate: 
(i) whether phosphofructokinase plays a rate-limiting 
role in spleen similar to that demonstrated for 
other mammalian tissues; and 
(ii) whether the allosteric properties of phosphofructokinase 
are so adapted to tissue function, that the lymphocyte 
response to immunological stimulation (increased 
glucose uptake) can be ascribed to its activation. 
In the present work, parallel studies have been conducted on spleen 
and thymus, to enable a direct metabolic comparison to be made between 
the heterogeneous spleen, and the almost homogeneous thymus. 
When small lymphocytes are stimulated by antigen, they undergo 
rapid transformation to blast cells that are capable of division and 
further differentiation. Most studies carried out to date on the 
activation of lymphocytes in vitro have used the plant mitogens 
phytohaemagglutinin (PHA) or concanavalin A (con A) as "antigen analogues". 
These agents cause non-specific stimulation of "resting" small lymphocytes, 
which then undergo a sequence of morphological changes (blastogenesis and 
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subsequent mitosis) that are indistinguishable from those caused in a 
much smaller proportion of the cell population by more highly specific 
antigens or by allogeneic cells. A detailed biochemical description of 
the activation process is not available at the present time, and its 
elucidation constitutes one of the central proble~s of cellular 
immunology. A sketchy outline of the early metabolic events associated 
with mitogen binding can be reconstructed from work reported in the 
literature, and is provided here to give a functional context to the 
experiments described below. 
Among the earliest events which are reported to follow mitogen 
binding to lymphocytes, changes in cyclic nucleotide levels have been 
given most prom1nence, but the evidence available is contradictory: 
cyclic AMP levels have been reported not to change during the first five 
minutes (107), or to increase by up to 300% (108), whilst cyclic GMP levels 
are reported to increase several-fold (107). Membrane-associated events 
such as increased turnover of phosphotidyl inositol (109) and lecithin 
(110) have been correlated, in time, with permeability changes to molecules 
2+ 
as diverse as Ca ions (111), hexoses (112), y-amino butyric acid (113) 
and uridine (114). Within twenty minutes of PHA or Con A addition, 
glycolytic flux to lactate increases 2-3 fold (106) and the new flux rate 
may be sustained for up to 3 days in a simple physiological saline 
medium (184). In contrast to the accelerated glycolysis associated with 
release of respiratory inhibition (Pasteur effect), this effect occurs 
in the presence of undiminished or slightly stimulated respiration (116), 
and is reported to be sensitive to puromycin inhibition (117). Roos and 
Loos (106) have proposed that increased glycolysis is essential for 
lymphocyte tr~nsform:1tion, :1s tiH' tr·:tnsformat]on process is blockeJ when 
both glycolysis and respi r·;~t io11 ;tre inhibited, hut sti 11 occurs if the 
inhibition is directed against respiration alone. Whether increased 
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glycolysis is required to provide energy for the transformation process, 
as is proposed, or whether it merely accompanies the increased glucose 
uptake needed to meet an essential requirement for pentose precursors 
but is not itself essential, is a point worthy of careful experimental 
consideration. Clearly such precursors are required within 24 hours of 
stimulation, as RNA and protein synthesis both reach a max1mum at about 
this time (118), and DNA synthesis, whose onset is delayed for about 48-
72 hours (118), would have a similar requirement. 
The work described in this thesis is part of a continuing, 
collaborative project designed to elucidate the control mechanisms that 
are responsible for changing glycolytic flux in rat spleen and thymus. 
Culvenor (115) and Keig (119), in our laboratory, have used mitogenic 
stimulation of rat thymocytes as a model system to identify possible 
sites of control 1n the glycolytic pathway, whilst Suter (20) has made 
a detailed study of the oxidation of endogenous fuels by the rat spleen 
slice and has examined the way in which the pattern of oxidation 1s 
modified by glucose, lactate, ketone bodies and long-chain fatty acids 
added to the medium. In these experiments certain generalizations have 
been arrived at that apply with equal force to both tissues. (U- 14c)-
glucose, at saturating concentrations (> 5 mM), can account, at most, for 
only 30 - 40% of the oxygen consumption of unstimulated lymphoid tissue, as 
assessed by the percentage dilution of the radioactivity appearing in the 
respired co2 . Because this value has never been observed to exceed 45%, 
even after addition of Con A or phytohaemagglutinin at optimal 
concentrations, or when high concentrations of (u- 14c)-lactate or 
14 (U- C)-pyruvate are used as alternative fuels, Suter (20) has suggested 
that the low activity of pyruvate dehydrogenase limits the rate of 
oxidation of carbohydrate fuels. The reaction catalyzed by this enzyme 
complex appears to be grossly out of equilibrium in lymphoid tissues (20, 120). 
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Acetoacetate, which 1s more readily oxidized than glucose but which 
produces acetyl-CoA independently of pyruvate dehydrogenase, by-passes 
this rate-limiting step and can label up to 70% of the respiratory co2. 
Thus, in the absence of specific activation of pyruvate dehydrogenase, 
the early increase in glucose uptake associated with mitogen stimulation 
is likely to result in lactate formation rather than pyruvate oxidation 
and this is, in fact, the pattern of glucose utilization found when rat 
thyrnocytes and human blood lymphocytes are exposed to phytohaemagglutinin 
(115, 117). 
In contrast, acetoacetate oxidation 1s unchanged when Con A is used 
to stimulate rat thymocytes (121), so the accelerating effect of mitogens 
on energy metabolism appears to be directed at a rate-limiting step in 
the glycolytic pathway that precedes pyruvate dehydrogenase, and that 
does not require a fall in respiration to bring about its activation. 
Results of these experiments will be presented in Chapter 4 of this thesis, 
where their direct bearing on the problem of glycolytic stimulation 1n 
lymphoid tissue and its relationship to the transformation of imrnuno 
competent cells will be discussed. 
1.6 AIMS OF THIS PROJECT 
In view of the possible importance of glycolysis as an energy source 
during the early stages of lyrnphocyte transformation, this project was 
initially planned with three main objectives: 
(i) to systematically determine the regulatory sites of 
glycolysis in rat spleen and thymus, using the 
procedures developed by Newsholme and Gevers (13), 
in a variety of experimental situations designed to 
hring about m~1rkcJ changes in flux; 
(ii) to undertake a partial purification and detailed 
kinetic study of phosphofructokinase from a maJor 
mammalian lymphoid organ (pig spleen) with a v1ew 
to establishing whether there are tissue-specific 
differences in its response to substrates and 
allosteric modifiers that may help to explain the 
relationship between immunological stimulation and 
accelerated glycolysis; and 
(iii) 1n light of this evidence, to consider whether, and 
to what extent, changes in the glycolytic flux 1n 
lymphoid tissues brought about by a variety of 
stimuli can be explained on the basis of the 
allosteric behaviour of phosphofructokinase. 
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Attention has been focused on phosphofructokinase in the present study 
because of its primary role as a glycolytic regulator in other mammalian 
tissues (see Section 1.3.5) and, under certain circumstances, in lymphoid 
tissues (Chapter 2), but this emphasis is not intended to prejudice the 
conclusions arrived at under objective (iii), and presented in the final 
chapter of this thesis. 
CHAPTER 2 
IDENTIFICATION OF THE REGULATORY SITES OF GLYCOLYSIS 
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CHAPTER 2 
IDENTIFICATION OF THE REGULATORY SITES OF GLYCOLYSIS 
2.1 INTRODUCTION 
This chapter 1s devoted to determining the regulatory steps of 
glycolysis in rat spleen and thymus, in accordance with the principles 
discussed in Chapter 1. In addition to methods more commonly used for 
identifying regulatory loci (experimental ischaemia and the use of 
anaesthetics), we have utilized the immunological nature of spleen and 
thymus, and identified regulatory sites by activating lymphocytes either 
by addition of Concanavalin A (Con A) to lymphocyte suspensions, or by 
initiating the Graft-versus-Host reaction in rat spleen in vivo. 
Concanavalin A is a globular protein extracted from the jack bean 
(Canavalia ensiformis), which has the ability to non-specifically 
stimulate "resting" small lymphocytes to undergo blastogenesis and 
subsequently, mitosis. One of the early events which occurs during 
transformation, is a stimulation of glycolysis (117). By measuring 
glycolytic and other intermediates during the first 4 hours of mitogen 
stimulation, it is possible to determine which loci mediate this 
activation process. 
By contrast, the Graft-versus-Host reaction is a very specific 
immunological reaction, in which a graft with very similar but not 
identical genetic composition, reacts against a host, which is itself 
unable to react against the graft. We have conducted this reaction in vivo, 
by injecting splenic lymphocytes from a homozygous parent strain rat (AA) 
into the tail vein of an Fl hybrid (AxB). The "B" component of the host's 
genetic makeup is foreign to the graft lymphocytes and they are 
s t i mtt L1 t t'd. 'l11e g r:t ft I ymplwc y t e s pro 1 i fer a tc within the host's sp 1 cen, 
so by freeze-clamping this organ anJ measuring the levels of intermediates 
within it at different time intervals after injection, it lS possible to 
follow the course of this stimulation. 
2.2 MATERIALS 
Reagents 
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D-Glucose was purchased from B.D.H. Co. Ltd., Poole, U.K. Sodium 
pyruvate (Type II) and cyclic AMP were purchased from the Sigma Chemical 
Co., St. Louis, Missouri. Butyl-PBD was from Koch-Light Laboratories, 
Colnbrook, U.K., whilst inulin-(carboxylic acid- 14c) was obtained from 
the Radiochemical Centre, Amersham, England. Adenine nucleotides, 
pyridine nucleotides and all substrates we }~e purchased from Boehringer 
Mannheim Gmbh, West Germany. Glyceraldehyde-3-P was obtained as the 
diethylacetal derivative, and glyceraldehyde-3-P was released according 
to the manufacturer's instructions. The r~sulting solution was adjusted 
to pH 6.0 with KHC0 3, then frozen at -20°C. Under these conditions, the 
compound was stable for approximately one week. All other chemicals used 
were of the highest purity available. 
Enzymes 
Hexokinase was obtained from either the Sigma Chemical Co. (Type III) 
or from Boehringer Mannheim. All other e·1zymes were from Boehringer 
Mannheim. 
Animals 
Outbred male albino Wistar rats we~ ·e used in all experiments unless 
indicated otherwise. They were obtained from the John Curtin School of 
Medical Research, A.N.U., at 3 weeks of 1ge, and reared in this Department 
until used at 8 - 10 weeks of ~ge. They were given food (Rural Rat and 
Mouse Cubes, Wagga Wagga, N.S.W.) and wcter ad libitum unless otherwise 
indicated. Lighting was maintained on c strict 12 hr. day:l2 hr. night 
regime, and the termperature was thermo :. tatically controlled at a constant 
25°. 
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2.3 :METHODS 
2.3.1 Preparation of tissue extracts for enzyme assays 
Spleen 
Animals were killed by cervical dislocation and their spleens 
removed. These were finely minced with scissors, then dispersed in 3 
I 
volumes of a buffer containing 50 mM Triethanolamine-HCl, 3 mM EDTA and 100 
mm KCl, and adjusted to pH 7.5 with SN KOH. This suspension was 
homogenized with ten up-and-down strokes in an ice-cooled Teflon glass 
tissue homogenizer (type B- A.H. Thomas, Philadelphia, U.S.A.). The 
homogenate was centrifuged for 30 minutes at 40,000 x g (4°C) in a Sorvall 
RC2B centrifuge, and the resultant supernatant decanted and used for 
enzyme assay immediately. It was found during the course of this work, 
that glyceraldehyde-3-phosphate dehydrogenase was extremely labile, and 
showed no activity after the preparative procedure described above. To 
enable a realistic assessment of its activity to be made, it was decided 
to forgo the centrifugation described above, and instead, to centrifuge 
the homogenate for only 2 minutes in an Eppendorf Microfuge at 5,000 x g. 
It was thus possible to assay the activity of this enzyme within 5 minutes 
of killing the animal. 
Thymus 
Animal~ were killed as before and their thymi removed. These were 
minced coarsely, then homogenized with 2 volumes of buffer and centrifuged 
as described above. The pellet was dispersed in buffer, and samples were 
examined for surviving whole cells by light microscopy. It was estimated 
that by this method, 95% or more of the cells were disrupted. 
Glyceraldehyde-3-phosphate dehydrogenase was labile in this tissue also, 
an<..I was prepared in the s~1mc way as the spleen enzyme. 
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2.3.2 Assay of enzyme activities 
All assays were conducted on a Zeiss PMQII spectrophotometer, with a 
Beckman recorder attached. The basic assay buffer contained 50 mM 
Triethanolamine, 1 mM EDTA and 10 mM MgC1 2, adjusted to pH 7.2 with SN 
KOH. This pH 1s lower than that used in comparable studies (e.g. 21, 22). 
It was chosen because, 
(i) it is a more physiological pH, and should give a truer 
indication of possible in vivo activities, and 
(ii) any regulatory properties that the individual 
enzymes may possess, will be seen more easily 
at this lower pH. 
All enzymes were assayed by coupling product formation to a 
reaction which involves the oxidation or reduction of one of the pyridine 
nucleotides. This enables the enzyme activity to be measured by following 
the change in optical density recorded at wavelength 340 n.m. For all 
assays, reactions were initiated by adding enzyme extract to cuvettes of 
1 cm light path, containing a final assay volume of 3.1 mls. For each 
enzyme, substrate concentrations were chosen to give maximal velocities. 
Besides the basic assay buffer, the following additions were made; 
for Hexokinase determination: 
0.5 mM glucose, 1.2 mM ATP, 3.0 U glucose-6-phosphate 
+ dehydrogenase, and 0.2 mM NADP ; 
Glucose-6-phosphate dehydrogenase: 
+ 0.8 mM G6P and 0.2 mM NADP ; 
Phosphohexose isomerase (back reaction only): 
1.3 mM F6P, 3.0 U glucose-6-phosphate dehydrogenase 
+ 
and 0.2 mM NADP ; 
Phosphofructokinase: 
3.1 mM F6P, 1.1 ~~ ATP, 2.5 U aldolase, 7.0 U triose-
phosphate isomerase, 2.0 U a-glycerophosphate 
dehydrogenase and 0.1 mM NADH; 
Aldolase: 
1.0 mM FDP, 7.0 U triose-phosphate isomerase, 
2.0 U a-glycerophosphate dehydrogenase and 
0.1 mM NADH; 
Triose-phosphate isomerase: 
0.8 mM glyceraldehyde-3-phosphate, 4.5 U 
a-glycerophosphate dehydrogenase ~nd 0.1 mM NADH; 
Glyceraldehyde-3-phosphate dehydrogenase: 
0.5 mM glyceraldehyde-3-phosphate, 12 mM arsenate 
+ 
and 0.2 mM NAD ; 
Phosphoglycerate kinase (back reaction only): 
3.1 mM 3-PGA, 1.6 mM ATP, 3.5 U glyceraldehyde-3-
phosphate dehydrogenase and 0.1 mM NADH; 
Phosphoglycerate mutase: 
1.7 mM 3-PGA, 2.3 mM ADP, 0.5 mM 2,3-diPGA, 
4.0 U enolase, 4.6 U pyruvate kinase, 4.0 U lactate 
dehydrogenase and 0.1 mM NADH; 
Enolase: 
1.7 mM 2-PGA, 2.3 mM ADP, 4.6 U pyruvate kinase, 
4.0 U lactate dehydrogenase and 0.1 mM NADH; 
Pyruvate kinase: 
2.0 mM PEP, 2.3 mM ADP, 4.6 U lactate 
dehydrogenase and 0.1 mM NADH; 
Lactate dehydrogenase: 
3.0 mM pyruvate and 0.1 mM NADH. 
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Usually between 20 and 50 vL of enzyme solution was used . In most 
cases this gave optical density changes between 0.05 and 0.30/minute. 
For triose-phosphate 1somerase, either 2 or 5 vL was added to initiate 
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the reaction. The enzy~es were tested at at least 2 extract 
concentrations and in all cases except phosphofructokinase, the observed 
activity was proportional to the concentration of extract added. The 
deviation from linearity with phosphofructokinase was of the order of 25%. 
The higher activity is reported in this study. The problem of non-linearity 
1s considered in more detail in Chapter 3. 
2 . 3.3 
The following points should be noted 1n relation to this study: 
(i) all buffers used were pH-adjusted with KOH. This 
ensured that K+ was saturating, which is supported 
by the observation that neither pyruvate kinase 
nor phosphofructokinase showed any activation if 
+ 
more K was added; and 
(ii) although 2,3-diPGA was added for the phosphoglycerate 
mutase reaction, it increased activity by only 10 -
20%. Clearly the tissue extract or substrates 
added contained enough of this cofactor to ensure 
maximal activity. 
Freeze-clamping 
In order to determine the in vivo concentrations of glycolytic and 
other intermediates, the technique of freeze-clamping was used (19). 
Animals were killed by cervical dislocation and either their spleens or 
thymi were rapidly removed. The organ was immediately crushed between 
aluminium tongs precooled to -180° in liquid nitrogen. On average, 
spleens were frozen within 5- 10 seconds of the animal's death, thymi 
within 10 - 15 seconds. The frozen tissue was quickly weighed and 
immediately transferred to a porcelain mortar containing liquid nitrogen. 
Pcrcltloric acid (3 ml of 12%) was added dropwise to the mortar and the 
frozen material ground to a powder and transferred quantitatively into an 
ice-cooled Teflon glass tissue homogenizer (A.H. Thomas, Philadelphia, 
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U.S.A.). The tissue was homogenized with ten up-and-down strokes as the 
material began to thaw. The homogenate was transferred quantitatively 
into 15 ml Corex centrifuge tubes and centrifuged at 45,000 x g for 15 
minutes to remove the protein pellet. The pellets were dried for 16 hr. 
at 125° and weighed to determine the dry weight of perchloric acid-treated 
starting material. 
The supernatants were decanted into graduated 10 ml stoppered tubes 
and adjusted to approximately pH 5.5 with K2co3 (5M) using one drop of 
"Universal" indicator. The tubes were centrifuged at 27,000 x g for 10 
minutes to remove the precipitated KC104 . The supernatants were decanted 
and used immediately for assays of the unstable intermediates, or were 
stored at -180° under liquid nitrogen. The results are expressed on a 
fresh weight basis, using the dry weights of the individual samples, and 
a conversion factor determined by subjecting control spleens to an 
identical perchloric acid extraction step prior to drying. 
2.3.4 Analytical methods 
Concentrations of all intermediates and cofactors were determined 
enzymatically using a Zeiss PMQII spectrophotometer, or a Zeiss PMQII 
spectrofluorimeter with ZFM4 fluorescence attachment. Glucose (122), 
glycogen (123), lactate (124), ammonia (125), ATP (126) ·, ADP and AMP (127) 
and inorganic phosphate (128) were determined spectrophotometrically us1ng 
published methods. Pyruvate (129), the hexose-monophosphates (130), the 
triose-phosphates and FOP (131), and the phosphoglycerates and PEP (129) 
were determined fluorimetrically, using suitable adaptations of published 
methods (115). 
2.3.5 Determination of the extracellular space 
Clearly the entire mass of an organ is not composed solely of the 
intracellular space of the cells within it, membranous tissues and 
the blood vessels supplying the organ will occupy a finite portion of 
th~1t mas s . There arc two major re;Jsons why an accurate assessment of the 
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extracellular space is important: 
(i) it enables an accurate estimate to be made of the 
intracellular concentrations of the various 
intermediates, and 
(ii) it enables an estimate to be made of the 
intracellular concentration of those metabolites 
which are found both intracellularly and in the 
circulating plasma, e.g. glucose and lactate. 
Williams and Woodbury (132) have determined the extracellular space 
of rat liver, using inulin. Inulin is a polysaccharide molecule which 
penetrates cell membranes with great difficulty. When radioactive inulin 
is injected into an animal intravenously, and time is given for it to 
diffuse freely through the extracellular fluid, then by comparing the 
amount of label within the tissue with the concentration of label 
circulating in the blood plasma, an estimate can be made of the 
extracellular space within the tissue. 
We have used the method of Williams and Woodbury (132), to estimate 
the extracellular spaces of spleen and thymus. 
(a) Preparation of tissue samples 
Bilateral nephrectomies of ether-anaesthetized animals were 
performed by Dr P. McCullagh of the John Curtin School of Medical Research, 
A.N.U. Four hours after the operation, experimental animals were injected 
"th o 5 1 f ·1 o 85° N c1 · · 3 c· f 14c · 1· · w1 . m o ster1 e . ?a a , conta1n1ng ~ 1 o -1nu 1n, v1a a 
cannula which had been inserted into the femoral vein at the time of 
operation. Animals were killed 30 - 60 minutes later, by stunning and 
subsequent severance of the carotid artery. 
Blood was collected in heparinized tubes and centrifuged for 10 
minutes at 16,000 x g. Plasma was separated from the cell pellets, and 
0.03 rnl volumes were digested for 15 hours in l.OM piperidine at 60°. 
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Spleens, thymi and livers were removed from each animal and blotted 
gently before weighing. Samples were dried to constant weight to allow 
determination of total tissue water. Samples from spleen, thymi and 
livers (0.2 - 0.5 g) were digested in l.OM piperidine for 30 hours at 60°. 
(b) Determination of radioactivity 
Samples of the spleen, thymus, liver and plasma digests were mixed 
with 10 mls of scintillation fluid (toluene:methoxyethanol:butyl-PBD; 
600 ml:400 ml:6 g), placed in glass scintillation vials and counted in a 
Packard Tri-Carb Liquid Scintillation Counter (Model 3375) until total 
counts reached at least 10,000. Corrections were made for quenching, and 
the values were converted to disintegrations per minute, by comparison 
with a 14c-n-hexadecane standard. 
(c) Calculation of the extracellular space 
The inulin space was calculated from the following formula: 
Inulin space (%) = d.p.m./g. wet wt. x 0.92 
d.p.m./ml. plasma 
X lOO· 
' 
where 0.92 1s a correction for the difference in water concentration in 
plasma and extracellular fluid due to the higher protein level in the 
former. Hence the inulin space represents the percentage of tissue 
weight in which inulin was distributed at a concentration similar to that 
found in the plasma. 
(d) Metabolite concentrations 1n rat plasma 
These determinations were made by Mrs G. Keig. Blood was collected 
into heparinized tubes and plasma separated from cells by centrifugation 
at 800 x g in the cold. Very little or no haemolysis was evident in any 
of the samples. Plasma samples were prepared for assay as described 1n 
Section 2.3.3. The only metabolites of which significant quantities were 
found in plasma, were glucose, pyruvate, lactate, phosphate and ammonia. 
The values quoted in the Results section have a l l been corr ected for 
these intermediates. 
(e) Calculations of intracellular met abolite concentr ations 
Intracellular concentrations of glycolytic i ntermediates, adenine 
nucleotides, inorganic phosphate and ammonia in rat spleen and thnnus 
were calculated in the following manner: 
(i) The extracellular concentration of a particular 
metabolite was assumed to be equal to its 
concentration in plasma. Then, 
(ii) Extracellular metabolite (n. moles/g. wet wt. ) = 
extracellular metabolite concentration (n. moles/ml 
extracellular water) x volume of extracellular 
water (ml/g. wet wt.). 
(iii) Intracellular metabolite (n. moles/g. wet wt.) = 
total tissue metabolite (n. moles/g. wet wt.) -
extracellular metabolite (n. moles/g. wet wt.). 
(iv) Intracellular metabolite concentration (n. moles/ml 
intracellular water) = intracellular metabolite 
(n. moles/g. wet wt.) ~ volume of intracellular 
water (ml/g. wet wt.). 
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The total metabolite concentrations 1n spleen and thymus were obtained 
from freeze-clamping experiments, as described in Sections 2.3.3 and 2.3.4 . 
2 . 3.6 Preparation and incubation of thymocytes for meas urement of 
Concanavalin A-stimulation 
Thymi were removed from 7-week old male albino Wistar rats, we i ghed, 
then teased apart with 22-gauge needles in Petri dishes containi ng a small 
amount of Krebs and de Gasquet buffer , pH 7 .4 (133) . Lar ge debr is was 
rt'movcd h y spinning 1n u be n ch ccntri l- l l 1~l' for ~0 second s :Jt SO x g, then 
the supl'rn ~ tt ant s wer e centri fugcd for 7 minu t es a t 800 x g to pellet the 
48 
thymocytes. These were resuspended in buffer with a Pasteur pi pet te , 
pooled, and after counting in a haemocytometer, were di luted with buffer 
to the appropriate concentrations. 
Cells were incubated in 25 ml Erlenmeyer flasks with rubber stopper s , 
at final concentrations of 108 cells/ml in 5 mls of buffer, in the 
presence of 5 mM glucose. After gassing with oxygen for 30 seconds, cells 
were incubated at 37° in a shaking water bath. After a one hour 
preincubation at 37° to allow complete equilibration, experiments were 
commenced. Zero time samples were taken at the time of addition of 
Concanavalin A. The final concentration of mitogen in Concanavalin A-
treated suspensions, was 20 ~g/10 7 cells. 
At the end of the incubation period, 0.5 ml of ice-cold 3N perchlori c 
acid was added. After standing on ice for at least 30 minutes, the 
contents of the flasks were transferred to 15 ml Corex centrifuge tubes 
and centrifuged for 15 minutes at 35,000 x g in a Sorvall RC2B centrifuge. 
The supernatant was treated as described in Section 2.3.3 for preparing 
the intermediates. Subsequent assays were performed as in Section 2.3.4. 
2.4 RESULTS 
2.4.1 Determin~tion of the extracellular spaces 
All the calculations reported in this section were made by Mrs G. 
Keig. Although interested primarily in the results for spleen and thymus, 
the liver space was also determined to permit comparison with published 
results. The one-hour inulin space for rat liver was calculated to be 
18.4%. By contrast, Williams and Woodbury (132) reported a space of only 
10%, whilst White and Rolf (134) reported a space of 14.3%. 
The higher value of 18.4% obtained 1n the present study can be 
attributed to the different methods used for drawing blood and killing the 
animals. White and Rolf (134) withdrew blood from the heart (presumably 
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under ether anaesthesia) and described the organs removed for analysis 
as "almost bloodless". Williams and Woodbury (132) withdrew blood from 
the terminal aorta after ether anaesthesia, and reported a low residual 
blood volume. However, ether anaesthesia has been found to alter the 
distribution of water between the plasma and extracellular compartments 
(135), and this introduces a source of error into isotope dilution studies 
(136) . 
The one hour inulin space for rat spleen was calculated to be 17.2%. 
There was more variation in the spleen inulin spaces of the six animals 
than in the liver inulin spaces. This must be attributed to variations 
in the amount of residual blood in the individual spleen samples. The 
connective tissue framework of the spleen collapses upon death, compressing 
the red pulp, and forcing blood out of the venous sinusoids (137). For 
this reason, a more marked variation between animals for spleen inulin 
spaces would be expected as a result of differences in the times taken 
for removal of the spleen and preparation of samples. These differences 
would lead to varying amounts of blood loss from the red pulp. 
The one hour inulin space for rat thymus was calculated to be 12.4%. 
As the intravescular space of the thymus is only about one-fifth that of 
the spleen (138), it is to be expected that its inulin space would also 
be smaller. 
2.4.2 Maximal enzyme activities in vitro 
In Tables 2.1 and 2.2, the maximal activities of glycolytic and 
related enzymes in rat spleen and thymus are shown. It is evident that 1n 
both tissues hexokinase, phosphofructokinase, aldolase and glucose-6-
phosphate dehydrogenase have much lower activities than the other enzymes. 
Suter, however (20), has shown that the rnaxirnllJll activity of each of these 
low activity enzymes is :tpproxim;t1"<.'ly 10 times gre;ttcr th :tn the maximal 
rate of glucose uti.li.zatjon observed in incubated spleen s lices . Cl early 
Table 2.1 
Enzyme activities 
ENZYME 
Hexokinase 
Phosphohexose-Isomerase 
(back) 
Phosphofructokinase 
Aldolase 
Triose-phosphate Isomerase 
Glyceraldehyde-3-
phosphate dehydrogenase 
Phosphoglycerate kinase 
(back) 
Phosphoglycerate mutase 
Enolase 
Pyruvate kinase 
Lactate dehydrogenase 
Glucose-6-phosphate 
dehydrogenase 
Fructose-diphosphatase 
Maximal activities of glycolytic and related enzymes in rat spleen 
are expressed as ~ moles substrate converted/min/g fresh wt at 23°, 
The number of determinations are given in parentheses. 
Km ACTIVITY 
c~ M) (fed) 
<20 (glucose) 0.8+0.1 (6) 
-
105 (back) 31.5+1. 3 (5) 
-
45 (ATP) 
130 (F6P) 1.6+0.1 (8) 
-
15 1.6+0 . 2 (6) 
183 +6 (3) 
15.8+0.3 (3) 
110 (back) 64.9+2.8 (5) 
-
215 39.3+1.9 (5) 
-
100 13.1+0.8 (6) 
-
30 (PEP) 45.8+0.8 (7) 
-
125 89.5+2.7 (7) 
-
40 6.8+0.6 (6) 
0.2 (3) 
+ S.E.M. 
ACTIVITY 
(fasted 72 hr) 
0.8+0.1 (5) 
-
26.9+1.0 (6) 
-
1.3+0.1 (6) 
-
1.4+0.1 (5) 
64.0+2.1 (6) 
-
39. 7+ 1. 5 (6) 
-
14.1+0.8 (6) 
-
47.4+1.2 (5) 
-
84.2+2.4 (7) 
-
6.3+0.2 (5) 
Vl 
0 
Table 2-2 
Maximal activities of glycolytic and related enzymes in rat thymus 
Enzyme activities are expressed as in Table 2-1. 
ENZYME 
Hexokinase 
Phospho-hexose Isomerase (back) 
Phosphofructokinase 
Aldolase 
Triose-phosphate isomerase 
Glyceraldehyde-3-phosphate dehydrogenase 
Phosphoglycerate kinase (back) 
Phosphoglycerate mutase 
Enolase 
Pyruvate Kinase 
Lactate dehydrogenase 
Glucose-6-phosphate dehydrogenase 
Fructose-diphosphatase 
ACTIVITY 
(Fed) 
1.0 + 0.1 (4) 
30 . 8 + 4 . 0 ( 4) 
2.2 + 0.1 (4) 
1.1 + 0.1 (4) 
104.2 + 8.2 (3) 
21.0 + 0.5 (3) 
49.9 + 3.0 (4) 
38.5 + 1.3 (4) 
18.7+2.2 (4) 
38.7 + 2. 3 (4) 
73.8 + 9.0 (4) 
3.1 + 0.1 (4) 
0 (4 ) 
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no enzyme of this series 1s rate-limiting with respect to its maximum 
activity. In addition to their low maximal activities, hexokinase, 
phosphofructokinase and glucose-6-phosphate dehydrogenase all catalyze 
reactions at sites that are teleologically advantageous for regulation. 
In Figure 2-1, the data in Tables 2-1 and 2-2 is expressed in 
diagramatical form. This layout emphasizes the low activities of both 
hexokinase and phosphofructokinase, and the potential they may possess 
for causing "bottle-necks" in flux. 
52 
It is interesting that a very low fructose-diphosphatase activity 
can be measured in spleen. Shonk and Boxer (22) also found a measurable 
activity for this enzyme. Suter, however (20), observed that after 
incubation of spleen slices with radioactive pyruvate or lactate, only 
very low levels of labelled glucose were recovered. It may well be that 
fructose-diphosphatase exists in spleen as it does in muscle (93), to 
provide substrate cycling between F6P and FDP, thus enhancing flux 
through phosphofructokinase when AMP levels rise. 
Table 2-1 also presents data showing the effect of 72 hours of 
starvation on the maximal activities of the glycolytic enzymes. Although 
several of the changes approach significance at the 5% level, it is 
evident that spleen and thymus metabolism too, is rather insensitive to 
dietary manipulation. Even fasting and refeeding (data not shown) caused 
little change. 
2.4.3 Identification of non-equilibrium reactions 
In Tables 2-3 and 2-4 the in vivo, intraceZZuZar concentrations of 
intermediates in rat spleen and thymus are listed. Those intermediates 
of which significant quantities were found in plasma (see Section 2.3.5(d)) 
have been corrected to allow determination of their intracellular 
concentrations. 
Figure 2-1 Max1mal activities of glycolytic enzymes 
(a) Spleen 
(b) Thymus 
Enzyme activities were drawn from Tables 2-1 and 2-2. Activities 
represent the forward reactions unless indicated by dashed lines. For 
reference, the activity of spleen hexokinase is 0.8, and thymus 
hexokinase 1.0 ~moles substrate converted/min ./g. fresh wt., at pH 7.2. 
KEY 
I. Hexokinase 
2. Phosphohexose 1somerase 
3. Phosphofructokinase 
4. Aldolase 
5. Triose phosphate isomerase 
6. Glyceraldehyde-3-phosphate dehydrogenase 
7. Phosphoglycerate kinase 
8. Phosphoglycerate mutase 
9. Enolase 
10. Pyruvate kinase 
11. Lactate dehydrogenase 
12. Glucose-6-phosphate dehydrogenase 
13. Fructose-diphosphatase 
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Table 2-3 
The in vivo concentrations of glycolytic and other intermediates 
found in the spleen of the well-fed rat 
The intermediates were assayed in extracts prepared from the 
freeze-clamped tissues as described in the text. The concentrations 
are expressed as n. moles/m! intracellular water. All results are 
the means + S.E.M. of at least 10 values. 
INTERMEDIATES CONCENTRATION 
Glucose (extracellular) 6671 + 4S8 
Glucose (intracellular) 1230 + 111 
Glucose-6-phosphate 160 + 6 
Fructose-6-phosphate 4S + 1.8 
Fructose-!, 6-diphosphate 23.8 + 1.4 
Triose-phosphates ss + 4 
3~phosphoglycerate 64 + 14 
2-phosphoglycerate 9.7 + 0.4 
Phosphoenol pyruvate 22.S + 0.6 
Pyruvate 81 + 6 
Lactate 8S4 + 180 
ATP 4347 + 181 
ADP 1181 + 37 
AMP 149 + 13 
Pi 389S + 103 
NH4 
+ 896 + 77 
Citrate 213 + 24 
55 
Table 2-4 
The in vivo concentrations of glycolytic and other intermediates 
found in the thymus of the well-fed rat 
The intermediates were assayed in extracts prepared from the 
freeze-clamped tissues as described in the text. The concentrations 
are expressed as n. moles/ml intracellular water. All results are 
the means + S.E.M. of at least 8 values. 
INTERMEDIATES CONCENTRATION 
Glucose (extracellular) 6710 + 458 
Glucose (intracellular) 720 + 204 
Glucose-6-phosphate 33.1 + 6.6 
Fructose-6-phosphate 10.9 + 1. 1 
Fructose-1, 6-diphosphate 41.0 + 7.4 
Triose-phosphates 37.6 + 7.1 
3-phosphoglycerate 38.9 + 7.5 
2-phosphoglycerate 7.8 + 2.1 
Phosphoenol pyruvate 11.5 + 2.5 
Pyruvate 89.8 + 31 
Lactate 2155 + 255 
ATP 3980 + 184 
ADP 1482 + 85 
AMP 289 + 20 
Pi 3261 + 182 
+ 1326 + 113 NH4 
Citrate 245 + 10 
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In Table 2-5 the mass action ratios for the glycolytic enzymes in 
spleen and thymus, and their apparent equilibrium positions are presented. 
For ease of identification of enzymes catalyzing non-equilibrium 
r 
reactions, the ratio K' has been used. The significance of this ratio 1s 
as follows: 
r 
K' 
r 
= 1, 
- > K' 1, 
r 
K' < 1, 
reaction at equilibrium. 
reaction 1n favour of products. 
reaction 1n favour of reactants. 
It is clear that in both tissues phosphohexose-isomerase, phosphoglycerate 
mutase and enolase catalyze equilibrium reactions in the unstimulated, 
well-fed rat, whilst the hexokinase, phosphofructokinase and pyruvate 
kinase reactions are significantly displaced from equilibrium. The 
reaction catalyzed by aldolase is also out of equilibrium, but to a lesser 
degree. Estimation of the intracellular and extracellular concentrations 
of glucose, show that the glucose carrier is in the intermediate range 
r (0.05 < K' < 0.20) that Rolleston (15) considers separates non-equilibrium 
from equilibrium reactions. 
Several of the mass-action ratios were calculated by indirect means. 
It 1s not possible to measure quantities of 1,3-diPGA in these tissues, 
so it is not possible to determine separate mass-action ratios for 
glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase. 
Instead, a combined mass-action ratio for these two reactions has been 
calculated. However, even this value is based upon an assumption as only 
total triose-phosphates were measured, without differentiating between 
dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. Triose-phosphate 
Table 2.5 Comparison between mass-action ratios and equilibrium constants for the reactions of glycolysis in spleen and thymus 
Mass-action ratios were calculated from the concentrations of intermediates given in Table 2.4. 
Intracellular phosphate was assumed equal to 60% of the measured value (153). 
Triose-phosphate isomerase was assumed to be at equilibrium with a value of 0.0408 for its apparent equilibrium constant. 
Apparent equilibrium constants were taken from the literature quoted, and a mean determined for those considered most reliable. 
Enzyme Reaction 
Glucose transport 
Hexokinase 
Phosphohexose isomerase 
Phosphofructokinase 
Aldolase 
Glyceraldehyde-3-phosphate 
dehydrogenase + phospho-
glycerate kinase 
Phosphoglycerate mutase 
Eno lase 
Pyruvate kinase 
Lactate dehydrogenase 
Adenylate kinase 
Ratio used 
[Glucose]. 1n 
[Glucose] t ou 
[G6P]IADP] 
illn 
TG6PT 
(G3P](DHAP] 
(FDP] 
(NADH)(3PGA)(ATP] 
[NAD+][G3P][ADP][Pi] 
+ 
fLactate]fNAD ] 
Pyruvate [NADH] 
[ATP][jf] 
[ADP 
Apparent 
equilibrium 
constant 
(K I) 
1.0 
4700 
0. 41 
1003 
9.6 X 10 -5 
59 
0.149 
2.93 
17,900 
11,100 
0.44 
Source 
151 
28,152 
28,152 
28,152,154 
28,152,155 
156 
28,152,155 
28,152,155 
28,152 
157 
158 
Spleen 
mass-action 
ratios 
observed (r) 
0.184 
-2 3.53 X 10 
0.281 
0.144 
4.8 X 10-6 
2 1. 09 X 10 
0.151 
2.32 
13.3 
0.46 
r 
Spleen K' 
0.184 
7.5 X 10-6 
0.686 
1.43 X 10- 4 
5.0 X 10-2 
1.85 
1. 01 
0.79 
7.4 X 10- 4 
Thymus 
mass-action 
ratios 
observed (r) 
0.107 
1.7 X 10- 2 
0.329 
1.40 
1.35 X 10 -4 
55.6 
0.201 
1.47 
21.0 
assumed at equilibrium 
1. 06 0.524 
r 
Thymus K' 
0.107 
3.64 X 10 -6 
0.803 
1.4 X 10- 3 
1.4 X 10- 2 
0.94 2 
1. 35 
0 .503 
1.17 X 10 -3 
1.19 
l,., 
~ 
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isomerase 1s the most active enzyme in both of these tissues, and if it 
is assumed to be at equilibrium (154), the concentrations of the individual 
triose-phosphates can be calculated. This in turn enables the calculation 
of mass-action ratios for the combined glyceraldehyde-3-phosphate 
dehydrogenase/phosphoglycerate kinase reactions, and for aldolase. The 
value of the free NAD+/NADH ratio for the cytoplasmic compartment was 
calculated from the lactate/pyruvate ratio, on the assumption that the 
lactate dehydrogenase reaction is sufficiently active to maintain 
equilibrium. 
Figure 2-2 shows the free energy changes for the individual reactions 
of glycolysis in both spleen and thymus. Values of ~G were calculated 
from the mass-action ratios and apparent equilibrium constants in Table 
2-5, by the following relationship derived from Morris (139). 
~G = ~Go + R.T. ln r. 
and since ~G 0 = - R.T. ln K', 
K' 
= - R.T. ln (y-) K. cals./mole, 
where ~G =free energy change at 37°, and pH assumed to be 7.0, 
R =universal gas constant (1.987 cal./mole degree), 
and T = temperature, degrees absolute. 
Most of the free energy change during glycolysis occurs in both tissues 
at the reactions catalyzed by hexokinase, phosphofructokinase and 
pyruvate kinase. In addition, significant changes in free energy occur 
during glucose transport and at the reaction catalyzed by aldolase. 
Figure 2-2 Relative free energy changes during the conversion 
of glucose to lactate, in spleen and thymus 
~G values were calculated as indicated in the text. 
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2.4.4 Identification of regulatory sites 
(a) Effect of ether anaesthesia 
Anaesthetisation of experimental animals with diethyl ether 
significantly changed the metabolite profiles in freeze-clamped spleens, 
when compared with those from animals killed by cervical dislocation 
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(Table 2-6). The levels of glucose, glycogen and all the adenine 
nucleotides fell significantly, whilst the level of lactate increased by 
80%. Clearly glycolysis has been stimulated. Using Krebs' principle (18) 
that a change in the substrate concentration of a non-equilibrium enzyme, 
1n the opposite direction to the net flux down that pathway is indicative 
of a regulatory role for that enzyme, it is apparent that hexokinase and 
phosphofructokinase are regulatory enzymes under these conditions. 
Although the concentration of PEP has also dropped, the difference 
observed is not statistically significant so pyruvate kinase cannot be 
positively identified as regulatory. Strictly speaking, it is not possible 
to positively identify hexokinase as regulatory either, as our measurements 
do not differentiate between intracellular glucose (i.e. the real 
substrate) and extracellular glucose. This data is presented in the form 
of a cross-over diagram in Figure 2-3. 
(b) Effect of experimental ischaemia 
Table 2-6 also contains information showing how the levels of 
glycolytic intermediates and other metabolites change during the onset of 
experimental ischaemia. Perhaps the most striking fact in this study is 
the delay before the metabolic consequences of oxygen deprivation become 
apparent. When the blood supply is severed, the tissue is entirely 
dependent on endogenous substrates for its energy supply. As the oxygen 
level drops, ATP supply comes primarily from glycolysis, and the rate of 
flux through this pathway increases enormously. Hems and Brosnan (25) 
found th onset of ischaemia in liver and kidney to be comparatively rapid, 
Time 
after 
cutting 
vessels 
(min.) 
0 
0 
5 
10 
15 
Table 2.6 Concentrations of glycolytic and other intermediates 1n the spleen of well-fed rats during ether anaesthesia 
and during the onset of ischaemia 
The intermediates were assayed in extracts prepared from the freeze-clamped tissue as described 1n the text. 
Treatment 
of 
animal 
Ether 
anaesthesia 
Cervical 
dislocation 
Cervical 
dislocation 
Cervical 
dislocation 
Cervical 
dislocation 
Glue. Glyc G-6-P 
· (Total) 
2334 1469 78 
+504 +180 +15 
3390 2108 97 
+280 +180 + 4 
2930 1686 75 
+210 + 46 + 3 
3070 1183 19 
+290 +204 + 1. 2 
1840 900 
+410 +110 
- -
The concentrations are expressed as n moles/g fresh wt. 
All results are the means + S.E.M. of at least 5 values. 
F-6-P FOP TP 3PGA 2PGA PEP Pyr. Lac. a GP ATP 
12 36 58 11 3 12 136 1545 51 1722 
+6 +14 +23 +13 +4 +7 +49 + 170 +18 +219 
27 14 33 39 7 14 81 854 96 2619 
+0.9 + 0.7 + 2 + 7 +0.4 +0.4 + 6 + 180 + 4 + 94 
22 9 28 31 8 9 68 1612 114 2148 
+0.3 + 1 + 2 + 3 +1 +1.2 + 7 + 31 + 7 + 60 
6 32 68 33 11 12 61 4590 349 1169 
+0.5 + 5 +10 + 4 +0.6 +1 + 2 +1288 +60 +Ill 
4887 
+1047 
-
ADP AMP 
428 45 
+121 +25 
712 91 
+ 30 +10 
686 167 
+ 26 +11 
856 579 
+ 45 +98 
Total 
Adn. 
2189 
+352 
3422 
+128 
3001 
+ 80 
2605 
+104 
Energy NH + 
charge 4 
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Figure 2-3 "Crossover" plot of the anaesthetised rat spleen 
The levels of glycolytic intermedi~tes in the anaesthetised 
rat spleen are plotted as a percentage of the control in vivo 
values. The levels of the intermediates in the control are 
expressed as 100%. 
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with total flux (as judged by lactate levels) up by at least 600% in 2 
minutes. By comparison, it took 10 minutes of ischaemia for lactate levels 
in rat spleen to increase by 500%. This data and that of Hems and Brosnan 
(25) for comparative purposes, are presented as a cross-over diagram in 
Figure 2-4. 
During the first 5 minutes of ischaemia, metabolic changes were 
small. Lactate production increased by less than 100%, and this could be 
accounted for by the decrease in glucose. Glycogen levels did not change 
significantly during this period. The second 5 minutes of ischaemia 
produced an enormous surge of lactate formation, which was, however, 
unaccompanied by an equivalent change in either glucose or glycogen levels. 
The last period examined, that between 10 and 15 minutes of ischaemia, 
found little change in either lactate or glucose levels, but was 
accompanied by a large disappearance of glycogen. It should be noted that 
the total amount of carbon in the glucose + glycogen + lactate pool had 
not significantly changed after 15 minutes of ischaemia, when compared 
with the zero time controls. 
The apparent lack of synchrony between the production of lactate 
and the disappearance of glucose and glycogen, can be explained by the 
very large standard errors found, particularly for lactate production. 
This would suggest that the onset of ischaemia varied greatly between 
individual spleens. It was observed that the blood content of ischaemic 
spleens varied considerably, hence it is reasonable to assume that their 
oxygen contents varied to a similar extent. Considering the smaller 
standard errors in the measurements of glycogen content, it is reasonable 
to state that the large surge in glycogen utilization for lactate 
production which Hems and Brosnan observed at 2 minutes in liver, does 
not occur for more than 10 minutes in spleen. 
Figure 2-4 "Crossover" plot of ischaemic rat spleen, kidney and liver 
The levels of glycolytic intermediates in the ischaemic rat spleen, 
kidney and liver are plotted as a percentage of the control (non-ischaemi 
in vivo levels. The levels of the intermediates in the control are 
expressed as 100%. Values for the 10 minute ischaemic spleen are taken 
from Table 2-6. Values for the 2 minute ischaemic liver and kidney are 
taken from Hems and Brosnan (25). 
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Changes in adenine nucleotide levels were much as expected in a 
tissue deprived of oxygen, with a drop in ATP during ischaemia, and an 
increase in the levels of both ADP and AMP. This process of interconversion 
was much slower, however, than in liver or kidney (25). 
It is apparent from the measured levels of intermediates, that after 
10 minutes of ischaemia, phosphofructokinase is regulatory. It is not 
possible to say whether hexokinase is regulatory under these conditions, 
as severing the blood supply makes the glucose concentration limiting. 
(c) Stimulation of thymocyte glycolysis by Concanavalin A 
Concanavalin A-stimulation of glycolysis was the method used to 
look for regulatory sites in rat thymus. Table 2-7 shows how the levels 
of the intermediates varied during incubation of the thymocytes with 
Concanavalin A at selected time intervals during a 4-hour incubation. 
In Figure 2-5, this data is presented in graphical form, compared with 
data for control cells incubated in the absence of Concanavalin A. It 1s 
apparent from this figure that Concanavalin A does not stimulate glycolysis 
immediately. Clearly nothing of great significance has occurred after 
20 minutes, although after one hour, the stimulation IS pronounced. 
During the 4 hours of incubation recorded, the glucose concentration 
dropped steadily, whilst lactate levels rose. No positive identification 
of regulatory enzymes could be made, as the substrate levels for 
phosphofructokinase and pyruvate kinase rose, whilst the glucose supply 
was limited. However, both the ATP/ADP, and the ATP/AMP ratios fell, 
. 
+ 
whilst the levels of phosphate and NH4 rose. These factors along wi
th 
significant increases in the concentrations of F6P and FOP, would all 
contribute to an increase in the activity of phosphofructokinase. Indeed 
at the 20 minute measurement, there is a slight suggestion of F6P levels 
dropping during the onset of glycolytic stimulation. A series of 
measurements around 20 minutes of incubation might indicate whether an 
Table 2.7 The concentrations of glycolytic and other intermediates during 4 hours incubation 
in the presence and absence of Con A 
Thymus cells from 32 rats were incubated in the presence and absence of Con A, as described in the text. 
Concentration of intermediates (nmoles/1010 cells) 
Glycolytic 
intermediate + 20 minutes + 1 hour + 4 hours 
Zero time -----------------------------------------------------------------------------------
- Con A + Con A - Con A + Con A - Con A + Con A 
-5 4.84+0.05 4.64 4.49 4.38 3.94 4.44 3.33 Glucose x 10 (4. 75,4.53) (4.17,4.81) (4.28,4.48) (3.88,4.00) (4.32,4.57) (3.39,3.27) -
Glucosc-6-phosphate 395+5 380 363 365 465 379 
580 
-
(373,386) (344,383) (397,332) (479 ,451) (421 ,338) (574,587) 
Fructose-6-phosphate 110+6 114 110 121 141 126 
179 
-
(113,115) (105,115) (102' 140) (137,145) (144' 109) ( 179, 180) 
Fructose-1,6-diphosphate 161+10 173 181 167 205 117 
283 
- (176' 169) (180,183) (169,165) (193,216) (112,121) (297,268) 
Triose-phosphates 308+17 412 440 562 599 799 
1973 
- (420,413) (453 ,427) (596,528) (561,636) (867,731) (1881 ,2064) 
3-phosphog1ycerate 64.2+3.1 74.5 88.2 102 82.3 304 
218 
- (74.5,n.d.) (90.1,86.3) (82.4,122) (82.3,n.d.) (271 '337) (243,192) 
2-phosphoglycerate 49.3+6.4 26.0 46.0 44.0 62.0 34.7 46.0 
-
(24.0,28.0) (36.0,56.0) (48.0,40.0) (60.0,64.0) (44.0,25.3) (44.0,48.0) 
Phosphoenolpyruvate 41. 0+3.4 50.0 34.0 60.0 62.0 103 111 
- (56.0,44.0) (32.0,36.0) (68.0,52.0) (68.0,56.0) (103' 104) (98.7,123) 
Pyruvate 5458+230 5918 5733 5658 6540 2949 
5335 
-
(5891,5945) (5383' 6083) (6139,5177) (7580,5500) (3213,2684) (5603,5067) 
Lactate 93700+1290 107000 105000 121000 146000 83000 199000 
- (105000' 109000) (102000' 107000) (125000' 118000) (145000' 148000) (84000,81000) (195000' 203000) 
ATP 3721+178 3900 3486 3741 3635 2734 3214 
- (3913,3887) (3188,3784) (3907,3576) (3693,3576) (3110,2358) (3602,2825) 
ADP 737+31 617 595 589 656 643 614 (595,639) (519,671) (595' 583) (652,660) (665,622) (576,652) 
AMP 152+2 115 198 144 171 102 253
 
- (115,115) (262 ,134) (134' 153) (175,167) (99.5,105) (239,267) 
0\ 
-.....J 
Figure 2-5 "Crossover" plot for thymocytes incubated with Con A 
for 20 minutes ( - • - ) , 1 hour f- -A- -) and 4 
hours c-·-0--· -) 
Values were calculated from the data in Table 2-7, and have 
been expressed as percentages of the values for controls at the 
same sampling times. 
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early activation of phosphofructokinase precedes the later r1se 1n G6P 
and F6P. This increase in level of the hexose-monophosphates, which is 
sustained thr'oughout the incubation period, indicates that the activation 
of a regulatory step anterior to phosphofructokinase (i.e. the glucose 
carrier or hexokinase) is at least partly responsible for the observed 
stimulation of glycolysis. 
2.5 REGULATION OF GLYCOLYSIS DURING THE GRAFT-VERSUS-HOST REACTION 
2.5.1 Introduction 
During the planning of this thesis, it was hoped that it would be 
possible to exploit in a separate study, the unique immunological 
properties that spleen and thymus possess compared to better studied 
organs. 
This has already been done with thymus, by stimulating lymphocytes 
with Concanavalin A. Concanavalin A is a fairly non-specific "antigen 
analogue", as it activates far more lymphocytes than would normally take 
part in an immune reaction. In spleen the problem is more difficult, as 
conventional methods of eliciting an immune response e.g. by reaction to 
an authentic antigen or to bacteria, causes only a very small population 
of cells to respond, and the net metabolic changes could be very difficult 
to monitor, without resorting to an in vitro culturing of responsive cells. 
However, it was felt that the Graft-versus-Host (GvH) reaction might be 
an effective model as it is known to cause a massive "stimulation" of the 
spleen. This system seemed to be particularly promising as there have 
been no reports published of metabolic changes accompanying the GvH 
reaction. 
2.5.2 The Graft-versus-Hos t (GvH) reaction 
Wlwt is now known :ts the Cvll re:tction, was first reported hy Murphy 
( 140) in 19 I (L He found t h:tl i noc ul :1 t ion of the eh or i o-:tl L an toi c membrane 
of chicken embryos, with fragments of spleen or bone marrow from adult 
chickens, resulted in a considerable enlargement of the host's spleen, 
70 
and the development of white nodules on the surface of the spleen and 
other tissues. Examination showed these nodules to be filled with 
leukocytes. Tissue from adult donors of xenogeneic spec1es failed to 
cause these systematic changes. Murphy failed to recognize the 
significance of his results and attributed them to stimulation of the 
host's spleen. Subsequent work has shown that the following prerequisites 
must be met before a GvH reaction can occur: 
(i) the graft must contain immuno-competent cells; 
(ii) the host must possess certain transplantation 
antigens that the graft lacks, thus making the 
host "foreign", and enabling the graft to attack 
it; and 
(iii) the host must be incapable of mounting an 1mmune 
attack against the graft, at least in the early 
stages of the reaction. 
Clearly the genetics of the GvH system are complex. It must be 
remembered that a GvH reaction will occur only when allogeneic lyrnphocytes 
(i.e. lyrnphocytes from an animal of the same strain, but slightly different 
genetic constitution) are used. Xenogeneic lyrnphocytes (where the donor 
and host animals are unrelated) do not produce a GvH reaction. Bach et al 
(141) working with mice, have shown that the important genetic difference 
which enables a GvH reaction to occur, is located in only one small sector 
of the H-2 histocompatibility locus. 
A rat suffering from GvH disease displays certain typical clinical 
and pathological symptoms. These include a falling in body temperature 
of 2°, a failure to gain weight, and a thickening or loss of skin 
elasticity. Death typically occurs after about 18 days. Development of 
GvH disease is usually accompanied by a striking enlargement of the spleen. 
Histological examination shows an abnormal and marked proliferation of 
blast cells and macrophages in the red pulp. 
GvH reactions are usually initiated in one of two ways: 
(i) the host is immune-incompetent (e.g. new-born) so 
that its lymphoid system will not react against 
the graft; or 
(ii) the graft and the host are of such a genetic 
constitution that the host 1s foreign to the graft 
but not vice-versa. Such a case would occur when 
allogeneic lymphocytes from a homozygote animal 
(AA) are injected into a host which is a first-
generation hybrid (Fl, AxB) of the donor strain 
and a different homozygote (BB). Under these 
conditions, the donor (AA) will not possess 
foreign antigens to stimulate the host's (AxB) 
lymphoid system. The host does, however, contain 
foreign antigens, and the injected lymphocytes 
will react against them. 
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The mass1ve effect on the host's spleen, suggested that the GvH 
reaction may be a suitable means of producing flux changes 1n glycolysis 
1n this tissue, allied to a specific immunological event. The remainder 
of this section describes how the GvH reaction was used 1n an attempt to 
identify regulatory sites of glycolysis in rat spleen. 
2.5.3 Methods 
It was decided to initiate the GvH reaction by injecting lymphocytes 
from a rat of homozygous strain, into a rat which was an Fl hybrid of the 
donor strain and a different heterozygote. 
Most of the methods used have already been described in Section 2.3 
:thovt'. The following, howcvt'r, :tr-e unique to this section. 
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(a) Preparation of donor lymphocytes 
Donor lyrnphocyte suspensions were obtained by remov1ng spleens from 
10- 12 week old donor rats (of either Hooded Wistar (HW) or DA strains ) , 
cutting these spleens into sections, and then rubbing them against a nylon 
mesh (500~) partially immersed in physiological saline, until the residual 
tissue was white in colour. Large tissue fragments were allowed to settle 
for 2 - 3 minutes, then the lymphocyte-containing supernatant was decanted 
into centrifuge tubes, and centrifuged for 5 minutes at 400 x g to pellet 
the cells. The supernatant was poured off, and 2 mls of water added to 
lyse the erythrocytes. After mixing the cells for 10 - 15 seconds, an 
equal volume of double-strength saline was added to restore the original 
tonicity. The cell suspension was then centrifuged for 5 minutes at 
400 x g to pellet the white blood cells. The red cell debris was decanted 
off and the cell pellets pooled and made up to a concentration of 
2 x 108/ml with physiological saline. 
(b) Injection of Fl rats 
Male Fl (HWxDA) rats (8 - 10 weeks old) were injected in the tail 
vein with 4 x 108 lymphocytes, whilst under ether anaesthesia. They were 
killed by cervical dislocation at appropriate times after injection, and 
the spleens and carcasses weighed separately to enable calculation of the 
body weight/spleen weight ratio. 
(c) Evide~ce for the occurrence of the GvH reaction 
One of the more striking changes in animals undergoing GvH reactions, 
1s a gross enlargement of the spleen. This can be quantified as a decreased 
body weight/spleen weight ratio, and has become accepted as positive 
evidence for the occurrence of a GvH reaction (142). It 1s the criterion 
we h:1ve useJ throughout this st udy. 
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2.5.4 Results 
(a) Choice of donor 
It was decided to use the first generation hybrid of an HWxDA cross 
as the host. The problem then was which parent homozygote to use for 
providing the "graft" lymphocytes. Figure 2-6 compares the efficiency 
of both parents in inducing GvH reactions in the Fl animals, at different 
times after the donor lymphocytes were injected. Both HW and DA cells 
lowered the body weight/spleen weight ratio after only 15 - 20 hours. 
However, the decreased ratio at this stage was probably due to the 
physical sequestering of foreign cells by the spleen and the entry of 
large numbers of blood phagocytes. Six-seven days after injection of HW 
lymphocytes, the ratio had dropped by 30 - 40%, and this was interpreted 
as evidence of a successfully induced GvH reaction. In contrast, DA 
lymphocytes gave only an 11% decrease in ratio after 7 days. The very 
large standard error in the body weight/spleen weight ratio, was a 
further indication that DA lymphocytes did not induce strong and 
reproducible GvH reactions. Hooded Wistars were used as lymphocyte donors 
in all subsequent experiments. 
(b) Maximal enzyme activities in vitro 
The activities of the individual glycolytic enzymes 1n Fl spleens 
are very similar to those reported earlier for outbred albino Wistars. 
Table 2-8 records the activities of the enzymes from Fl spleens, both in 
normal tissue and in tissue undergoing a GvH reaction. The activities in 
these two groups are also very similar. As in the spleens of albino 
Wistars, the low activity enzymes are hexokinase, phosphofructokinase, 
aldolase and glucose-6-phosphate dehydrogenase. 
(c) Identification of non-equilibrium reactions 
Table 2-9 shows the mass-action ratios and the apparent equilibrium 
constants for the individual reactions of glycolysis in freeze-clamped Fl 
Figure 2-6 Effect of time and lymphocyte source on the body 
weight/spleen weight ratio during a GvH reaction 
8 Fl (HWxDA) rats were injected with 4 x 10 lymphocytes from 
the spleens of either DA or HW donors. Body weight/spleen weight 
ratios are plotted as a percentage of the control ratios (obtained 
from uninjected animals) at different times after injection and the 
results are the means + S.E.M. 
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Table 2-8 
Glycolytic enzyme activities in the spleen of inbred male Fl rats, 
progeny of an H.W. x D.A. cross 
The enzyme activities in 40,000 x g supernatants of spleen 
homogenates were assayed as described in the text. The number of 
determinations are given in parentheses. 
ACTIVITY 
ENZYME (ll moles/min./g. fresh wt. at 
NORMAL GvH* 
Hexokinase 1.2 + 0.1 (4) 1.1 + 0. 1 
Phosphoglucoseisomerase 27.5 + 1.7 (4) 24.3 + 2.5 
(back) 
Phosphofructokinase 1.8 + 0.2 (4) 2.4 + 0.3 
Aldolase 1.5 + 0.1 (3) 1.5 + 0.1 
Triose phosphate isomerase 180 + IS (2) 146 + 20 
Glyceraldehyde-3-phosphate 10.6 + 1.3 (2) 14.7 + 2.5 
dehydrogenase 
Phosphoglycerate kinase 74.0 + 2.8 (4) 78.2 + 5.8 
Phosphoglycerate mutase 45.6 + 2.5 (4) 49.7 + 2.5 
Enolase 19.8 + 1.1 (4) 20.6 + 1.3 
Pyruvate kinase 4 7.1 + 3.0 (5) 56.0 + 1.8 
Lactate dehydrogenase 90.8 + 3.2 (5) 96.9 + 8.4 
Glucose-6-phosphate 5.8 + 0.3 (4) 6.2 + 0.4 
dehydrogenase 
Fructose-1, 6-diphosphatase <0.2 (2) <0.2 
8 
*GvH animals were prepared by injecting 4 x 10 parental 
HW lymphocytes into the tail veins of each Fl rat. 
Animals were killed 6 days after injection. 
25°) 
(4) 
( 3) 
(5) 
(3) 
(2) 
(2) 
(3) 
(3) 
(3) 
(5) 
(5) 
(4) 
(2) 
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Table 2-9 
Mass-action ratios versus equilibrium constants for the glycolytic 
pathway in Fl (D.A. x H.W.) freeze-clamped spleens 
Mass-action ratios were calculated from the concentrations of 
intermediates given in Table 2-10. Concentrations given as n. moles/ 
g. fresh wt. were taken as equivalent to ~M. The remaining details 
of calculation were as for Table 2-5. 
ENZYME REACTION 
Hexokinase 
Phosphoglucoseisomerase 
Phosphofructokinase 
Aldolase 
G-3P-dh plus 
phosphoglycerate kinase 
Phosphoglyce~ate mutase 
Enolase 
Pyruvate kinase 
Lactate dehydrogenase 
Adenylate kinase 
APPARENT MASS-ACTION EQUILIBRIUM RATIO RATIO CONSTANT (f) f/K' (K') 
4700 1.1 X 10-2 2.34 X 10 -6 
0.41 2.8 X 10-l 0.68 
1003 4.2 X 10-l 4.2 X 10-4 
9.6 X 10-S 5.4 X l0- 6M 5.6 X 10- 2 
59 92 1.56 
0.15 3.1 X 10-l 2.06 
2.93 7.5 X 10-l 0.26 
17,900 16.1 9 X 10-4 
assumed at equilibrium 
0.44 0.31 0.72 
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spleens. As with the albino Wistar sp l eens, phospho f r uctokinas e, aldolase 
and pyruvate kinase all catalyze non-equil i brium reacti ons. Although no 
I 
attempt has been made to differentiate between intra- and extra-ce llular 
glucose, the results indicate, by analogy with the results from alb i no 
Wistar spleens, that hexokinase also catalyzes a non-equilibrium reaction 
in Fl spleen. 
(d) Identification of regulatory enzymes using the GvH reaction 
The levels of glycolytic and other intermediates in the freeze-
clamped spleens from both normal Fl rats and Fl rats undergoing a GvH 
reaction, are presented in Table 2-10. Although the body weight/spleen 
weight ratio had decreased by 40% after 6 days GvH, there is no indication 
of a change in glycolytic flux rate. There is a suggest i on that glucose 
levels have fallen, but the difference is not significant. Changes in 
the glycolytic intermediates are presented as a cross-over diagram 1n 
Figure 2-7. The concentrations of both hexose-monophosphates have 
increased significantly, whilst the concentrations of FDP and the 
phosphoglycerates have fallen significantly. This data suggests a 
decreased flux through phosphofructokinase. 
Changes in the levels of non-glycolytic intermediates agree with an 
inhibition of phosphofructokinase. ATP levels rose, and ADP levels fell, 
whilst both the ATP/ADP and ATP/ADPxPi ratios increased. In view of the 
extreme sensitivity of phosphofructokinase to changes in these ratios, an 
inhibition is to be expected. It should be noted that the concentration 
of the potent stimulator AMP; increased under the same conditions. 
However, spleen phosphofructokinase has an apparent KA for AMP much lower 
than the levels observed here (see · Chapter 3), so it is probable that the 
change had little effect. 
TI1e data presented above lS somewhat contradictory, in that although 
there appears to be decreased flux through phosphofructokinase, the net 
Table 2-10 
Levels of glycolytic and related intermediates In freeze-clamped 
spleens from normal and GvH Fl rats 
The intermediates were assayed in extracts prepared as described 
In the text. The concentrations are expressed as n. moles/g. fresh 
wt. All results are the means + S.E.M. of 4 or 5 values as indicated 
in parentheses. Where results have been tested for statistical 
significance: N.S., means not statistically significant. 
PARAMETER 
MEASURED 
Body wt./spleen wt. 
Glucose 
G-6-P 
F-6-P 
FDP 
Triose-P 
CONTROL 
(5) 
(uninj ected) 
459 + 15 
2206 + 149 
84 + 6 
24 + 2 
35 + 4 
76 + 10 
GvH 
(5) 
(15 hr.) 
351 + 36 
1955 + 53 
87 + 6 
26 + 2 
17 + 2 
49 + 6 
GvH 
(4) 
(6 day) 
286 + 20 
1924 + 97 
113 + 8 
36 + 3 
22 + 1 
65 + 12 
Sig. p 
Sig. p 
Si g. p 
N.S. 
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<5% 
<2% 
<5% 
3-PGA 90 + 4 24 + 5 37 + 2 Sig. <0.1% 
2-PGA 28 + 4 17 + 3 17 + 3 p <5% 
PEP 21 + 3 14 + 1 20 + 3 N.S. 
Pyruvate 94 + 8 59 + 3 79 + 6 N.S. 
Lactate 1267 + 113 1004 + 107 1388 + 186 N.S. 
Lac/Pyr 13.6 + 1.2 17.3 + 2.3 22.2 + 1.9 
ATP 2565 + 78 2670 + 144 2655 + 69 
ADP 718 + 37 639 + 42 606 + 28 
AMP 63 + 3 53 + 4 84 + 7 
Pi 2614 + 62 2633 + 186 2622 + 98 
ATP/ADP 3.60 + 0.17 4.20 + 0.09 4.40 + 0.16 
Energy Charge 0.87 + 0.004 0.89 + 0.002 0.89 + 0.006 
ATP/ADP x Pi 2303 + 128 2725 + 248 2807 + 147 
(measured) 
Figure 2-7 "Crossover" plot during a GvH reaction 
The levels of glycolytic intermediates 1n the IS hour and 
6 day GvH spleens are plotted as a percentage of the control. The 
levels of the intermediates in the control are expressed as 100% 
and all the values are taken from Table 2-10. 
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flux, as indicated both by the lactate concenttation, and by Suter's 
studies (20) with slices from GvH spleens, appears to be unchanged. The 
most logical means 'of reconciling these apparently contradictory facts, 
is to postulate increased pentose-phosphate pathway activity. This would 
serve to maintain the levels of triose phosphates required for the 
unaltered rate of formation of lactate, and would provide additionally, 
pentose precursors for the nucleic acid synthesis accompanying cellular 
proliferation. Suter (20) has examined the role of the pentose-phosphate 
pathway in spleen slices from rats undergoing the GvH reaction. He found 
no increase in the activity of the oxidative segment of the pathway. 
However, Gumaa and McLean (143) have reported that in the 
phosphofructokinase-deficient yeast Rhodolorula gracilis, 80% of the 
pentose moieties formed, originated via the non-oxidative transketolase-
transaldolase route, according to the following net equation, 
2F6P + glyceraldehyde-3-P ---~ 3 pentose-5-P 
Suter (20) has shown that there is a considerable stimulation of nucleic 
acid and protein synthesis after the sixth day of the GvH reaction. If, 
as he has shown, the activity of the oxidative segment of the pathway does 
not change, then increased activity of the non-oxidative segment is the 
most reasonable explanation. Indirect evidence in support of this 
hypothesis is: 
(i) on teleological grounds, transketolase 1s a likely 
site for regulation; 
(ii) both reactions catalyzed by transketolase are non-
equilibrium (143); and 
(iii) the increased level of F6P may be a further factor 
in increasing flux through this segment of the 
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pentose-phosphate pathway. 
It is unfortunate that the results presented in this work are not 
more clear cut. However, this project is concerned with the identification 
of regulatory enzymes, not with the quantitative aspects of glucose 
metabolism. The results presented in this section do suggest that 
glycolysis has been inhibited at the locus of phosphofructokinase, and 
that increased pentose-phosphate pathway activity may be responsible for 
maintaining lactate at a level similar to that of the controls. More 
recent data from Weidemann (121) suggests that the sequence of metabolic 
events involved in lyrnphocyte transformation may involve multiple control 
points, and that the apparent inhibition of phosphofructokinase observed 
here may be genu1ne. These results will be discussed more fully in 
Chapter 4, where a consideration of the role of glycolysis in the 
initiation of lymphocyte transformation is presented. 
2.6 ENZYME STUDIES 
2.6.1 Introduction 
The results described in the earlier part of this chapter, have shown 
that phosphofructokinase can nearly always be identified as a step .which 
controls the rate of flux through the glycolytic pathway 1n lymphoid 
tissue. To complete this section of the work, two small studies were 
undertaken: 
(i) a brief examination of the properties of rat spleen 
phosphofructokinase in a crude supernatant preparation, 
to see whether it displayed any of the properties 
which a regulatory enzyme might be expected to 
possess, and 
(ii) an investigation of the isoenzymes of spleen pyruvate 
kinase and lactate dehydrogenase. 
One problem which was still of some concern, ~as the question of which 
cell types were responsible for the observed metabolic activity. Spleen 
comprises three major cell types, lymphocytes, erythrocytes and 
phagocytes. It was hoped that by determining the isoenzyme spectrum for 
these two enzymes it would be possible to say with more precision which 
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of the three cell types contributed most to the observed activity patterns. 
2.6.2 Phosphofructokinase 
Rat spleen phosphofructokinase was prepared by homogenizing tissue 
1n 3 volumes of a buffer containing SO mM Triethanolamine-HCl, pH 7.5, 
containing 1 mM EDTA. The resultant suspension was centrifuged twice, 
for 15 minutes at 20,000 x g to remove mitochondria, and for 60 minutes at 
100,000 x g to settle all microsomes. All assays were conducted at pH 7.0 
in the Imidazole buffer used by Underwood and Newsholme (52). The 
following properties were observed: 
(i) in the presence of only 0.7 mM ATP, titration of 
phosphofructokinase activity with F6P produced a 
strongly sigmoidal curve with a Hill coefficient 
of 1.6; 
(ii) 1n the presence of 0.7 mM ATP, AMP (0.5 mM) 
stimulated phosphofructokinase activity nearly 
3-fold when F6P levels were low (0.1 mM). If, 
however, the F6P concentration was raised to 
0.3 mM, AMP caused little activation, and 
(iii) under similar conditions to (ii) above, both ADP 
and cAMP were also stimulatory, ADP only slightly, 
but cAMP to nearly the same extent as AMP. 
A sigmoidal response to one of its substrates, and activation or 
inhibition by some molecule which 1s not a substrate for the reaction it 
catalyzes, are two properties which a regulatory enzyme typically possesses. 
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This confirmation of phosphofructokinase's regulatory capacity l eads to 
Chapter 3 of this thesis, which presents an in-depth exami nation of the 
kinetic properties of a partially-purified phosphofructokinase from sp l een . 
2.6.3 Isoenzyme studies 
(a) Pyruvate Kinase 
The most obvious differentiation of cell types in spleen, is into 
erythrocytes and leukocytes. Suter (20) has found that rat spleen 
contains approximately equal proportions of each cell type. Pyruvate 
kinase exists in two enzymatic forms, liver (L)-type and muscle (M)-type. 
The L-isoenzyme 1s activated by the allosteric effector FDP and is the 
only form found 1n erythrocytes, whilst the M-isoenzyme is not activated 
by FDP and is the only type present in leukocytes (144). Thus by 
determining which isoenzyme is predominant in spleen extracts, it 1s 
possible to say which cell type contributes most to the observed 
metabolic activity. 
Spleen pyruvate kinase was assayed for activation by FDP, by the 
method of Taylor and Bailey (145). FDP had no effect at all on pyruvate 
kinase kinetics, implying that erythrocytes contribute very little, if 
at all, to the metabolic activity in rat spleen. 
(b) Lactate dehydrogenase 
There are two basically different forms of lactate dehydrogenase 
1n animal tissues. The form which predominates in heart is composed of 
four identical subunits and is called the H enzyme. The form which 
predominates in skeletal muscle is also composed of identical subunits 
different from those in heart and is called the M enzyme. These two 
forms of lactate dehydrogenase exist to different extents in the various 
tissues of the body, and it 1s possible to have any of five different 
isoenzyrnes present, of form H4, H3M1 , H2M2, H1M3 and M4 . 
The H enzyme 1s strongly inhibited by concentrations of pyruvate 
greater than 1 mM, whilst the M enzyme is relatively insensitive to 
inhibition by its substrate. By comparing the activity of lactate 
dehydrogenas e in the presence of 0.3 mM pyruvate, to that in 1.0 mM 
pyruvate, it is possible to make an approximate assessment of the ratio 
of Hand M subunits of the enzyme present (146). For spleen lactate 
. activity 1n 0 3 mM pyruvate dehydrogenase, the rat1o . . · is 1.4, whilst for 
act1v1ty 1n 10 mM pyruvate 
the thymus enzyme the value is 1.8. By reference to the results of Wilson 
et al (146) this suggests that spleen lactate dehydrogenase is composed 
of approximately 40% H subunits, whilst thymus lactate dehydrogenase 
comprises approximately SO% H subunits. Thymus contains an almost pure 
population of lymphocytes, so it is probable that thymocytes contain 
approximately equal mixtures of H and M subunits. Granulocytes and other 
phagocytic cells are reported to contain a preponderance of M subunits 
(147). Thus it seems probable that the glucose metabolism of spleen 1s 
due largely to the lymphocytes within it, though with a definite 
contribution from the phagocytic cells. Suter (20) has reached the same 
general conclusion in his studies on the quantitative aspects of glucose 
metabolism in spleen slices. 
2.7 DISCUSSION 
The aim of the work reported in this chapter, was to determine, in 
accordance with the principles established by Newsholme and Gevers (13), 
which enzymes regulate glycolytic flux in the two major mammalian 
lymphoid tissues, spleen and thymus. 
Freeze-clamping of both tissues, and subsequent determination of the 
levels of glycolytic intermediates, proviJc s an experimental basis for 
iJentifying which metabolic reactions arc significantly removed from 
equilibrium, as it is the enzymes catalyzing these reactions which may 
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possess regulatory properties. As a refinement, extracellular spaces 
were calculated, allowing separate estimations of the equilibrium posit i on s 
of the glucose carrier and hexokinase to be made. It was concluded that 
hexokinase, phosphofructokinase and pyruvate kinase, catalyze reactions 
removed far from equilibrium, whilst the glucose carrier and aldolase 
catalyze reactions which are "intermediate" between the equilibril.Dll and 
non-equilibrium states. 
When glycolysis was varied experimentally in lymphoid tissues, it 
became apparent that two subtle though distinctly different patterns 
emerged, depending on the means utilized to perturb flux. Utilizing 
Krebs' principle (18) that a change in substrate concentration of a 
non-equilibrium enzyme in the opposite direction to the change 1n net 
flux is indicative of an enzyme being regulatory, it 1s clear that 
phosphofructokinase meets this criterion during both ether anaesthesia 
and anoxia. A drop 1n total glucose concentration indicated that the 
glucose carrier and/or hexokinase were regulatory during anaesthesia. 
It is not possible to positively ascribe any regulatory role to either 
the glucose carrier or hexokinase during anoxia, as severance of the blood 
supply and isolation of the organ made the glucose supply limited. The 
metabolic pattern observed during anox1a 1s very similar to that seen in 
other tissues; indeed, as can be seen in Figure 2-4, the pattern for the 
ten minute anoxic spleen can almost be superimposed upon that of the two 
minute anoxic kidney. In situations where changes in metabolic flux are 
induced by challenging the integrity of the tissue's respiratory system, 
the term emergency glycolysis is used. In the present work where such a 
stress has been applied (i.e. anoxia, ether anaesthesia), it is clear that 
phosphofructokinase is primarily responsible for regulating flux through 
the pathway, whilst the glucose carrier and/or hexokinase may also be 
involved, either directly (e.g. by activation of the carrier) or indirectly 
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(e.g. by deinhibition) , following intermediate changes brought about by 
the activation of phosphofructokinase. 
The other pattern of glycolysis observed, 1s that which occurs when 
the organ's immunological defences are challenged. For convenience, the 
term immunological glycolysis is used. Two examples of this condition 
are offered, the Con A-activation of thymocytes, and the GvH reaction 
in rat spleen. During the GvH reaction, the most note-worthy events are 
the reduction in glucose concentration, the increase in hexose-
monophosphate concentration, and the apparent constancy of flux. During 
the Con A-activation of thymocytes, the levels of the hexose-monophosphates 
increase steadily 1n the same direction as the flux rate, whilst the 
levels of FOP and triose-phosphates increase later, but to a much greater 
extent. The only regulatory step which can be positively identified 
during either of these processes is the glucose carrier and/or hexokinase 
during the GvH reaction. Although phosphofructokinase cannot be 
positively identified as regulatory according to the criteria employed 
above, changes in the levels of its effectors are consistent with it being 
regulatory under both conditions: inhibited during the GvH reaction and 
activated during Con A stimulation . 
On first inspection it appears unreasonable to compare Con A-
activation and the GvH reaction, as one demonstrates a strong activation 
of glycolysis, whilst the other, if not inhibition, at least indicates 
no change. However, it must be remembered that Con A is a non-specific 
activator which affects a far larger population of lymphocytes (-SO%) 
than those normally taking part in a true immunological reaction (<5%). 
The GvH reaction on the other hand is highly specific, immunologically, 
and would not necessarily exhibit an identical metabolic pattern. What 
is of prime importance 1n both cases, is the increased concentration of 
hexose-monophosphates. Weidemann and Kolbuch (121) have recently produced 
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evidence which suggests th.1t significant glycogen synthesis may occur 
during the first 3 hours of Con A stimulation. The appropriate results 
will be quoted in Chapter 4, where an attempt will be made to define the 
role of glycolysis during lymphocyte activation. If, as Weidemann 
suggests (121), glycogen storage is a feature of the early events 
associated with glucose uptake then, clearly, an initial activation of 
glucose transport and/or hexokinase, may produce the raised level of G6P 
necessary to direct glucose carbon to glycogen. The apparently 
inconsistent data relating to phosphofructokinase, i.e. apparent 
activation with Con A, and apparent inhibition during the GvH reaction, 
can be reconciled with this data. The GvH reaction is a very specific 
immunological reaction, and furthermore, the measurements reported here 
were carried out at time intervals much later than 3 hours after 
initiation of the reaction. All the measurements on the Con A-activation 
of thymocytes were carried out at time intervals less than 4 hours after 
mitogen addition. When the events observed after long term incubation 
with mitogen are considered, then the two sets of data become 
reconcilable. Glycolytic flux rate is reported to be elevated between 
30 minutes and 8 hours after mitogen addition (115), whilst RNA and 
protein synthesis and DNA synthesis are not activated till approximately 
24 (118) and 60 hours (118) respectively. Thus although during the GvH 
reaction the period of glycolytic stimulation is over, pentose moieties 
are still required for the subsequent synthetic events. This will expl ain 
in turn, the apparently steady state of glycolyti~ flux, and the increased 
utilization of glucose and elevated levels of hexose-monophosphates. 
From the two experiments conducted relating to immunological g lycolysis ~ 
it seems that the prime regulatory event is the activation of glucose 
transport and/or hexokinase, whilst regulation at the phosphofructokinas e 
locus may be of secondary importance. 
One point of interest when comparing the intermediate profiles of 
spleen and thymus (see Tables 2-3 and 2-4), is the difference in the 
lactate/pyruvate ratios. In spleen, this value is 10.5, whereas in the 
thymus it is 23.9. If the tissues are similar in metabolic properties , 
it is likely that their lactate/pyruvate ratios will be the same. ~fuen 
tissues become anoxic, their lactate/pyruvate ratios increase as the 
oxidation/reduction state of the cytoplasmic NAD+/NADH ratio is perturbed, 
and it might seem, at first, that the thymii used in the determination of 
enzyme equilibrium positions were at least partially anoxic. However, 
calculations of the energy charge made from adenine nucleotide 
determinations on the same tissues, gave a value of 0.83, indicative of 
healthy aerobic organs. In addition, Weidemann (121) has found the 
lactate/pyruvate ratio in aerobic thymocytes incubated in the presence of 
glucose and 100% oxygen to be 21.5. Thus, this high ratio appears to be 
characteristic of the tissue. 
The differences 1n the lactate/pyruvate ratio, appears to be the 
major difference between the two tissues. The studies reported in Section 
2.6 showed differences, but not of any great extent. It must be remembered, 
that during the GvH reaction spleens nearly doubled in size, and as this 
is primarily a lymphocyte-proliferative reaction, it is clear that 
lymphocytes contribute a large proportion of the metabolic activity within 
this tissue. 
The results contained 1n this Chapter, indicate clearly that both 
phosphofructokinase and the glucose carrier/hexokinase locus are 
important regulatory sites in the metabolism of glucose. A preliminary 
investigation of the properties of phosphofructokinase (see Section 2.6) 
showed that it possessed properties indicative of a regulatory function. 
Chapter 3 reports the purification and examination of the properties of 
phosphofructokinase, whilst the Discussion of that chapter considers 
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whether the observed properties are compatible with phosphofructokinase 
regulating glycolysis in lymphoid tissue. 
CHAPTER 3 
THE PURIFICATION AND PROPERTIES OF PIG SPLEEN PHOSPHOFRUCTOKINASE 
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CHAPTER 3 
THE PURIFICATION AND PROPERTIES OF PIG SPLEEN PHOSPHOFRUCTOKINASE 
3.1 INTRODUCTION 
The work recorded 1n Chapter 2 of this thesis, shows that 
phosphofructokinase is, at least under conditions of oxygen deprivation 
or ether anaesthesia, the enzyme primarily responsible for controlling 
glycolytic flux in rat spleen. The next logical step in the investigation 
should be to purify and make a detailed kinetic study of spleen 
phosphofructokinase. 
Although no results will be presented, a pilot study was conducted 
with the enzyme from rat spleen. To this end, a partially purified 
preparation with a Specific Activity of only 3U/mg protein was obtained. 
However, the physical quantity obtained in a single preparation from 30 
spleens was so small that detailed kinetic studies were not feasible. 
It was finally decided to purify the enzyme from pig spleen, where 
starting material was available in kilogram quantities. This chapter, 
besides recording the purification and some of the kinetic properties of 
pig spleen phosphofructokinase, also reports a comparison of some of the 
more significant kinetic properties of the enzyme from pig spleen, rat 
spleen and rat thymus, and concludes with some experiments simulating the 
effect of in vivo conditions on phosphofructokinase activity. 
3.2 MATERIALS 
All nucleotides and fine chemicals used in this study, were purchased 
from Boehringer Mannheim. + They were either purchased as the Na -salts, 
. + 
or were converted to this form w1th Na -Dowex hefore use. All other 
chemicals used were of analytical grade. 
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The coupling enzymes used, namely aldolase, triose-phosphate 
isomerase, a-glycerophosphate dehydrogenase, pyruvate kinase and lactate 
dehydrogenase, were purchased from either Boehringer Mannheim, or the 
Sigma Chemical Co., St. Louis, Missouri. 
Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) was 
purcha,sed from Sigma, and DE 52 DEAE-cellulose from the Whatman Company. 
Pig spleens were obtained from the Canberra Abbatoirs. They were 
placed oh ice within 5 minutes of death and transported back to the 
laboratory in a large Dewar flask. Fat was trimmed off samples, which 
were then cut into pieces of approximately 10 g weight before being 
frozen at -20°. 
3. 3 METHODS 
3.3.1 Enzyme assays 
Measurements of phosphofructokinase activity are usually made in 
either of two pH regions; 
(i) pH 8.0 - 8.2, at which activity is maximal, or 
(ii) pH 6.8- 7.2, which is near-physiological, and at 
which the regulatory properties of the enzyme can 
be clearly seen. 
Ideally the buffer used should have good buffering capacity in both of 
these pH ranges, i.e. it should have an intermediate pKa. Commonly used 
buffers such as Tris, glycylglycine and imidazole are effective buffers in 
only one of these pH regions. Hepes, however, has an intermediate pKa of 
7.55, and does not bind metal ions (148), so for this reason it was 
selected as the assay buffer. 
For examination of its regulatory properties, phosphofructokinase 
w~ts ass:tycd in SO mM Hepes-NaOH pH 7.0, containing ATP, F6P and effectors 
as indicated, with 0.1 mM NADH. All solutions of effectors were adjusted 
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to pH 7.0 with NaOH. Mg2+ was always 3 mM in excess of the ATP 
concentration. Phosphofructokinase activity was measured by the decrease 
in optical density at 340 nm on a Zeiss PMQII spectrophotometer using 
aldolase, triose-phosphate 1somerase and a-glycerophosphate dehydrogenase, 
approximately ten times in excess of the observed activity of 
phosphofructokinase. Coupling enzymes were dialyzed for 24 hr. against 
3 one litre volumes of 50 mM Tris-Cl pH 8.0, containing 0.05 mM EDTA, to 
+ No NH4 could be detected on subsequent enzymatic 
assay. Immediately before assay, stock solutions of phosphofructokinase 
were diluted with 80 mM potassium phosphate buffer pH 8.0, containing 1 
mM EDTA, until a suitable optical density change could be recorded. 
For assays of maximal activity during enzyme purification, 
phosphofructokinase was assayed in 50 mM Hepes-NaOH pH 8.0, containing 
0.4 mM ATP, 2.0 mM F6P, 3.0 mM Mg2+ and 0.1 mM NADH. Coupling enzymes 
were added in approximately tenfold excess, but without prior dialysis. 
It is commonly reported in the literature that assays of 
f k . d d f" d . f M 2+ phospho ructo 1nase are con ucte at a 1xe concentrat1on o g . As 
results presented later in this thesis show, the relative levels of Mg2+ 
and ATP are of considerable importance 1n determining what the absolute 
activity of the enzyme will be. Computer calculations (not recorded) 
using the stability constants of Morrison and Heyde (149) showed that 
only when Mg 2+ is present in considerable excess, is the ATP nearly 
quantitatively bound. For this reason, the practice of Paetkau and Lardy 
(6 7) f k · Mg2 + 1 3 mM . h ATP . o eep1ng constant y 1n excess over t e concentrat1ons 
has been adopted. 
Newsholme et al (150) have shown that NADH will inhibit the coupling 
enzymes used 1n this assay system. For this reason, the initial level of 
NADH is kept constant and low at 0.1 mM. 
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Reported methods of initiating enzyme assays vary. For example, 
Kemp (54) and Mansour and Ahlfors (65) preincubated phosphofructokinase 
with ATP for 2 minutes before initiating the reaction with F6P. Other 
workers (e.g. 11, 57, 60) initiated the reaction with enzyme. In our 
studies, we have found that phosphofructokinase is rapidly inactivated 
when preincubated with ATP. Bearing in mind the proposed association/ 
dissociation model for regulation of phosphofructokinase activity (103), 
it is apparent that preincubating with either substrate at the expense 
of the other would create a physiologically unnatural state where the 
enzyme tends to be either far more, or far less aggregated than would be 
the case in vivo. On the other hand, if the reaction is initiated with 
the enzyme, it will be exposed to all the substrates and effectors 
simultaneously, and apparently the equilibrium position between active 
and inactive forms will be reached more rapidly. For this reason, in all 
the kinetic experiments reported below, reactions were initiated by 
addition of enzyme. 
3.3.2 Enzyme purification 
Pig spleen phosphofructokinase was purified by a modification of 
the method of Massey and Deal (159). Full details of the purification 
procedure are contained in Section 3.4.1 below. Buffers used were as 
follows: 
Buffer A 
Buffer B 
Buffer C 
50 mM Tris-Cl, 50 mM 8-mercaptoethanol and 
5 mM EDTA, pH 8.0; 
50 mM Tris-Cl, 50 mM 8-mercaptoethanol, 5 mM 
MgC1 2, 0.1 mM ATP and 0.1 ~ FDP, pH 8.0, 
Buffer B + 110 mM (NH4) 2 .so4 ; and 
Buffer D 80 mM potassium phosphate and 1 mM EDTA, pH 8.0. 
R;tt sp1 een phosphofructokinase was prep;tred in the same manner as 
l . f h M 2+ . . . t1c ptg spleen enzyme, as ar as t e g -prec1p1tat1on step . Rat 
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thymocyte phosphofructokinase was prepared essentially as described 1n 
Section 2.3.1 above, save that Buffer A for the purification of pig spleen 
phosphofructokinase was used for homogenization. 
3.3.3 Protein determination 
Protein concentrations were determined by a m1nor modification of 
Hartree's method (160). In our system, 8-mercaptoethanol gave a large 
blank which made it difficult to obtain accurate readings. Therefore, as 
a routine procedure, all protein samples were precipitated prior to assay 
by adding TCA to a final concentration of 5%. Samples were allowed to 
stand in the cold for 30 minutes, then the precipitates were collected by 
centrifugation, and made up to volume. Subsequent steps were as described 
by Hartree (160). 
3.3.4 Analytical methods 
The concentrations of all substrate and effector molecules were 
accurately determined by enzymatic assay, using the methods described 1n 
Section 2.3.4. 
3. 4 RESULTS 
3.4.1 Purification of pig spleen phosphofructokinase 
Pig spleen phosphofructokinase was partially purified by a 
modification of the method of Massey and Deal (159). Unless indicated 
otherwise, all procedures were conducted at 4°. 
1 . Homogenization. Frozen spleens were thawed overnight on ice. 
They were minced coarsely, then placed in a Waring Blendor with 2 volumes 
of ice-cold Buffer A. The suspension was then homogenized: once for 30 
seconds on "fast", and twice for 40 seconds on "slow". The resulting 
homogenate was then centrifuged for 40 minutes at 13,000 x g in a Sorvall 
RC-2B refrigerated centrifuge, and the supernatant removed by decanting. 
2 . 1/eai- e ihanol tPeatment. To the surcrnatant fluid, 8-rnercaptoethanol 
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(1 ml/100 ml solution) and 95% ethanol (20 ml/100 ml solution) were added. 
The solution was placed in a water bath at 41° and shaken at 100 
oscillations per minute for 45 minutes. At the end of the incubation 
period the suspension was centrifuged for 15 minutes at 10,000 x g, and 
the cleat red supernatant decanted and stored. 
3. Magnesium-precipitation (see Figure 3-1). 1 M MgC1 2 (5 ml/100 ml 
solution) was slowly added to the supernatant, which was then stirred for 
45 minutes in the cold. The enzyme-containing precipitate was collected 
by centrifugation for 15 minutes at 12,000 x g. 
4 . Washing. The red-brown pellets obtained were pooled and 
dispersed with a glass rod in 10 mls of Buffer B, then centrifuged for 
15 minutes at 30,000 x g. The supernatant was poured off and the washing 
procedure repeated twice more. At this stage the enzyme-containing pellet 
was red-brown in colour, and the supernatant obtained after each washing 
had changed in colour from red to nearly colourless. Phosphofructokinase 
was solubilized from the pellet by addition of Buffer C, in the ratio of 
1 ml/70 g starting material. After lengthy dispersal 1n this buffer, the 
solution was centrifuged and the supernatant decanted and stored. 
Prolonged dialysis against three changes of Buffer D, gave the "washed" 
enzyme, which was used for the majority of the kinetic experiments 
reported below. However, about 20% of the studies conducted were made 
with a more highly purified form of enzyme, prepared as described below. 
5. DEAE-cellulose column chromatography. This step was introduced 
primarily to see if any different enzymatic forms of phosphofructokinase 
could be separated. The dialyzed "washed" enzyme was applied to a column 
(15 cm x 1.5 cm) containing DEAE-cellulose equilibrated with Buffer D, and 
was washed with 50 ml of the same buffer. A gradient was then introduced 
with the same buffer plus 0 - 500 mM (NH4) 2.so4 . Five ml samples were 
collected, and both the wash and gradient-elution fractions assayed for 
Figure 3-1 Th M 2+ . . t• b d . f . 1 e g -prec1p1ta 1on oun ar1es o p1g sp een 
phosphofructokinase 
Phosphofructokinase was precipitated and solubilized as 
described in Section 3.4.1. Assays of maximal activity were 
conducted as in Section 3.3.1. The concentration used during 
the purification procedure is SO mM. 
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+ phosphofructokinase activity and NH4 content. Figure 3-2 shows the 
elution profile. Fractions containing most of the activity in each peak 
were pooled, and phosphofr11ctokinase precipitated by adding solid (NH
4
)
2
.so
4 
to 65% saturation. After stirring overnight in the cold, precipitates were 
collected by centrifugation, dissolved in a minimal amount of Buffer D, and 
dialyzed extensively against the same buffer. The resultant solution 
contained the most highly purified phosphofructokinase obtained. A typical 
purification schedule is shown in Table 3-1. 
Both "wash" and "column" phosphofructokinase had similar 
stabilities in Buffer D, los ing 10 - 15% of the initial activity 1n one 
month, and retaining a considerable proportion (40 - 60%) of their activity 
after 2 - 3 months. In developing the system of preparing and storing 
phosphofructokinase, several stabilizing compounds including ATP, (NH
4
)
2
.so
4
, 
FDP and F6P were examined. All of these compounds significantly increased 
the stability of the stored enzyme, with FDP being by far the most 
effective. However, the majority of these stabilizing molecules have 
profound effects on the kinetic behaviour of phosphofructokinase 1n 
solution, and it was felt that for a project such as this, in which 
sensitivity to a wide variety of molecules was of major importance, 
stability should not be the supreme goal. A compromise choice was made, 
and the enzyme was stored in a potassium phosphate buffer at optimal pH. 
The reasons embodied in this choice were: 
(i) + 2-both K and P04 are abundant in the cell, so their 
stabilizing effect will be a natural one; 
(ii) on dilution in a cuvette, their concentration will 
be quite low (cf intracellular); 
(iii) their apparent K0 's suggest that they should 
instantly dissociate from the enzyme upon dilution; 
and 
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Table 3.1 
FRACTIONATION STEP 
1. Initial Supernatant 
2. Heat-ethanol supernatant 
3 \1 2+ . . . d . t'g -prec1p1tat1on an 
wash 
4. DEAE-cellulose + (NH4) 2.so4 
- Peak 1 
- Peak 2 
Purification schedule for pig spleen phosphofructokinase 
VOLUME 
(mls) 
1040 
912 
7.5 
3 
2 
TOTAL 
ACTIVITY 
(units) 
1139 
753 
235 
108 
88 
TOTAL 
PROTEIN 
(mg) 
51376 
7852 
31 
} 24 
SPECIFIC 
ACTIVITY 
(U/mg) 
0 . 023 
0.096 
7.45 
5.6 
18.6 
YIELD 
(%) 
100 
67 
21 
} 17 
PURIFICATION 
1 
4 
324 
81 5 
(Peak 2) 
(iv) t hese stabilizers appeared to have less effect 
on the kinetic behaviour of phosphofructokinase 
than any of the other molecules tested. 
Potassium phosphate will keep the enzyme active enough for only about 2 
months, whereas the same buffer containing 0.2 rnM ATP, 0.1 mM F6P, 2 mM 
(NH4) 2 .so4 and 0.2 mM dithiothreitol leaves the enzyme with 70% of its 
original act ivity after 4 months. Some stabilizers are essential as if 
the enzyme is dia lyzed against Tris-Cl pH 8.0, it will rapidly lose its 
activity and is unusable after 3 days. 
Neither of the two isoenzymes separated on the column displayed 
lOO 
much affinity for the DEAE-cellulose. The first came through in the wash, 
and the second was eluted by the addition of less than 50 mM (NH4 ) 2.so4 . 
Initial attempts to purify rat spleen phosphofructokinase utilized the 
batch DEAE-cellulose method of Tarui et al (57). This procedure was 
rejected when it was found that less than SO% of the activity in the 
initial supernatant was adsorbed. 
Each isoenzyme from the DEAE-cellulose column was compared in its 
response to the following effectors: + NH4 , AMP and ATP. Kemp (54) has 
shown that responses to AMP and ATP addition, demonstrate most clearly 
the kinetic differences between the two principal forms of 
phosphofructokinase, "muscle-type", and "liver-type". On this basis 
it was concluded that the two isoenzymes separate4 were kinetically 
almost identi cal, and all future experiments were conducted with either a 
1:1 mixture of the two types, or the "wash" enzyme. The more highly 
purified enzyme prepared by column chromatography, showed no differences 
in either stability or kinetic properties to the enzyme from the previous 
11\v:tsh" stage. 
3.4.2 Justification of the assay method 
The assay system, in most of the experiments reported 1n Chapter 3, 
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has depended upon the quantitative conversion of the product of the 
phosphofructokinase reaction, FDP, via 3 coupling enzymes, to 
a-glycerophosphate, with the subsequent oxidation of NADH. Although such 
coupled enzyme assays are described routinely in the literature, it was 
felt advisable to check the validity of the method in the present system. 
Figure 3-3 compares the reaction rates determined with the coupled 
enzyme method, and the direct assay method. Cuvette contents were as 
described in Section 3.3.1 for examination of regulatory properties. For 
direct assay, reaction mixtures were pipetted into cuvettes which contained 
no coupling enzymes. Reactions were initiated by the addition of 
phosphofructokinase, and at 15 second intervals were stopped by the 
addition of 100 ~L 5N HCl (lowers pH to <2.0). Samples were mixed 
thorough! and stood for 30 seconds before neutralization with 110 ~L 5N 
KOH. The optical density was read and the total amount of FDP formed was 
determined by addition of coupling enzymes, and measuring the oxidation 
of NADH. Corrections were made for the slight volume differences. Clearly, 
under the conditions used, the two methods gave identical results. 
3.4.3 Some general properties of phosphofructokinase 
In this section some of the more general properties of 
phosphofructokinase are presented. Figure 3-4 shows the sigmoidal 
response of phosphofructokinase to increasing F6P concentration, when 
assayed at pH 7.0 in the presence of fixed concentrations of MgATP. The 
sigrnoidicity observed 1s a function of the MgATP concentration. When 0.8 
mM MgATP was present, the Hill Coefficient was calculated to be 1.41 , and 
when 1.5 mM MgATP was used, the Hill Coefficient increased to 1.79. As 
presented in the diagram, it h7ould appear that the maximal velocity 
observed is also a fliDction of the MgATP concentration. However, such 
an interpretation is superficial, as, when the protein concentration is 
d u11 'd, m;1xilllal velo itics at both cone ntrations of Mg Ti> ;1re increased, 
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Figure 3-3 Comparison of coupled and direct enzyme assays 
Conditions as described in the text. 
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and the disparity between the velocities recorded at high F6P concentration 
becomes less pronounced. Accompanying this change in protein concentration, 
the Hill Coefficients fall. This effect is shown later in Table 3-14. 
The ability of the enzyme to display sigmoidal kinetics parallels its 
ability to respond to effector molecules. As will be shown later, many 
factors control the response of phosphofructokinase to its effector 
molecules, including the MgATP concentration, protein concentration, pH 
and the presence of other effectors. 
Both Table 3-2 and Figure 3-5 reflect the sensitivity of 
phosphofructokinase to pH. In Table 3-2, the concentrations of substrates 
required to give half-maximal velocity (Km) at both pH 7.0 and 8.0, are 
shown. 
Table 3-2 
Michaelis constants for the substrates of phosphofructokinase 
K 
m 
F6P Mg.ATP 
(llM) (llM) 
pH 7.0 350 40 
pH 8.0 32 60 
At each pH, one substrate was held steady at constant, saturating levels, 
whilst the activity was titrated with respect to the second substrate. 
When the K for F6P was measured, the MgATP concentration was held steady 
m 
at 2.0 mM, and when the K for MgATP was measured, the F6P level was fixed 
m 
at 2.0 mM. Of greatest interest is the large increase in K for F6P as m 
the PH d Crea e from 8 0 to 7 0 When the nonnal ~n v~vo levels of F6P e S S o o o V V 
are considered (see Table 2-3), it is apparent that in the presence of 
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Figure 3-5 The effect of pH on phosphofructokinase activity 
Assays were conducted at the indicated pH, as described 
1n Section 3.3.1. 
--··0·-- 0. 2 mM F6P, 2. 0 mM Mg .ATP; 
--·- 0.2 mM F6P, 0.4 mM Mg.ATP; 
-·-O-· 1. 0 mM F6P, 0. 2 mM Mg .ATP. 
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physiological concentrations of ATP, phosphofructokinase will be very 
inhibited. Although no values are shown here the K for F6P at pH 7.0 
' m 
increases as the MgATP concentration increases. Kemp (54), has also 
observed this. In his system, increasing the MgATP concentration from 
0.5 to 2.0 mM raised the K for F6P 2-3 fold. 
m 
In Figure 3-5, phosphofructokinase was assayed at different pH values 
under 3 sets of conditions: 
(i) with substrates present at near-optimal concentrations; 
(ii) with substrates present at mildly inhibitory 
concentrations; and 
(iii) with substrates at highly inhibitory concentrations. 
The three curves are drawn on the same scale to emphasize the degree of 
inhibition at the different pH's. However, at the optimal pH of 8.2, the 
velocity with optimal substrate concentrations present was only 20% higher 
than that observed in the presence of highly inhibitory substrate 
concentrations. Evidently the different velocities observed at different 
pH's, represent primarily differing sensitivities to MgATP inhibition. 
The intracellular pH of the circulating human lymphocyte is 7.3 (161) 
though it may decrease significantly during periods of increased metabolic 
activity, as increased levels of acidic metabolic end products accumulate. 
It is in this pH region that phosphofructokinase is most sensitive to 
inhibition by MgATP. 
3.4.4 Survey of effector molecules 
In this section, a variety of potential effector molecules have been 
tested. This is not intended to be an exhaustive examination of all 
possible effectors, but is an attempt to scan several families of molecules, 
members of which have been reported previously to be effectors of 
phosphofructokinase, or for which some regulatory role might be anticipated 
on teleological grounds. For this survey, all assays were conducted at 
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pH 7.0, a pH at which the regulatory properties of the en zyme are most 
easily visualized. Concentrations used are not intended to approximate 
physiological levels in any way, but are high enough to ensure that any 
potential effect will be seen. Any molecules which were found to 
significantly alter phosphofructokinase activity were subsequently 
examined in greater detail, and these results recorded in Sections 
3.4 . 5 and 3.4.6 below. 
The ability of the glycolytic intermediates to alter 
phosphofructokinase activity is shown in Table 3-3. 
Table 3-3 
The effect of glycolytic intermediates on 
phosphofructokinase activity 
Assays were conducted at pH 7.0 with 0.2 mM F6P and 1.0 mM MgATP. 
For assay of FDP effect, an excess of dialyzed pyruvate kinase, and 
lactate dehydrogenase in glycerol suspension was added, with 0.8 mM 
PEP. Activity was observed as the oxidation of NADH at 340 n.m. 
ADDITION 
None 
D-Glucose (4 mM) 
G6P (1. 3 mM) 
FDP (0. 3 mM) 
3-PGA (2. 0 mM) 
2-PGA (2. 3 mM) 
PEP (2. 0 mM) 
Pvruvate (~.s mM) 
-----
RELATIVE 
ACTIVITY 
100 
107 
91 
122 
62 
78 
40 
105 
All intermediates except F6P, the triose-phosphates and 1,3-JjPGA were 
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tested. The ability of F6P to activate phosphofructokinase was discussed 
earlier in Chapter 1 of this thesis. More will be said of its role later. 
Of the intermediates examined, glucose, G6P and pyruvate appeared to be 
ineffective, whilst FDP was a weak activator, and 3-PGA, 2-PGA and PEP 
were inhibitory to varying degrees. FDP is reported to be a potent 
activator of phosphofructokinase from several mammalian tissues (52, 58). 
At no time, and under no conditions during the present study, did it 
increase activity by more than 40%. These results were reproducible, and 
it was concluded that the low degree of activation was a real property of 
the spleen enzyme. The inhibition by the phosphoglycerates and PEP has 
been observed for phosphofructokinases isolated from several tissues (49, 
59). The concentrations of these molecules were far higher than is found 
in lymphoid tissues in vivo. A more detailed study of the kinetics of 
this inhibition is presented 1n Section 3.4.6 below. 
Suter (20), during his investigations into the fuels of respiration 
of the rat spleen slice, found that the levels of some endogenous amino 
acids changed when incubations were conducted in the presence as opposed 
to the absence, of glucose. The only one which changed significantly was 
aspartate, the levels of which fell from 13.2 to 9.5 ~moles/g. dry wt., 
when slices were incubated for 60 minutes with 3 mM glucose. The levels 
of several other amino acids also changed, but with such large standard 
errors that the differences were not significant. Table 3-4 shows how 
these amino acids alter phosphofructokinase activity. Clearly none are 
inhibitory, and glutamine and aspartate appear to be stimulatory. So far 
as is known, this is the first report of an am1no acid being an effector 
for phosphofructokinase. A study of the kinetics of activation by 
aspartate is presented in Section 3. 4.5. 
Table 3-4 
Effect of some arn1no acids on phosphofructokinase activity 
Assay conditions as for Table 3-3. 
ADDITION 
None 
Glutamate (2. 5 mM) 
Glutamine (2.5 mM) 
Glycine (2.5 mM) 
Aspartate (2.5 mM) 
Alanine (2.5 mM) 
RELATIVE 
ACTIVITY 
100 
102 
135 
112 
160 
113 
109 
Regulation of phosphofructokinase activity by adenine nucleotides 
has been well documented. As shown in Table 3-5, ATP is the only 
nucleotide to significantly inhibit phosphofructokinase, whilst ADP, AMP 
and cAMP are the only nucleotides to cause a large activation. 
Table 3-5 
Effect of some nucleotides and nucleosides 
on phosphofructokinase 
Assay conditions as for Table 3-3. 
ADDITION 
None 
ATP (2.0 mM) 
ADP (1. 0 mM) 
AMP (1.0 mM) 
cAMP (1.0 mM) 
Adenosine (2.5 mM) 
IDP (2. 5 mM) 
IMP (2. 5 mM) 
Inosine (2. 5 mM) 
cGMP (0.2 mM) 
-
- - - -- - ----- -- -
RELATIVE 
ACTIVITY 
100 
55 
125 
195 
161 
116 
89 
87 
103 
102 
110 
Other nucleoside triphosphates (NTP's) were examined, (Table 3-6), but 
clearly it is only the adenine nucleotides which have significant effects 
on enzyme activity. A detailed study of their effects is presented in 
Sections 3.4.5 and 3.4.6. 
A related study, that of the ability of other NTP's to act as 
substrates and inhibitors of phosphofructokinase, is presented 1n Table 3-6. 
Table 3-6 
The ability of various nucleoside triphosphates to act as 
substrates and inhibitors of phosphofructokinase 
Assays conducted at pH27.0, as described in Section 3.3.1, 
with 0.2 mM F6P and Mg + 3 mM in excess of the NTP. 
ACTIVITY+ IN VL 
NUCLEOTIDE 0 .3 mM 3.0 mM VH 
NTP NTP 
ATP 100* 22 4.55 
dATP 15 <1 
ITP 89 83 1.07 
GTP 103 67 1.54 
UTP 54 42 1.29 
CTP 47 34 1.38 
+ All values are expressed as a percentage of the activity 
in 0.3 mM ATP. 
*0.3 mM ATP is already mildly inhibitory. 
It must be understood that in the following section, when a NTP is 
referreu to as being a substrate or inhibitor, it is acting 1n this manner 
2+ . I 1 onlv \~hl'll hound :-ts a Mg -nucleot He l·omp ex. Several workers have 
considered this question, with varying results. Uyeda and Racker (49) 
2-found that ATP, ITP, UTP and CTP would all act as P04 donors for the 
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reaction catalyzed by skeletal muscle phosphofructokinase and, furthermore, 
that both ATP and UTP were highly inhibitory at high concentrations. 
Neither ITP nor CTP showed much inhibitory capacity. Lowry and Passoneau 
) 2-(58 found that the brain enzyme could use all the above NTP's as P04 
donors, and GTP and TTP as well . Of all these, ATP, ITP and UTP were 
inhibitory. In Table 3-6, all the NTP's were tested at a low concentration 
where they should nearly maximally activate the enzyme, and also at a 
concentration ten times higher, to see if any inhibitory effect was 
apparent. ATP, GTP and ITP appeared to be good substrates, UTP and CTP 
decidedly less efficient ones, and dATP a very poor one. Both ATP and 
dATP were strongly inhibitory at the higher concentration, whilst GTP, CTP 
and UTP were only slightly inhibitory. ITP apparently serves only as a 
substrate. Both Uyeda and Racker (49), and Lowry and Passoneau (58) 
found UTP to be inhibitory, but disagreed as to the effectiveness of ITP 
as an inhibitor. The results presented here agree with Uyeda and Racker 
that ITP is non-inhibitory, but are in contradiction to both groups in 
finding that UTP is only weakly inhibitory. 
Table 3-7 contains a miscellany of effector molecules: four Krebs-
cycle intermediates, P-creatine (which is reported to be an inhibitor of 
phosphofructokinase) 2- 2-and two radicals P04 and so4 which are also 
thought to be effectors for the enzyme. Citrate and succinate inhibit 
phosphofructokinase to a considerable extent, though at high 
concentrations. Malate is a poor inhibitor, and fumarate ineffective at 
the same concentrations. In all reports published to date, citrate, of 
all the Krchs'-cyc]c intermeJiatcs has been shown to be the most effective 
inhibitor of phosphofructokinase. 
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Table 3-7 
Effect of some Krebs' cycle intermediates and other 
metabolites on phosphofructokinase activity 
Assay conditions as for Table 3-3. 
ADDITION RELATIVE ACTIVITY 
None 100 
Citrate (2. 0 mM) 40 
Fumarate (2. 5 mM) 90 
Malate (2. 5 mM) 76 
Succinate (2. 5 mM) 65 
so 2-
4 (3.0 mM) 112 
PO 2- (3.0 mM) 109 4 
P-creatine (1.5 mM) 112 
As noted in Chapter 1, as far as inhibitors are concerned, it is very 
difficult to make quantitative comparisons with the results of other 
workers. However, Kemp (54) in his comparison of liver and muscle 
phosphofructokinases, found that the muscle enzyme was extremely sensitive 
to citrate, being almost totally inhibited by 0.5 mM, whilst the liver 
enzyme was less than SO% inhibited by 2 mM citrate. It is reasonable to 
suggest from the data in Table 3-7, that spleen phosphofructokinase is 
more similar in this respect to the liver than the muscle enzyme. A more 
detailed study of the citrate inhibition is presented in Section 3.4.6. 
Passoneau and Lowry (92) and Underwood and Newsholme (60) have also looked 
;1t the l'l-rccts of Krchs'-cyclc intcrmedi;ltcs on phosphofructokinase 
activity . Tn agreement with the results presented ;1hovc, they also found 
citrate to he the most effective inhibitor, whilst malate and succinate 
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were weakly inhibitory~ and fumarate ineffective. 
P-creatine is reported to inhibit phosphofructokinase activity (49). 
However~ from Table 3-7 it is apparent that no inhibition can be observed. 
Kemp (54) also found P-creatine to have little effect on enzyme activity. 
2- 2-P04 and so4 have only a small stimulatory effect on phosphofructokinase, 
but an additional property of both radicals, namely an ability to protect 
the enzyme from inactivation by MgATP, has led to a more detailed study 
of their effect. These results are contained in Section 3.4.7. 
MgATP is the natural substrate for phosphofructokinase. Muntz (45) 
reported that the brain enzyme could also use MnATP and CoATP as substrates. 
In Table 3-8 the ability of several divalent metal ions to substitute for 
2+ Mg is tested. 
Table 3-8 
d . 1 . 1 M 2+ The ability of some 1valent meta 1ons to rep ace g 
as substrate for the phosphofructokinase reaction 
Assays were conducted as 2~scribed in Table 3.3, save 
that instead of an excess of Mg , the particular metal ion, at the 
indicated concentration, was added. 
ADDITION RELATIVE ACTIVITY 
MgC1 2 (1. 5 mM) 100 
CaC1 2 (1. 5 mM) 0 
MnC1 2 (1.5 mM) 63 
CoC1 2 (1. 5 mM) 39 
SrC1 2 (1. 5 mM) 1 
CdC1 2 (1. 5 mM) 0 
BaCl 2 (1. 5 mM) 0 
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Instead of the normal 3 mM excess of metal 1on over ATP, onl y 1.5 mM 
metal ion was added in the presence of 1.0 mM ATP. This was done to 
ensure that any inhibition by free metal ions was kept to a minimum. As 
2+ 2+ 2+ 
with the brain enzyme, Mg , Mn and Co (as the Me-ATP complexes) were 
able to act as substrates for phosphofructokinase. Figure 3-6 shows the 
effect on enzyme activity, when these three metal ions are titrated at a 
fixed concentration of ATP. To clearly understand the significance of 
this data, it is necessary to refer to Table 3-12 in Section 3.4.7 later 
in this thesis. 
2+ This shows that both free Mg and free ATP inhibit 
2+ 
phosphofructokinase, but that free ATP is more inhibitory than free Mg . 
As referred to in Section 3.3.1, an excess of divalent metal ion is 
required before all of the ATP is quantitatively bound. Referring back 
. 3 6 . b h Mg 2+ d h 1 AT to F1gure . , 1t can e seen t at, as excee s t e tota P 
concentration, activity continues to rise. Under these circumstances 
free Mg2+ will be increasing rapidly, whilst free ATP levels will be low 
and falling. The conclusion to be drawn here is that free ATP is so 
highly inhibitory, that removing it, even by adding a large excess of 
another inhibitor (free Mg2+) causes an increase in activity. This data 
could be explained in another way, namely that there are two allosteric 
sites ilie enzyme for free 
2+ 
activator site with a high on Mg ' one an 
affinity for 2+ Mg , the other an inhibitor site, with a low affinity. 
However, considering the data in Table 3-12, and the results of Lowry and 
Passoneau (58), the above conclusion seems more appropriate. When, 
2+ 2+ however, either Mn or Co are titrated at a single concentration of ATP, 
2+ 2+ . 
maximal activity is reached when ATP and either Mn or Co are present 
in a ratio of approximately 1:1. 
2+ 2+ This suggests that Mn and Co are 
inhibitory to the same degree as ATP, and that all three species are far 
more inhibitory than Mg 2+ 
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Assays were conduct e d as in Table 3-·3, save tl1at tr.e metal 
t\)'l · onc ~n tT<lti.ons were v:1ri ·d ; 1 ~ inuicated . 
+ + Both K and NH4 are potent stimulators of phosphofruct okinase 
activity (83). Table 3-9 lists several other monovalent cations which 
were tested for their effect on the enzyme. 
Table 3-9 
The effect of some monovalent metal ions 
on phosphofructokinase activity 
Assays were conducted as described in Table 3-3, 1n the presence 
of the stated concentration of monovalent metal ion. 
ADDITION RELATIVE ACTIVITY 
None 100 
KCl (100 mM) 870 
LiCl (100 mM) 11 
CsCl (100 mM) 30 
NH4 .Cl ( 10 mM) 680 
Rb.Cl (100 mM) 430 
11 6 
K+, NH4+ and Rb+ showed strong stimulatory effects, whilst Li+ and Cs+ 
were inhibitory. A more detailed study of the kinetics of activation 1s 
presented in Section 3.4.5. 
3.4.5 Activators 
In Section 3.4.4, aspartate, AMP, cAMP, K+, NH4+ and Rb+ were all 
shown to markedly stimulate phosphofructokinase activity. In addition, 
2- 2-FDP, glutamine, ADP and possibly P04 , so4 and P-creatine gave some 
signs of activator potential. In this section, a more detailed examination 
will be ·made of the kinetics of activation by the more important of these 
effectors. 
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+ + + In Figure 3-7, the ability of K , NH4 and Rb to stimulate 
phosphofructokinase activity is demonstrated. In order of stimulatory 
. + + + 
capac1ty, K > NH4 > Rb . Of greatest interest is the difference in 
apparent activation constants (KA's) for the three ions. Both K+ and Rb+ 
+ have KA's of the order of 10 - 12 mM, whilst for NH4 this value is only 
0.35 mM. There is some suggestion that a high concentration of each cation 
causes a slight inhibition of enzyme activity. 
Regulation of phosphofructokinase activity by adenine nucleotides 
1s well documented (162, 163). Perhaps the single most important factor 
governing phosphofructokinase activity in vivo , is its almost total 
inhibition in the presence of the very high levels of ATP and very low 
levels of F6P found in living tissue. Newsholme (163) has pointed out 
that regulation of phosphofructokinase activity by variations in ATP levels 
alone would be unrealistic, as the extent of the necess ary change would 
affect too many other energy-requiring processes within the cell. However, 
small percentage changes in ATP levels are amplified via the adenylate 
kinase equilibrium into much larger percentage changes in the levels of 
ADP and AMP, both activator molecules. Figure 3-8 shows the ability of 
ADP, AMP and cAMP to activate phosphofructokinase. The calculated K 's A 
for these three nucleotides were 0.035 mM, 0.028 mM and 0.031 mM 
respectively. In order of stimulatory capacity; AMP > cAMP > ADP. 
Figure 3- 9 shows the act ivation of phosphofructokinase by aspartate. 
The apparent KA was calculated to be 0.7 mM. So far as is known, there 
have been no previous reports of activation by aspartate. 
2-Both FDP and P04 have been reported to significantly activate 
phosphofructokinase (58). However, as was mentioned briefly in Section 
3.4.4, they were not observed to have any great stimulatory effect on the 
p1g spleen enzyme. What was noted with Po4
2
- and indirectly with FOP, 
wa s that thC'SC' regulators appear to be most effective in blocking inhibition 
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Figure 3-7 Th b . . f + + d + e a 1l1ty o K , NH4 an Rb to stimulate 
phosphofructokinase 
Assays were conducted as described in Table 3-3, save that 
the monovalent metal ion concentrations were varied as indicated. 
Figure 3-8 The ability of ADP, AMP and cAMP to stimulate 
phosphofructokinase 
Assays were conducted as in Table 3-3, in the presence 
of the indicated concentration of nucleotide. 
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Fig:.tre 3-9 The ability of Aspartate to stimulate phosphofructokinase 
Assays were conducted as 1n Table 3-3 , with the indicated 
concentration of Aspartate. 
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or inactivation by MgATP. On the basis of experiments conducted with the 
pig spleen enzyme, it appears that a more appropriate description of their 
function would be protectors rather than activators. A consideration of 
this property is contained in Section 3.4.7 below. 
3.4.6 Inhibitors 
Phosphofructokinase exists in vivo 1n a highly inhibited state. 
Suter (20), on the basis of his studies of glycolysis in rat spleen slices, 
estimated that even when glycolysis was occurring at its maximal rate 
(during anaerobiosis), phosphofructokinase activity only achieved about 
10% of its maximal catalytic capacity, i.e. when assayed in the presence 
of optimal concentrations of substrates in vitro. In this section, the 
inhibitors identified in Section 3.4.4 are examined in greater detail, 1n 
an attempt to determine which molecules might be primarily responsible 
for the very low activity of phosphofructokinase in vivo. 
MgATP is a potent inhibitor of pig spleen phosphofructokinase. In 
Figure 3-10 the ability of MgATP to inhibit the enzyme at two different 
concentrations of F6P is shown. Evidently the presence or absence of F6P 
is of considerable importance in determining the degree of inhibition by 
MgATP. In the presence of 0.2 mM F6P, the apparent K. for MgATP is only 
1 
1.3 mM, whilst 1n the presence of 0.5 mM F6P, the apparent K. 1ncreases 
1 
to 3.0 mM. It 1s also noteworthy that in the presence of 0.5 mM F6P, 
maximal activity is not reached until 0.3 mM MgATP is present, whereas 
with only 0.2 mM F6P maximal activity 1s reached in the presence of only 
0.1 mM MgATP. In the freeze-clamped rat spleen, the intracellular 
concentration of ATP is 4.3 mM, whilst that of F6P is only 0.05 mM (see 
T:thle ~-3). Clearly phosphofructokinase will be highly inhibited under 
these conditions. 
In Figure 3-11 the inhibitory effects of citrate and PEP are shown. 
Citrate has a differential inhibitory effect on the enzyme from different 
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Figure 3-10 Inhibition of phosphofructokinase by MgATP, and the 
ability of F6P to counter this inhibition 
J\ssays were conducted ~sin Tabl e 3- 3. 
Figure 3-11 Inhibition of phosphofructokinase by citrate 
and PEP 
Assays conducted as in Table 3-3. 
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sources, being a particularly potent inhibitor of muscle phosphofructokinase 
(83) . In this study the apparent K. for citrate was found to be of the 
l 
order of 1.2 mM. PEP had a very similar effect on enzyme activity, the 
apparent K. for this effector being approximately 1.5 mM. l 
The phosphoglycerates are reported to be inhibitors of 
phosphofructokinase (59). Figure 3-12 compares the inhibitory capacity 
of 3-PGA, 2-PGA and 2,3-diPGA. None of these molecules proved to be very 
effective inhibitors of the enzyme, with the apparent K. for 3-PGA being 
l 
approximately 3.0 mM, and for 2,3-diPGA approximately 2.2 mM. 
The ability of metal ions to control enzyme activity is considered 
to be an important possible means of metabolic control (164). MgATP is 
the substrate for phosphofructokinase and availability of Mg2+ may be 
important both for controlling substrate availability, and for chelating 
free ATP, thus preventing inhibition by this highly inhibitory agent 
(see reference 58, and Section 3.4.7 below). It has already been shown 
that eaATP is not a substrate for phosphofructokinase (Table 3-8). This 
metal ion could conceivably act as an inhibitor of phosphofructokinase by 
competitively binding ATP, thus reducing availability of MgATP as a 
2+ 2+ 
substrate. In Figure 3-13, both Mg and ea were titrated at a fixed 
2+ ATP concentration. It is apparent that free Mg has a negligible 
inhibitory capacity of its own, with an apparent K. of the order of 20 mM. 
l 
2+ 
ea also is inhibitory, but here the situation is more difficult to 
interpret as a number of ionic species are present. The observed 
inhibition will be due to both ea2+ 
possibly also to inhibition by free 
. . h Mg 2+ f A P d compet1ng w1t or T , an 
ea
2
+. For this reason, a K. cannot be 
l 
given for any particular ionic species, only an apparent K. for "calcium" 
l 
of 1.2 mM; 
3.4.7 Kinetic data relating to the role of different effector molecules 
During the course of this work, it became apparent that the various 
Figure 3-12 Inhibition of phosphofructokinase by 
phosphoglycerates 
Assays conducted as in Table 3-3. 
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Figure 3-13 Inhibition of phosphofructokinase by Mg2+ 
2+ 
and Ca 
Assays were conducted as in Table 3-3, save that for 
examination of the Mg2+ effect, ATP levels were held at 1 mM, 
2+ 
whilst for examination of Ca effect, ATP was held at 1 mM, 
and Mg2+ and 4 mM. 
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effector molecules examined caused their alterations 1n enzyme activity 
in several different ways. In this section, kinetic evidence is 
presented which helps to clarify the mechanism by which various effectors 
modulate enzyme activity. Although it might be said that an investigation 
of the mechanism of control is not directly relevant to the mainstream 
of this thesis, it was felt that the information which could be obtained 
was relevant to the investigation of phosphofructokinase from any source. 
It was shown earlier in this thesis (Table 3-6) that whilst both 
MgATP and MgiTP will act as substrates for phosphofructokinase, only MgATP 
is inhibitory. Kemp has presented evidence (165) which suggests that 
MgiTP does not bind to the MgATP allosteric site. Utilizing this property, 
it 1s possible to divide effectors into two groups, those which act 
by binding at, or influence binding at the MgATP allosteric site, and 
those which bind at entirely unrelated sites. In Table 3-10, the ability 
+ 
of AMP and NH4 to synergistically activate phosphofructokinase is examined. 
The concentrations of NH4+ used are non-saturating and near-saturating 
respectively, whilst the AMP concentration is saturating. + Clearly NH4 
will stimulate when either MgATP or MgiTP is the substrate, whilst AMP 
will stimulate only when MgATP is used. Thus there is a fundamental 
difference in the mode of activation by the two effectors: activation by 
AMP is dependent upon the occupation of the MgATP allosteric site by 
+ inhibitor, whereas NH4 activates independently of the occupation of this 
+ 
site. It is also clear that NH4 and AMP act synergistically when each 
ligand 1s present at saturating concentrations. 
+ + Table 3-11 examines the synergism between NH4 and K under the same 
experimental conditions. + + . Clearly both NH4 and K st1mulate 
phosphofructokinase activity when either MgATP or MgiTP is used as the 
phosphate donor, and the activation by one ligand can be demonstrated in 
the presence of saturating concentrations of the other. 
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Table 3-10 
Synergistic activation of phosphofructokinase 
+ by NH4 and AMP 
Assays were conducted as in Table 3-3, save that where appropriate, 
ITP was substituted for ATP. 
NH + NH + PHOSPHOFRUCTOKINASE ACTIVITY AMP % in MgiTP % (0 .17g mM) (1. 754rnM) (1. 0 mM) in MgATP stim. stim. (U/ml) (U/ml) 
0.256 0 0.246 0 
+ 0.569 120 0.610 150 
+ 1.003 290 0.819 230 
+ 0.453 90 0.273 10 
+ + 0.919 260 0.567 120 
+ + 1.367 430 0.831 240 
Table 3-11 
Synergistic activation of phosphofructokinase 
+ + by NH4 and K 
Assays were conducted as in Table 3-3, save that where appropriate, 
ITP was substituted for ATP. 
PHOSPHOFRUCTOKINASE ACTIVITY 
NH + K+ 
in MgATP % stim. in MgiTP % stim. (10 ~) (100 mM) (U/ml) (U/ml) 
0.31 0 0.26 0 
+ 1.47 374 1.61 619 
+ 2.37 663 2.26 871 
+ + 3.61 1161 2.58 994 
129 
This result is important as it has been suggested that NH4+ and K+ share 
the same binding site in analogous manner to pyruvate kinase (86). 
However, other workers have also observed stimulation by NH4+ in the 
presence of K+ (83, 166). This result in no way conclusively proves that 
NH4+ and K+ bind at separate sites, but it does suggest that NH4+ can 
stimulate phosphofructokinase in vivo in the presence of physiological 
. f + concentrat1ons o K . 
As mentioned 1n Chapter 1, evidence has accumulated which suggests 
that MgATP binding to its allosteric site inhibits by causing the enzyme 
to dissociate into inactive subunits. The next group of experiments 
utilizes this property of rapid inhibition when phosphofructokinase is 
preincubated with MgATP. Preliminary experiments were conducted in which 
reactions were initiated by adding highly diluted phosphofructokinase to 
buffer (pH 6.70), which contained high concentrations of MgATP. This 
approach was dropped subsequently for two reasons: 
(i) initiation of the reaction with enzyme, even under 
highly unfavourable circumstances, did not present 
as clear a picture of subsequent events as the 
method finally chosen; and 
(ii) to visualize enzyme activity at all, a high 
concentration of K+ had to be included in the 
assay buffer. 
+ As will be shown later in this section, the presence of K and F6P 
together can mask some very interesting results. A system where enzyme 
is preincubated with MgATP in the presence and absence of effectors, was 
finally chosen as the one from which most information could be obtained, 
particularly with respect to the mechanism by which effectors modulate 
enzyme activity. 
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Figure 3-14 shows the time course of inactivation of 
phosphofructokinase at two concentrations of MgAT-P, 1n the absence of 
other effectors. Reactions were initiated with 0.2 mM F6P and in all 
cases unless specifically mentioned, the reaction velocities were linear. 
This experiment shows clearly that the MgATP allosteric site is filled at 
very low concentrations of MgATP when F6P is absent (cf Figure 3-10), and 
that the inactivation process is a rapid one. 
In Table 3-12, the effect of preincubating phosphofructokinase with 
a variety of molecules, both singly and together, is shown. 
Table 3-12 
The effect on activity of preincubating 
phosphofructokinase with various of its substrates 
To cuvettes containing the indicated substrate(s), 
phosphofructokinase was added, then after 30 seconds the reaction was 
initiated with the other substrate(s). Samples marked "None", means 
that the reaction was initiated by adding phosphofructokinase to 
cuvettes already containing all the substrates. 
PREINCUBATION (30 seconds) 
WITH: 
None (0.2 mM F6P) 
Buffer alone 
0.4 mM ATP 
2+ 3.3 mM Mg 
0.2 mM F6P 
2+ 
0.4 mM ATP + 3.3 mM Mg 
0.4 mM ATP + 0.2 mM F6P 
03.3 mM Mg2+ + 0.2 mM F6P 
None (1.0 mM F6P) 
1.0 mM F6P 
0.4 mM ATP + 1.0 mM F6P 
3.3 mM Mg2+ + 1.0 mM F6P 
RELATIVE 
ACTIVITY 
100 
111 
0 
0 
112 
0 
36 
72 
113 
110 
110 
119 
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Figure 3-1 4 The effect on activity of preincubating 
phosphofructokinase with MgATP 
To cuvettes containing the indicated concentration of MgATP, 
phosphofructokinase was added and after the appropriate time 
int erval had elapsed, reactions were in i ti ated with 0.2 mM F6P. 
The following points are noteworthy: 
(i) initiating the reaction with enzyme, and preincubating 
the enzyme either with buffer alone, or with F6P, 
produce very similar results; 
(ii) preincubation with Mg2+ alone, causes a total loss 
of activity over the time interval used; 
(iii) preincubation with ATP alone also causes a total 
loss of activity; 
(iv) as expected from Figure 3-14, MgATP (plus a 3 mM 
excess of Mg2+) causes a total loss of activity; 
and 
(v) low levels of F6P are more effective at overcoming 
inhibition by Mg2+ than by ATP. 
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It was not possible to distinguish differences 1n the pattern of inhibition 
by free ATP, as compared to that found with MgATP plus Mg2+, which might 
be indicative of the preferential binding of either ATP or MgATP to the 
allosteric site. The inability of F6P to greatly increase the activity 
of phosphofructokinase on preincubation, suggests that the enzyme as 
stored and as used to initiate reactions, was fully active (i.e. fully 
aggregated). 
Figure 3-15 demonstrates the ability of F6P to block the inactivation 
of phosphofructokinase by ATP. If it is assumed that ATP inactivates the 
enzyme in similar fashion to MgATP, then this figure is of considerable 
interest when considering the in vivo situation, as it demonstrates how 
comparatively small changes in F6P concentration can change the activity 
of phosphofructokinase quite markedly. 
In Table 3-13, data is presented which shows how various of the 
effector molecules influence the inactivation of phosphofructokinase, 
during preincubation with MgATP. At first glance there would only appear 
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Figure 3-15 The ability of F6P to overcome the ATP preincubation 
of phosphofructokinase 
Samples were preincubated with either 0.5 or 2.0 mM ATP, and the 
indicated concentration of F6P. After 20 seconds the reaction was 
2+ 
initiated with either 3.3 or 5.1 mM Mg . 
Table 3.13 Time course of inactivation of phosphofructokinase when preincubated with 0.4mM Mg ATP 
and the indicated concentration of effector molecule 
After preincubation for the indicated period, reaction was initiated with 0.5mM F6P. 
TIME 
PREINCUBATED 
(seconds) 
0 
5 
10 
20 
NONE 
100 
13 
8 
5 
= 0.5mM AMP 7.0mM P04 
100 100 
72 62 
58 43 
52 12 
RELATIVE ACTIVITY (% V ) max 
ADDITION 
= 2.omM so4 2.7mM Asp 
100 100 
62 12 
39 9 
20 6 
5mM NH + 
4 
100 
18 
12 
5 
lmM citrate 
100 100 
17 4 
11 0 
9 0 
to be three groups of effector mol ecules present: 
(i) those which significantly slow the inactivation 
. 2- 2-process 1.e. AMP, P04 and so4 , 
(ii) those which appear to have little effect when 
+ 
compared to the control, i.e. aspartate, K and 
+ NH4 , and 
(iii) those which accelerate the MgATP-mediated 
inactivation of phosphofructokinase. Citrate 
is a representative of this group. 
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However, further subdivision must be made of the effectors in groups (i) 
and (ii). 2-Whilst all of AMP, P04 and 
both an activator and protector, whilst 
so 2-
4 
PO 2-
4 
protect the enzyme, AMP 1s 
2-
and so4 have only a 
protective function. In group (ii), with both NH4+ and K+, on addition of 
F6P initial velocity rates were low, as indicated in Table 3-13. However, 
after a lag period of 10 - 15 seconds, velocity was observed to steadily 
increase till after 2 minutes a linear velocity was obtained, similar to 
that observed if the enzyme was not preincubated. It must be emphasized 
that in all other cases, when reaction rates were initiated with F6P 
reaction rates were linear with respect to time. It was difficult to 
quantitate the final velocity reached, but it did appear that the longer 
the preincubation the further from V0 was the final velocity obtained. 
This might be taken to indicate that the inactivation of phosphofructokinase 
occurs in two stages, the first being a rapid inactivation which is readily 
reversible in the presence of appropriate effectors, and the second being 
a slower process which effectors are unable to reverse, at least over a 
short time interval. 
Unfortunately, to determine the effect of FDP it would have been 
necessary to couple the phosphofructokinase reaction to pyruvate kinase 
and lactate dehydrogenase. Pyruvate kinase is active only in the presence 
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+ 
of K , and as shown above this ion produces an effect which would have 
masked the effect of FDP. However, as mentioned in Section 3.4.1, FDP 
was the most effective stabilizer of the stored enzyme. In this respect, 
2- 2-its effect appears to be quite similar to that of P04 and so4 . 
The last part of this section deals with the role of enzyme 
concentration in determining both activity and kinetic behaviour. Figure 
3-16 shows that enzyme activity is not linearly proportional to enzyme 
concentration. The earlier results in this thesis were obtained using a 
phosphofructokinase solution concentrated enough for activity to be 
directly proportional to concentration. To show this concentration-
dependent effect it was necessary to go to a very low protein level (-300 
~g/ml, prior to a further 20- lOO-fold dilution in the reaction cuvette). 
With phosphofructokinase as dilute as this, K+ had to be added to ensure 
that activity could be visualized. The enzyme is saturated with K+ in 
vivo~ so the result here is very pertinent when considering the 
physiological role of phosphofructokinase. The activity using 50 ~L of 
enzyme solution was nearly 20x greater than with 5 ~L of enzyme, rather 
than the expected lOx greater activity. 
Table 3-14 demonstrates that the cooperative behaviour of 
phosphofructokinase is also dependent upon enzyme concentration. 
Table 3-14 
The effect of dilution on the sigmoidal response 
of phosphofructokinase to F6P 
Dilutions were conducted as in Figure 3-16. Assays were 
conducted as in Table 3-3. 
DILUTION FACTOR 
lx 
2.5x 
S.Ox 
HILL NO. 
1.24 
1.65 
1.87 
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The effect of dilution on phosphofructokinase activity 
Assays were conducted as in Table 3-3, save that 8S mM (saturating) 
+ K was added. Stock phosphofructokinase solution was diluted in the 
same buffer (80 mM potassium phosphate + 1 mM EDTA, pH 8.0) till S pL 
enzyme gave a small but clearly reCidable OD change. This was a 12x 
dilution. To avoid discrepancies due to widely ~..Hffering volumes of 
potassiwn phosphate buffer audcd (S -SO pL), enzyme+ diluting buffer 
was always added to a total volume of SO ~1 L. 
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Ordinary stock solutions of phosphofructokinase gave a Hill Coefficient 
of only 1.24, whereas a Sx-diluted solution gave a value of 1.87. The 
value of the Hill Coefficient g1ves some indication of the extent of 
interaction between the MgATP allosteric and the F6P substrate sites. It 
is apparent from Figure 3-16 that increasing the concentration of enzyme 
does not reduce specific activity, hence the decreased cooperativity at 
high protein concentration must be due to decreased binding of MgATP to 
its allosteric site. That it is the phosphofructokinase concentration 
which is important, is very apparent when a comparison is made with the 
data reported in Section 2.6.2. In crude supernatant solution, with 
protein concentrations of the order of 50 mg/ml, a sigmoidal response for 
phosphofructokinase could be clearly demonstrated. 
3.4.8 Simulation of in vivo conditions 
Although the results presented in the earlier part of this thesis 
have thoroughly covered the known effectors of phosphofructokinase, there 
1s a flaw in them (and in nearly all published work in the field), 
they were all conducted in the presence of ATP alone. In normal, living 
cells, although ATP is the predominant adenosine phosphate, significant 
amounts of ADP and AMP are also found and their relative levels are 
related through the action of adenylate kinase. Atkinson and coworkers 
(167, 168, 169) have suggested that it is the energy charge (half the 
average number of anhydride-bound phosphate groups per adenosine moiety) 
which may be the primary determinant of phosphofructokinase activity. 
In Figure 3-17 the role of the energy charge in regulating 
phosphofructokinase activity is examined. Rather than scan all the 
effector molecules that have been tested, representative effectors have 
been used. All activities are expressed relative to that observed at an 
energy charge of 0.59, under the conditions tested. Of particular interest 
is the extreme sensitivity to F6P concentration. In previous experiments 
done at an energy charge of 1.0, phosphofructokinase was strongly inhibited 
Figure 3-17 The interaction between energy charge and 
effector molecules in regulating 
phosphofructokinase activity 
Total adenine nucleotide concentration in each assay 
was 4 mM. Adenine nucleotides were added so that the ratio 
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1n the presence of 0.2 mM F6P. In the presence of physiological ratios 
and concentrations of adenine nucleotides (energy charge ~ 0.85), 
phosphofructokinase activity is completely unaffected when compared to the 
activity determined at a lower energy charge. If however the F6P 
' ' 
concentration is lowered till it approximates that found in vivo (see 
Table 2-3) then phosphofructokinase activity is inhibited at higher energy 
charges. The same qualitative effect was observed regardless of whether 
+ 
the experiment was conducted in the presence or absence of K . Sulphate 
appears to act in a manner directly analogous to that of phosphate, 
although it is effective at lower concentrations (see Table 3-13). Clearly 
its effect is to reduce the sensitivity of phosphofructokinase to energy 
charge regulation. Citrate on the other hand appears to slightly potentiate 
the sensitivity of phosphofructokinase to energy charge inhibition. It 
must be remembered that for the spleen enzyme, phosphofructokinase has a 
high K. for citrate (approximately 1.3 mM). In tissues such as muscle, 
1 
where phosphofructokinase is extremely sensitive to citrate inhibition, 
the effect of this inhibitor is probably far more pronounced. 
As shown earlier (Figure 3-13), free ATP greatly inhibits 
phosphofructokinase. Thiers and Vallee (170) found the concentration of 
total Mg2+ in the supernatant of rat liver to be only 1.4 mM, whilst the 
concentration of ATP in this tissue is of the order of double this value 
Mg 2+ (25). As can be seen in Figure 3-17, when the concentration of is 
reduced till it 1s equimolar or slightly less than the ATP concentration 
present, then even in the presence of somewhat raised F6P levels, 
phosphofructokinase becomes extremely sensitive to energy charge regulation. 
3.4.9 Comparative studies 
One nim of this thesis has been a comparison of some of the metabolic 
properties of spleen and thymus. Tn Table 3-15, some of the more important 
kinetic properties of pig spleen, rat spleen and rat thymus 
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phosphofructokinase are compared. 
Table 3-15 
Comparison of some apparent effector constants 
for phosphofructokinase from various sources 
The values for liver and muscle are from Kemp (54), and the values 
for pig spleen from earlier in this chapter. 
APPARENT PHOSPHOFRUCTOKINASE FROM: EFFECTOR 
CONSTANT Liver Muscle Pig spleen (mM) Rat spleen Rat thymus 
K. MgATP 1.6 3.0 1.5 1.6 1.1 
l 
K. citrate >2.0 0.3 1.3 1.6 
l 
KA AMP 0.21 0.035 0.03 0.03 0.04 
+ 
KA NH4 0.35 0.35 0.35 
0.37 0.40 
For comparison, Kemp's corresponding values (54) for the liver and muscle 
enzyme are included. However, it must be emphasized that the enzymes he 
used were prepared in very different fashion to the lymphoid enzymes, and 
the various kinetic constants he obtained may not be genuinely comparable. 
Pig spleen and rat spleen phosphofructokinases have essentially 
the same kinetic parameters. The only ones which are distinguishable are 
the respective K. 's for citrate, and it is questionable whether these are 
l 
significant. Of the three parameters measured for the thymus enzyme, the 
only difference distinguishing it from the spleen enzyme is that it is 
slightly more susceptible to MgATP inhibition. A more detailed 
consideration of the similarities and differences between spleen and thymus 
phosphofructokinase will be made in the Discussion. Tt is not possjblc 
to say from the data above, whether the lymphoid enzyme 1s more similar 
to the liver or muscle enzyme. When compared to Kemp's data (54) the KA 
for AMP is almost identical with that of the muscle enzyme. Lymphoid 
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phosphofructokinase is, however, far less sensitive to citrate inhibition 
than is the muscle enzyme. It appears likely from these studies that 
lymphoid phosphofructokinase is a hybrid form, and as suggested from 
electrophoretic data (171), intermediate between the liver and muscle 
enzymes in properties. 
3.5 DISCUSSION 
3.5.1 General considerations 
Phosphofructokinase is an extremely labile enzyme, and considerable 
difficulty was experienced in developing a satisfactory purification 
method. The procedure of Massey and Deal (159) was finally adopted. One 
important point which must be considered here, is the significance of the 
low yield obtained. Such a result immediately raises the possibility of 
the specific loss of one or more isoenzymes. However, comparison of 
Massey and Deal's original data (159) with that in Table 3-1, shows that 
such an expectation is probably unreasonable. Liver phosphofructokinase 
1s a homogeneous enzyme, and recoveries after successive purification 
steps were 39%, 36% and 17% (to the end of the "wash" step). Comparable 
recoveries in the present work were 67%, unknown and 21% (separate 
d d h M 2+ . . d ) determinations were not con ucte on t e g -prec1p1tate enzyme . 
Further evidence that no losses were experienced during purification, can 
be found in the electrophoretic data of Kurata et al (171), who 
demonstrated the presence of two isoenzymes in crude extracts from rat 
spleen. 
Although direct compar1son with other results in the literature can 
frequently be misleading, the affinity of spleen phosphofructokinase for 
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DEAE-cellulose does bear some comment. Reported column fractionation 
methods have of course used different buffers and indeed, different 
materials (DEAE-cellulose or DEAE-Sephadex). The results however, have 
been qualitatively very similar: the muscle enzyme has a low affinity 
for DEAE-cellulose (or DEAE-Sephadex) and is eluted readily (56, 78), 
whilst the liver enzyme has a much greater affinity, and a considerable 
change in ionic strength is required before this isoenzyme is eluted (78). 
No reports have noted that any isoenzymatic form of phosphofructokinase 
did not bind to DEAE-cellulose or DEAE-Sephadex. It must be remembered 
that fractionation with DEAE-cellulose was tried by both column and batch 
preparative methods, the latter under identical conditions to those 
described by Tarui et al (57), and similar results were obtained each 
time. Two different batches of DEAE-cellulose were used at various times, 
and similar results were obtained. It must be concluded that at least 
one isoenzyrne of spleen phosphofructokinase has somewhat different charge 
properties, to those of previously reported isoenzymes. 
Studies on the pH optimum of spleen phosphofructokinase produced 
results essentially similar to those already recorded (56, 65). Under all 
three conditions tested, the pH optimum was found to be 8.2. As noted 
earlier, the different velocities observed at different pH's are very 
much a function of the relative concentrations of MgATP and F6P. At 
physiological pH, and in the presence of physiological concentrations of 
effectors, it 1s probable that phosphofructokinase will exist in a highly 
inhibited state. Intracellular pH can vary depending on the metabolic 
conditions that prevail, and it 1s probable, as Trivedi and Danforth have 
suggested (172), that small changes in the intracellular pH may be 
important ·in regulating the ;Ict ·ivity of phosphofructokinase. 
The data presented in Pigurc 3-4 and it accompanying text, and 
Table 3-14, lend some credence to Bloxham and Lardy's suggestion (73) that 
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in some cases sigmoidal kinetics may represent an experimental artefact. 
Dilution of phosphofructokinase leads to inactivation (Figure 3-16) and 
to an increased sigmoidal response (Table 3-14). Binding of MgATP to its 
allosteric site is necessary for cooperative kinetics (102), and causes 
inactivation. Thus a sigmoidal response is a function of MgATP binding 
to its allosteric site. With little knowledge available as to the precise 
intracellular environment that phosphofructokinase exists in, it is not 
possible to offer any meaningful comment as to the importance or otherwise, 
that sigmoidal kinetics may play in the regulatory behaviour of this enzyme. 
3.5.2 The effector molecules of spleen phosphofructokinase 
The data contained in Tables 3-3 - 3-9 inclusive suggests that the 
following molecules may affect phosphofructokinase activity in some manner; 
+ + 2-ATP, ADP, AMP, cAMP, F6P, FOP, Aspartate, K , NH4 , P04 , citrate, and 
the interrelationship between divalent metal ions and ATP. 
Adenine nucleotides. It has long been recognized that adenine nucleotides 
are the principal regulators of phosphofructokinase in vivo (89, 162). 
Both ATP and MgATP are potent inhibitors of enzyme activity (58, 67), 
whilst both ADP and AMP relieve this inhibition (162). Although 
considerable work has been done on the manner in which these individual 
effectors regulate phosphofructokinase activity, comparison of Figures 
3-10 and 3-17, show that they are best considered together. Their role, 
under the heading of energy charge regulation of phosphofructokinase 
activity, will be discussed more fully in Section 3.5.4 below. 
F6P and FDP. The role of F6P in regulating enzyme activity will also 
be considered in Section 3.5.4. The apparent lack of significant 
activation by FDP is the most puzzling result 1n this thesis. Lowry and 
Passoneau reported (58) that the apparent KA for this effector was of the 
order of 1 ~M or less. In addition to conducting experiments directly on 
the effect of FOP using a pyruvate kinase/lactate dehydrogenase couple, 
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Figure 3-3 also supports the assertion that FOP is a weak activator. 
When the direct assay system was tested, FOP was allowed to accumulate. 
At the longest time interval used, FOP concentration in the cuvette was 
of the order of 20 ~M, -- well above the reported KA, yet no suggestion 
of an increased rate was observed. On the other hand, FOP was found to 
be an excellent stabiliser of the enzyme. The net conclusion reached on 
the basis of the in vitro studies reported here, must be that FOP is an 
effector of phosphofructokinase, but that its effect on the spleen enzyme 
is far less pronounced than that observed for the enzyme from other sources. 
Aspartate. During the preliminary screening of possible effector 
molecules, aspartate was found to activate the spleen enzyme with an 
apparent KA of approximately 0.7 mM. Greenbaum et al (88) calculated the 
cytoplasmic concentration of aspartate in liver to be 0.65 mM, and found 
that this level fell during starvation, and rose during the refeeding of 
a high carbohydrate diet. In addition to the finding that its level, in 
vivo~ is very close to the apparent KA' the excellent correlation between 
aspartate levels and phosphofructokinase activity, supports the contention 
that aspartate 1s a regulator of enzyme activity in liver. 
The role of aspartate in regulating phosphofructokinase 1n spleen 
and thymus is less certain. Chan (120) has measured aspartate levels in 
both tissues, and calculated the cytoplasmic concentration by the method 
of Williamson (173). In spleen this value was 1.7 mM, and 1n thymus 2.5 
mM, i.e. both well above the apparent KA. Under no conditions observed, 
did the levels of aspartate drop to anywhere near the KA concentration. 
As however, the effects of other regulatory molecules can still be observed 
1n the presence of aspartate, it is unlikely that aspartate is an important 
regulator 1n lymphoid tissue. It is more likely to be of importance in 
tissues like liver or muscle, where sensitivity to a wide range of effector 
molecules will enable large changes in activity to occur. 
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+ + K and NH4 . The strong activatory capacity of both K+ and NH4+ has 
long been known (43, 45, 174). Although phosphofructokinase has a greater 
affinity for NH4+ (apparent KA 0.3 mM), than forK+ (apparent KA 10- 15 
+ 
mM), K appears to be favoured as it is present in the cell at 
concentrations which will saturate phosphofructokinase (84). + NH4 could 
still be an important regulatory molecule if there is a separate binding 
site for it on the enzyme. Several reports (52, 83, 166), in addition to 
work contained in this thesis, have reported activation by NH4+ in the 
f . . f K+. presence o saturat1ng concentrat1ons o However, other work 
contained in this thesis has served only to emphasize the similarity of 
the activation by both ions. Final comment on the possible physiological 
role of NH4+ as an activator of phosphofructokinase, will have to await 
competitive binding experiments with homogeneous enzyme. 
Phosphate. The results in this thesis are essentially 1n agreement with 
published reports (82, 175), that P04
2
- is an effector for 
phosphofructokinase. However, rather than the activation observed 1n 
2-
earlier reports, the principal role of P04 on the lymphoid enzyme appears 
to be as a protective agent. 
1s contained in Section 3.5.4. 
Further consideration of the role of PO 2-4 
Citrate. Citrate inhibits spleen phosphofructokinase as it does the 
enzyme from all mammalian tissues studied. Chan (120) has measured citrate 
levels in spleen and thymus, and found the cytoplasmic concentrations of 
both to be of the order 0.15 - 0.25 mM. Although citrate is undoubtedly 
a potent inhibitor of phosphofructokinase activity in tissues such as 
muscle, it appears unlikely that the spleen enzyme, which has a Ki for 
citrate 5 - 10 times greater than the intracellular concentration, will 
be greatly affected. 
Divalent cations and free ATP. Free Mg2+ is a weak inhibitor, and it 
is unlikely that this 10n would, itself, be of any importance as a 
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regulator of phosphofructokinase activity. Its more usual form within 
the cell is as a complex, either to various proteins, or as MgATP. ca2+ 
probably exists in very similar ionic forms as does Mg 2+. However, CaATP 
is not a substrate for phosphofructokinase (see Table 3-8), and thus may 
act as an inhibitor by competing with MgATP for the catalytic site. One 
intriguing possibility which remains, 1s that of inhibition of free ATP. 
Rolleston (176) has postulated that free ATP may be of physiological 
importance in regulating cerebral cortex hexokinase activity. As Lolley 
has shown (177), a large proportion of the divalent metal 1ons present 
within the cell, may be bound to intracellular components other than ATP. 
2+ 
As demonstrated in Figure 3-17, when the levels of available Mg and ATP 
are finely balanced a slight increase in energy charge may cause a 
significant inhibition of enzyme activity by ATP. Thus the possibility 
that free ATP is a physiological regulator of phosphofructokinase activity 
cannot be dismissed lightly. 
3.5.3 Mechanism of action of effector molecules 
The introductory section and the results relating to 
phosphofructokinase have been consciously presented with the association/ 
dissociation model for the enzyme in mind. So much evidence 1s available 
that phosphofructokinase exists in forms of different molecular weights 
(65, 68, 178, 179, 180, 181, 182) that further justification is not 
required. 
With the information that is already available 1n the literature on 
the binding of effectors to phosphofructokinase, the data in this thesis 
provides a useful insight as to the mechanism of action of effector 
ligands. From the data collected in Section 3.4, it appears that: 
(i) the binding of either ATP or MgATP to the 
allosteric site, inactivates the enzyme, probably 
by causing it to dissociate into inactive diners; 
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(ii) F6 2-P, AMP and P04 block this inactivation process, 
either by competitively binding to the ATP 
allosteric site, or by decreasing affinity at 
this site for (Mg)ATP; 
(iii) citrate enhances the binding of ATP to its 
allosteric site; 
(iv) aspartate appears to exert its stimulatory effect 
in some manner completely unrelated to the ATP 
allosteric site; and 
(v) + + K and NH4 do not appear to directly influence 
binding to the ATP allosteric site, but appear 
to do so in the presence of F6P (see text 
associated with Table 3-13). 
It must be emphasized that this data enables classification only into 
groups. Information as to the actual number and nature of binding sites, 
can only come with work on homogeneous enzymes. For this reason, no 
attempt is made to present a diagramatic model of phosphofructokinase. 
3.5.4 Similarities of the spleen and thymus enzymes 
As the data 1n this thesis has shown, spleen and thymus display 
similar metabolic properties, as do the phosphofructokinases from both 
sources. Although no work has been published comparing the kinetic 
properties of the spleen and thymus enzymes, two papers are relevant 1n 
this discussion. Yamada and Ohyama (63) partially purified the thymocyte 
enzyme and separated two isoenzymes by TEAE-cellulose chromatography, the 
minor one eluting in very similar fashion to a commercial muscle 
phosphofructokinase preparation. They compared some of the properties of 
the major component with those of the muscle enzyme, and found that the 
thymocyte enzyme was more susceptible to ATP inhibition, and more sensitive 
to activation by the other adenine nucleotides. Tsai and Kemp (81) tested 
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the effect of anti-sera to purified muscle and liver phosphofructokinases, 
on the enzyme from different tissues. Treatment with both anti-sera 
removed 98% of the activity of the spleen enzyme, but only SO% of the 
thymus enzyme activity. Thus, although similar in their kinetic behaviour, 
the spleen and thymus enzymes are immunoZogicaZZy distinct. 
3.5.5 In vivo regulation of phosphofructokinase, in relation to the 
observed alterations in glycolytic flux 
It has long been recognized that the adenine nucleotides together, 
are perhaps the primary regulators of phosphofructokinase activity (89, 
162). It was Atkinson who first presented data (167) which showed that 
physiological concentrations of all the adenine nucleotides could cause 
profound changes in enzyme activity. Most studies on the regulation of 
phosphofructokinase activity have been conducted with ATP or AMP, either 
singly or together. ADP is known to be an activator, but its role has 
largely been ignored, even though its concentration is usually many times 
that of AMP. Kemp and Krebs have demonstrated (69) that ATP, ADP and AMP 
all bind competitively at the one allosteric site, so meaningful 
consideration of the in vivo regulation of phosphofructokinase activity, 
requires the role of all 3 nucleotides to be examined. 
The data contained in Figure 3-17, 
Po4
2
- (so4
2
- acts in very similar manner 
suggests that F6P, free ATP and 
2-to P04 ) may all be important 
regulators of phosphofructokinase activity in vivo. Referring back to 
Chapter 2, four methods were used to perturb glycolytic flux. These 
were anaesthesia, anoxia, the GvH reaction and Con A stimulation. During 
the GvH reaction glycolytic flux rate appeared unchanged, whilst during 
the other conditions flux increased. Clearly regulation of 
phosphofructokinase is not by energy charge alone, as the only occasion 
on which this parameter changed largely was during anoxia, when it dropped 
1n accordance with expectations. Under none of the conditions utilized, 
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was it possible to test for inhibition by free ATP. Only during the GvH 
reaction did both the energy charge and the ATP concentration increase, 
and even here the change was small with the energy charge going from 
0.87 - 0.89. As the glycolytic rate does not change during the GvH 
reaction (20), no conclusions can be reached as to the possible role of 
free ATP in regulating phosphofructokinase activity. 
Increased glycolytic flux correlates poorly with F6P levels, as 
during two of the three conditions which caused increased flux, F6P levels 
dropped. However, increased flux rates correlated very well with increases 
2- 2 in both FDP and P04 . Although no value is shown for P04 - during 
anaesthesia, the large decrease in the adenine nucleotide pool ensured 
that Po4
2
- levels increased. During the GvH reaction, when glycolytic 
flux appeared unchanged, FDP levels dropped, whilst P04
2
- levels remained 
constant. Thus the most effective correlation observed is for Po4
2
-. 
Increased influxes of Po4
2
- have been reported to occur during the 
early stages of mitogen stimulation of thymocytes (183). Reference to 
Figure 2-5 where the progressive activation of glycolysis in thymocytes 
is shown, provides further indirect evidence of a role for Po4
2
- during 
the Con A-mediated stimulation of glycolysis. G6P is an inhibitor of 
hexokinase (33), and if elevated levels of this intermediate are to be 
maintained during glycolytic stimulation and glycogen synthesis, then the 
G6P inhibition must be overcome. Po4
2
- relieves the G6P inhibition of 
hexokinase (33). Thus, this hypothesis perfectly fits the observed data 
for the Con A stimulation of glycolysis. During the GvH reaction however, 
there is some suggestion of an increased activity of the glucose carrier 
and/or hexokinase (as indicated by a decreased glucose concentration), 1n 
the presence of raised levels of G6P, and while Po4
2
- levels remain 
constant. Thus the major problem outstanding in explaining glycolytic 
regulation in the lymphoid organs spleen and thymus, appears to be 
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associated with the other regulatory locus of the pathway, glucose 
transport/hexokinase. 
2-It has not been the intention in this Section, to imply that P04 
1s the sole regulator of phosphofructokinase activity. It has been 
demonstrated kinetically 1n this thesis, that many of the effectors of 
phosphofructokinase bind at different sites on the enzyme, and although 
their individual effects may be slight, it is quite conceivable that they 
might synergistically activate or inhibit the enzyme. However, both from 
in vitro experimentation and from examination of intermediate data, it 
2-does appear that P04 plays a key role in regulating phosphofructokinase 
activity in vivo. 
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PHOSPHOFRUCTOKINASE AND GLYCOLYSIS DURING 
LYt@HOCYTE TRANSFORMATION 
CHAPTER 4 
PHOSPHOFRUCTOKINASE AND GLYCOLYSIS DURING 
LYMPHOCYTE TRANSFORMATION 
4.1 INTRODUCTION 
This chapter 1s intended to provide a wider metabolic context for 
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the work presented 1n Chapters 2 and 3, and in doing so to briefly consider 
work done at the whole cell level by others, in so far as it sheds light 
on the role of glycolysis during lymphocyte transformation. 
4.2 PHOSPHOFRUCTOKINASE AND THE REGULATION OF GLYCOLYSIS IN 
LYMPHOID TISSUE 
Chapters 2 and 3 have presented in considerable detail, evidence 
which shows that the regulation of glycolysis in lymphoid tissues, occurs 
primarily at two enzyme loci the glucose carrier/hexokinase and 
phosphofructokinase. It is quite clear that two separate patterns of 
regulation can be distinguished: 
(i) an emergency glycolysis~ which functions when the 
tissue's respiratory system 1s challenged, and which 
depends upon the activation of phosphofructokinase 
as the primary metabolic response to the 
critically lowered energy charge associated with 
respiratory failure; and 
(ii) immunological glycolysis~ where phosphofructokinase 
can still be considered regulatory but where its 
activation appears to play a secondary role to the 
accelerated glucose transport and increased 
hexokinase activity. 
A detailed examination of the effector molecules of 
phosphofructokinase, both as measured and as are reported 1n the 
literature, is consistent with the enzyme being regulatory under all of 
the conditions examined. 
4.3 THE ROLE OF GLYCOLYSIS DURING LYMPHOCYTE ACTIVATION 
153 
The work contained in Chapters 2 and 3 fully covers the a1ms set 
out in the introduction to this thesis (see Section 1.6). This work 
would, however, be incomplete if some consideration were not given to the 
relationship it bears to the major problem: the specific role played by 
glycolysis during lymphocyte transformation. The work presented below is 
in no way intended to cover the entire topic, but rather to indicate 1n 
general terms, what is currently known about the activation of this 
pathway. 
Recent evidence from this laboratory (121, 185) suggests that the 
stimulation of glycolysis, which occurs during the early stages of 
thymocyte activation by Con A, may be accompanied by the utilization of 
glucose by other pathways. One characteristic of immunological glycolysis 
is the increased steady-state concentration of hexose-monophosphates. 
G6P, besides being an intermediate in glucose oxidation, can also be 
diverted to glycogen synthesis and pentose phosphate formation, and it may 
be that accelerated flux through these pathways is of some importance for 
the transforming cell. 
Accepting that there is a stimulation of glycolysis during lyrnphocyte 
transformation, the following possibilities appear to cover the likely 
explanations: 
(i) enhanced energy production, in the form of ATP, 1s 
the major requirement that is fulfilled by 
accelerated conversion of glucose into lactate, 1n 
4.3.1 
cells that lack a large complement of mitochondria; 
(ii) it is not ATP per se, but the increased 
concentration of G6P which is important. This 
intermediate also serves the pathways of glycogen 
and pentose phosphate synthesis, so elevation of 
its level places the cell in a state of functional 
readiness in the event of metabolic demands. Under 
these conditions, accelerated glycolysis may still 
be an essential part of the activation process, or 
merely a useful energy-yielding bonus. 
(iii) The increased glucose uptake and metabolism may be 
a consequence of the membrane perturbations which 
accompany mitogen binding (186), leading to a 
specific influx of ionic signals (e.g. ca2+), which 
may lower cytoplasmic ATP levels, thus requ1r1ng 
an increment of ATP synthesis to make up this deficit 
v1a an increased glycolysis; or 
(iv) the same membrane perturbations may lead to a 
non-specific stimulation of all carrier-mediated 
uptake processes, causing a gratuitous increase in 
glycolysis, due to increased intracellular glucose 
and phosphate levels. 
Glycolysis as an energy source 
154 
In Table 4-1, oxygen consumption and glycolytic rates of rat 
thyrnocytes incubated in the presence and absence of Con A are presented, 
accompanied by calculations relating to the contribution to ATP synthesis 
under each condition. Weidemann and Kolbuch (121) have shown that 5 mM 
acetoacetate is readily oxidised by rat thyrnocytes and can contribute 66% 
to the fuel of respiration of the incubated cell suspension. Under these 
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Table 4-1 
The stimulation of ATP synthesis during the 
first 3 hours of the Con A activation of thymocytes 
The figures for the oxygen consumption and lactate production 
are from Weidemann and Kolbuch (121). In the absence of Con A, glucose 
contributes 37% to the oxygen consumption, whilst in the presence of 
Con1* this value is 45% (calculated on the basis of dilution of label in co2) . It is assumed that the balance of the oxygen consumption 
comes from triglyceride. Calculations are based on a P/0 ratio for 
pyruvate of 3 and a P/0 ratio for triglyceride-derived fatty acids of 
2.7. 
oxygen consumption 
10 c~ moles/10 cells/3 hr.) 
glycolytic rate 
c~ moles glucose equiv./1010 cells/3 hr.) 
- Con A + Con A 
360 391 
33 96 
ATP synthesis 
10 (p moles/10 cells/3 hr.) 
oxidative 2024 2216 
glycolytic 66 192 
TOTAL 2090 2408 
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conditions, where acetyl-CoA enters the Krebs cycle independently of 
pyruvate dehydrogenase, neither the oxygen consumption nor the utilization 
of acetoacetate by the cells is stimulated by Con A. Conversely, the 
presence of acetoacetate together with glucose does not diminish the 
accelerated conversion of glucose to lactate, brought about by Con A 
treatment. Thus the stimulation of oxygen consumption in the presence of 
Con A, when glucose is the added substrate, is dependent on the activation 
of a site on the pathway of glucose oxidation prior to the oxidation of 
acetyl-CoA, and can be explained on the basis of the 3 - 4 fold increase 
in the pyruvate concentration (10 to 40 ~M) which accompanies the rise 1n 
lactate formation. Thus the entire 15% 1ncrease in ATP synthesis 1s 
ultimately dependent upon the stimulation of the glycolytic rate. 
4.3.2 Glucose utilization for biosynthetic events 
Table 4-2 presents in summary form the maJor parameters measured 
during examination of [U- 14c]-glucose oxidation by Con A-stimulated 
thyrnocytes. Between 20 and 40% of the glucose carbon utilized 1s 
unaccounted for by the products measured, and although a small proportion 
of the label may be incorporated into intermediates like glutamate and 
aspartate by exchange reactions (20) without net synthesis, the majority 
of the unidentified carbon may be metabolized via pathways other than 
glycolysis. Puckle (185) has shown for example, that the incorporation of 
label from [u- 14c]-glucose into the protein and RNA fractions isolated 
from rat thyrnocytes more than doubles during the first 3 hours of Con A-
stimulation. The implication is that the elevated levels of G6P are 
connected with the utilization of glucose carbon for purposes other than 
merely ATP synthesis. During the later stages of immunological reactions 
(e.g. the GvH reaction and long term studies on mitogen activation) the 
rate of nucleic acid and protein synthesis increases markedly (20, 118). 
Weidemann has suggested (121) that a small, but perhaps still significant 
Table 4-2 
Stimulation of glycolysis in rat thymocytes 
This data 1s from Weidemann and Kolbuch (121). 
GLUCOSE ALONE CON A A23187 
OXYGEN CONSUMPTION 
GLUCOSE DISAPPEARANCE 
LACTATE PRODUCTION 
PYRUVATE PRODUCTION 
LACTATE/PYRUVATE 
14co PRODUCTION 2 
GLUCOSE NOT ACCOUNTED FOR 
c~ moles/1010 cells/3 hr.) 
360 391 362 
ss 122 117 
27 134 98 
1.3 4.5 6.2 
20.7 29.7 16 
19 26 31 
21.5 26.5 
1S7 
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portion of the glucose utilized and unaccounted for, may be either stored 
initially as glycogen, or utilized directly via the pentose phosphate 
pathway as a net source of ribose moieties for nucleic acid synthesis. 
4 3 3 S . f" . . 2+ . . peel lC act1vat10n by Ca 
A23187 is a carboxylic acid ionophorous antibiotic which is specific 
for divalent metal ions (187). It forms lipid soluble complexes with 
cations, thereby facilitating diffusion of the cation across biological 
membranes. Maino et al (188) have recently used this ionophore to 
2+ demonstrate that Ca influx can initiate transformation of pig lymph node 
lymphocytes, as judged by the uptake of [6- 3H]-thymidine into DNA after 
45 hours of culture, and by morphological changes characteristic of 
lymphoblast formation. 
Table 4-2 presents data showing the effects on glucose metabolism of 
incubating rat thymocytes with A23187 in a normal phosphate buffered 
saline containing 1.2 mM CaC1 2 . The ionophore produces early metabolic 
changes which are qualitatively very similar to those observed with Con 
A; stimulating glucose uptake, lactate production and glucose oxidation. 
There is, however, no stimulation of oxygen consumption, no increased 
incorporation of labelled glucose into the protein and RNA fractions and, 
as judged by the lactate/pyruvate ratio, the cytoplasmic NAD+/NADH ratio 
1s more oxidised than with mitogen. Furthermore, the Con A stimulation 
1s partially sensitive to puromycin inhibition, whilst the A23187 stimulation 
1s not (121). There is an absolute requirement for Ca2+ ions for 
transformation by the mitogen phytohaemagglutinin (189), which rapidly 
stimulates ca2+ uptake (111). Although it may appear naive to suggest 
that ca2+ alone is responsible for initiating transformation, the 
experimental evidence supports the view that accelerated entry of this 
cation may play a key role in the process. Weidemann has recently 
demonstrated (121), using the Ca2+-buffer nitrolo-triacetate (190), that 
159 
. . h . 2+ 1ncreas1ng t e cytoplasm1c free Ca concentration from 20 ~M to 40 ~M is 
sufficient to cause the stimulation of glucose uptake shown in Table 4-2. 
The mechanism of this stimulus is unknown, but considering that an increase 
. h 1 . f 2+ 1n t e cytop asm1c ree Ca concentration would remove the inhibition 
which normally prevents the translocation of ATP from the cytoplasm back 
into the mitochondria (191), a strong possibility exists that deinhibition 
of both hexokinase and phosphofructokinase, occurs as a consequence of the 
removal of ATP from the cytoplasm. 
4.3.4 Non-specific glycolytic stimulation 
The first event which occurs during lymphocyte transformation, is the 
binding of the mitogen to glycoprotein receptors on the outer surface of 
the lymphocyte's plasma membrane. Immediately after this binding, a 
whole series of membrane changes occur. Resch et al (192) have demonstrated 
a stimulated incorporation of oleate into membrane lecithin immediately 
after the surface binding of phytohaemagglutinin, whilst Fisher and 
Mueller (109) have similarly shown a stimulated incorporation of 32Po4
2
-
into phosphatidic acid. Singer and Nicholson (193) have shown that changes 
in the membrane phospholipids can cause perturbations in the membrane 
proteins, whilst at the same time there is a greatly increased fluidity 
of membrane lipids (186). When it is considered that these processes 
correlate with permeability changes to molecules as diverse as glucose 
(194), K+ (194), ca2+ (111), hexoses (112), y-aminobutyric acid (113), 
phosphate (183) and uridine (114), then it must be admitted that the 
membrane changes may be so great as to cause a general activation of 
carr1ers. 
4.3.5 Conclusions 
Of the four possibilities presented above, there is no evidence 
available at present whjch demonstrates any one to be correct at the 
expense of any other. llowever, certain conclusions can be reached. 
The involvement of Ca2+ 1n the transformation of lymphocytes is 
indisputable: 
(i) its presence 1s essential for mitogen transformation 
(189); 
(ii) mitogens enhance its uptake by the lymphocyte (111); 
and 
(iii) Ca2+ alone can induce transformation 1n the presence 
of an appropriate ionophore (188). 
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It is conceivable that the stimulated uptake of ca2+ is simply part of the 
generalized carrier activation already considered. We do not believe 
this to be likely, however, for several reasons. 
On purely teleological grounds, this hypothesis is unacceptable. 
Transformation converts the lymphocyte from a comparatively quiescent 
state to one of intense metabolic activity. The synthesis of nucleic 
acids, proteins and other complex cellular components required before 
mitosis can occur, necessitates the utilization of considerable energy, 
and it is highly unlikely that energetically-unnecessary steps such as 
the transport of non-essential metabolites would occur. 
The experiments reported in Section 4.3.3 above, could be considered 
as indirect evidence for this argument. Entry into the cell of only one 
. 2+ f . 1on, Ca , causes trans ormat1on. This is specificity of the highest 
order. Recent work by Crumpton and coworkers (M.J. Crumpton, personal 
communication) suggests that entry into the cell of Ca2+ alone (using 
A23187) initiates a sequence of metabolic events similar to that which 
occurs after the binding of mitogen. This strongly suggests that the 
membrane-regulated fluxes of ions and metabolites into the lymphocyte are 
2+ dependent upon the prior entry into the cell of Ca , and as this proposed 
initial step is highly specific, it is perhaps reasonable to believe that 
the associated fluxes are also specific. It is with this hypothesis 1n 
mind that two possible explanations for the observed glycolytic 
stimulation will now be considered. 
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As stated earlier, the binding of Con A to the lymphocyte plasma 
membrane initiates a whole sequence of biosynthetic events which continue 
for several day.s and require a considerable expenditure of energy. 
Lymphocytes have little glycogen or triglyceride stored for use as an 
energy-providing fuel (20) so it 1s entirely possible that glycolysis 1s 
essential to enable the required synthetic activity to occur. Under 
these conditions, stimulated transport of glucose and phosphate for 
example, could be considered as specific events in that they accelerate 
an essential associated process. In Section 4.3.1 above, it was calculated 
that the stimulation of glycolysis increased ATP synthesis by 15%, and 
considering that glycolytic stimulation is still continuing after 3 days 
(184), the increment of ATP gained from glycolytic stimulation is 
considerable. Weidemann has suggested (M.J. Weidemann, personal 
communication) that the observed oxygen consumption during Con A 
stimulation, is approaching the maximal capacity of the lymphocyte's 
respiratory system. Such a maximal utilization of the cell's energy-
producing resources, would support the contention that a maximal return 
from the cell's energy-producing system is essential for lymphocyte 
transformation. 
The other possible explanation for the observed glycolytic 
stimulation is also consistent with glycolysis being essential in the 
transformation process, but for a different reason. Raising the 
intracellular ca2+ concentration may cause both an uncoupling of oxidative 
phosphorylation, and an uptake of ATP by the mitochondria (191). The net 
effect would be a lowered cytoplasmic ATP concentration, and this would 
lead to a stimulated glycolytic rate, as a consequence of deinhibition of 
phosphofructokinase and perhaps also of hexokinase. The slightly different 
emphasis here 1s that glycolysis is necessary to r epa1r the metabolic 
2+ 
"damage" done by ea , rather than to promote bio synthet ic activity. 
No consideration has been given as yet in this section, t o t he 
possibility of glucose carbon being utilized via pathways other than 
glycolysis. Lymphocytes have little glycogen stored for use as an 
energy-providing fuel in time of need, and it is certainly conceivable 
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that in the early stages of lymphocyte activation, when the energy demand 
is relatively light, carbon may be diverted into glycogen for use at a 
later stage of the transformation process. No evidence is available to 
support this hypothesis and it is presented merely as a possibility. The 
pentose phosphate pathway provides, amongst other things, pentose moie t i es 
for nucleic acid synthesis. Suter (20) has shown a large stimulation of 
incorporation of glucose carbon into nucleic acids 5 days after the 
initiation of the GvH reaction. It is not possible to say at present 
whether glucose carbon is of any importance in nucleic acid synthesis 
under these conditions. 
In summary: the primary cytoplasmic event in the transformation of 
. f h . e 2+ lymphocytes appears to be an elevat1on o t e 1ntracellular a 
concentration. 
2+ Following this entry of ea , a series of membrane-
associated events occur which lead to a stimulated influx into the cell of 
a variety of ions and metabolites. Shortly thereafter, glycolytic rate 
increases, whether as a consequence of stimulation by elevated levels of 
. Po
4
2
-, or as an indirect stimulation, by ea2+ caus1ng decreased cytoplasmic 
ATP concentrations, is uncertain. Either or both of these will 
coordinately increase the activity of both hexokinase and phosphofructok i nase. 
The glycolytic stimulation continues for at least 3 days, and it is 
estimated that this stimulus leads to an 1ncrease in ATP synthesis of the 
order of 15%. In view of the great demand for energy during the 
transformation process, glycolysis may well be essential as an energy source. 
163 
4.4 FUTURE WORK 
It is clear from the work presented in the previous section, that 
the dominant question associated with lymphocyte transformation at the 
present time is the precise nature of the transforming agent. Although 
Maino et al (188) found that Ca2+ (with A23187) would initiate 
transformation in a qualitatively very similar manner to that observed 
with mitogen, the degree of stimulation, as judged by tritiated thymidine 
incorporation into DNA, was only about one-third that obtained when 
phytohaemagglutinin was the stimulating agent. This may indicate that 
only a sub-population of the mixed ·T and B cells of a pig lymph node is 
2+ 
susceptible to transformation by Ca . The possibility of a cotransforming 
or potentiating agent which would increase the sensitivity of the cells 
to ca2+ is also very real. Allied to this problem is the need for an 
in-depth investigation of the multitude of events which both accompany 
and follow mitogen binding and, in particular, a description of their 
prec1se sequence and mutual dependency. The questions to be asked here 
are: 
(i) are the membrane-associated and intracellular metabolic 
events which follow mitogen binding all essential for 
the transformation process?; and, if so, 
(ii) what is their specific function? 
It is still not proven that glycolytic activation 1s essential for 
lymphocyte transformation, even though the energy increment generated 
by this process is considerable. 
Although a great deal of exploratory work still rema1ns to be done 
at the whole cell level, this thesis was written primarily in the context 
of regulation at the enzyme level, and some consideration must be given 
to future work in this direction. 
164 
Regulation of glycolysis in lymphoid tissue occurs at two distinct 
loci: glucose transport/hexokinase, and phosphofructokinase. Evidence 
available suggests that the primary regulatory events encountered during 
immunological stimulation occur at the sites of glucose entry and/or 
phosphorylation. No detailed kinetic investigations of either the glucose 
carrier or hexokinase have been reported for lymphoid tissues. In v1ew 
of the hypothesis proposed in this thesis, i.e. that increased levels of 
intracellular phosphate may coordinately activate both hexokinase and 
phosphofructokinase during transformation, a detailed examination of the 
kinetic and allosteric properties of a lymphoid hexokinase needs to be 
undertaken. 
Recent evidence from Laird and Weidemann (personal communication) 
indicates that glucose transport occurs in unstimulated rat thymocytes 
at a very low initial rate, consistent with rate-limitation of carbon 
flux at the point of glucose entry. Questions to be answered in relation 
to the glucose carrier include: 
(i) does the rate of transport change on mitogen binding, 
or do the membrane perturbations described earlier 
uncover cryptic carrier sites, thus increasing the 
maximal velocity for transport, by increasing the 
total number of effective carrier molecules available?; 
and 
(ii) does reverse transport play an important role in 
determining the intracellular concentration of 
glucose, and if so, do the characteristics of this 
reverse transport process change after mitogen 
binding? 
Once the mechanism of regulation at these two inter-related sites 
1s more clearly understood, further efforts will need to be directed to 
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understanding the inter-relationship of glucose metabolism via glycolysis, 
with the regulation of related pathways e.g. the pentose phosphate 
pathway, and ultimately, to the whole pattern of energy-producing and 
precursor-generating metabolic processes, both cytoplasmic and mitochondrial, 
associated with lymphocyte transformation. 
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PHOSPHOFRUCTOKINASE AND THE REGULATION OF GLYCOLYSIS IN 
LYMPHOID TISSUE 
ERRA TA 
. . 
1. The following abbreviations s hould be included on page v . 
2 . 
3 . 
4. 
adrenocorticotropic hormone ACTH 
ATP:D-fructose-6-phosphate 1-phosphotransfera s e 
(E. C. 2 . 7.1 .1 1) .... phosphofructokinase 
sodium dodecylsulphate SD S 
2-0n p . 22 the KA for P0 4 is quoted as being "of the ord e r 4-5 mM" , but no reference is given . The appropriat e reference 
lS (58), but should be accompanied by a statement th at the 
apparent KA is dependent upon both the ATP and F6P concentra-
tions . 
On p. 39 should be ' inulin- ( 14 c -carboxylic acid)', and on th e 
second-last line, ' temperature' is spelt incorrectly. 
On p . 49, para . 3 , 
spe .! i: . 
line 2, ~ni:ravascular ' is incorrectl y 
5 . On p . 78, the units for ATP/ADP x Pi are M- 1 . 
6 . On p . 82, the Hill coefficient is referred to without a 
reference; this is Hill A.V. (1 910 ) J. Physiol. 40, 4P. 
7 . On p, . 
read 
84 , four line s from the top of the page , should 
.t o that in 10 mM pyruvate'. 
8. On p . 88 , eight lines from the top of th e pa g e , 'thymi' J.S 
incorrectly spe lt. 
9 . On p . 9 1, last paragraph , it should be s tated that all enzyme 
assays were conduct ed at 23° . 
10. On p . 110, no explanation is given of the ratio~~ ln Tab l e 
3 . 6 . The le g end should explain that thi s ratio 
i s a comparison of the enz yme ' s activity in 0 . 3 mM NTP as 
opposed to that in 3 . 0 mM NTP . 
ERRATA (continued) 
11 . Legend to Fig. 3 . 13, p . 126, last"line should read 'and Mg 2+ 
at 4 mM '. 
12 . On p . 135, half-way down page, is the statement 'reaction 
rates were initiated with F6P '. Delete ' rates' . 
13 . On p . 137, ln the legend to Figure 3-16 , should be included 
a statement to the effect that the dashed line represents the 
expected curve if the activity is proportional to enzyme 
concentration . 
1 4. On p . 146 , seven l ines from the top is found ' Several reports 
( 52 , 83 , 166) , . . . . Reference 52 should not be included 
here as these workers used (NH4)2 . S04 . 
15 . On p . 147 , the last word should be ' dimers '. 
16 . On p . 157 , Table 4 . 2 , with A23187 ' glucose not accounted for' 
should be 23.9 . 
ERRATA ( continued) 
BIB LI OGRAPHY 
Reference 4 . ' Robison A. 1 shoul d read ' Robison R .' 
Reference 21 . 'Ep penberger R . 1 sho uld r ead 'Eppe nb erger H.' 
Reference 23 . 1 Koven B.' s hould read ' Koven B . J .' 
References 27,58,74,87, 92 ,154 and 1 62 . 
read ' Passonneau J . V.' 
' Passoneau J . V.' should 
Re ference 33 . ' p . 285 ' should read ' p . 277 ' 
Reference 59 . ' Matchins ky F . M.' should read ' Matschinsky F . M.' 
Reference 73 . '( 1972)' should read '(1973)' 
Refe rence 89 . ' p . 58 4' s houl d be in serted . 
Reference 9 7 . ' Holland P . G.' should read ' Holland P . C .' 
Refe renc es 101 and 11 6 . Journ al should be abbreviated ' Hoppe - Seyler 's 
Z . Physiol . Chemie '. 
~ 
Reference 148. ' S ingh R .' should read ' S in gh R .M. M.' 
Reference 151 . _Page number i s ' 2965 ' . 
Reference 153 . ' Raijmah L. ' should read ' Raijman L .' 
Refere nc e 156 . 'Ener gy Le vels' should read ' The Energy Leve l' 
Reference 177 . 'Lolle y R .M.' should read ' Lolley R . N.' 
-
Reference 189 . ' Ahl ford ' should read ' Alford '. 
